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ABSTRACT
Extraordinary medical advances have led to significant reductions in the burden of infec-
tious diseases in humans. However, infectious diseases still account for more than 13 mil-
lion annual deaths. This large burden is partly due to some pathogens having found suitable
conditions to emerge and spread in denser and more connected host populations, and others
having evolved to escape the pressures imposed by the rampant use of antibiotics. It is then
critical to improve our understanding of how diseases spread in these modern landscapes,
characterized by new host population structures and socio-economic environments, as well
as containment measures such as the deployment of drugs. Thus, the motivation of this dis-
sertation is two-fold. First, we study, using both data-driven and modeling approaches, the
the spread of infectious diseases in urban areas. As a case study, we use confirmed-cases
data on sexually transmitted diseases (STDs) in the United States to assess the conducive-
ness of population size of urban areas and their socio-economic characteristics as predictors
of STD incidence. We find that the scaling of STD incidence in cities is superlinear, and
that the percent of African-Americans residing in cities largely determines these statistical
patterns. Since disparities in access to health care are often exacerbated in urban areas,
within this project we also develop two modeling frameworks to study the effect of health
care disparities on epidemic outcomes. Discrepant results between the two approaches in-
dicate that knowledge of the shape of the recovery period distribution, not just its mean
and variance, is key for assessing the epidemiological impact of inequalities. The second
project proposes to study, from a modeling perspective, the spread of drug resistance in
human populations featuring vital dynamics, stochasticity and contact structure. We derive
effective treatment regimes that minimize both the overall disease burden and the spread
of resistance. Additionally, targeted treatment in structured host populations may lead to
higher levels of drug resistance, and if drug-resistant strains are compensated, they can
spread widely even when the wild-type strain is below its epidemic threshold.
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Chapter 1
OVERVIEW
A pressing challenge nowadays is to understand and predict how social changes re-
sulting from urbanization (e.g., growing populations, increased migration, industrializa-
tion, medical care access) will reflect on the interactions between nature and society. An
important aspect within this overarching challenge relates to the spread and evolution of
infectious diseases in modern social landscapes Lebarbenchon et al. (2007).
Infectious diseases have been among us since the dawn of human kind, standing as one
of the main causes of deaths and morbidity, and even influencing the course of historical
events in several occasions Clark (2010); Brauer (2009). Extraordinary medical advances
in diagnostics, therapeutics, and vaccines, have led to significant reductions in the burden
of infectious diseases among humans. In fact, the eradication of smallpox in 1976 fu-
eled the optimistic idea that, with the help of modern medicine and worldwide eradication
campaigns, most pathogens would soon be eliminated from the face of the Earth McNeill
(2010). The emergence and reemergence of novel and ancient pathogens, such as HIV and
drug-resistant tuberculosis, in the following decades shattered this perspective. According
to the World Health Organization (WHO), today infectious diseases account for more than
13 million deaths a year. Infectious diseases have found suitable conditions to emerge and
spread in denser, larger and more interconnected host populations (i.e., urbanization and
globalization), and have evolved mechanisms to escape the pressures imposed by the ram-
pant use of antimicrobials (i.e., drug resistance) Morens and Fauci (2013); Castillo-Chavez
et al. (2002). It is thus critical to improve our understanding of how diseases spread in
different landscapes– determined in part by the host’s population structure and its socio-
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economic context – and how they react to different containment measures, such as the
deployment of antimicrobial agents.
Thus, the motivation of this dissertation is two-fold. First, we are interested in quan-
tifying, using both data-driven and modeling approaches, the effect of urbanization on the
spread of infectious diseases. For this project we use confirmed-cases data on sexually
transmitted diseases in the United Sates to assess the conduciveness of population size of
urban areas and their socio-economic landscape as predictors of the number of new infected
cases. Also, since disparities in access to health care are often exacerbated in urban areas,
within this project we develop modeling frameworks to study the effect of health care in-
equalities on epidemic outcomes. The second project proposes to study, from a modeling
perspective, the spread of drug resistance in human populations featuring vital dynamics,
stochasticity and contact structure, important aspects whose impact is not yet well under-
stood.
Urbanization and Infectious Diseases
Urbanization has already been associated with a recent “epidemiological transition”: the
shift from a predominance of communicable diseases to a predominance of chronic non-
communicable diseases in adults Harpham and Molyneux (2001), with cardiovascular dis-
eases (∼ 17 million annual deaths) and cancers (∼ 8 million) as the leading causes of mor-
tality worldwide (source: WHO). However, infectious diseases (IDs) still remain a leading
cause of mortality and morbidity Alirol et al. (2011); Harpham and Molyneux (2001);
Dye (2008), causing about 25% of annual deaths worldwide Fauci et al. (2005); Fauci and
Morens (2012), with HIV (∼ 2 million annual deaths), Tuberculosis (∼ 1.5 million) and
Malaria (∼1 million) taking the largest toll. The impact of IDs is particularly concern-
ing for developing countries, where 55% of all deaths are attributed to them, in contrast
2
to 14% in developed countries 1. IDs are also the leading cause of death of children and
adolescents worldwide. Moreover, it has been proposed that increased population density
and urbanization may have played a critical role in the worldwide dissemination of HIV
Quinn (1994); Cohen et al. (2010); Bettencourt et al. (2007b), the worsening of epidemics
of major respiratory viruses (e.g., Influenza, RSV) Glezen (2004), as well as the incidence
of tuberculosis (especially among the urban poor) Alirol et al. (2011); Stephens (1996);
Lo¨nnroth et al. (2009); Aparicio et al. (2002). We have found, nevertheless, that the cur-
rent literature lacks generalizable quantitative and mechanistic frameworks to inform how
urbanization processes across cities affect the transmission of IDs.
The first part of the dissertation addresses these issues both empirically and theoreti-
cally. First, we propose a statistical framework to assess the strength of the relationship
between the population size of urban entities and the variation in annual incidence rates
of sexually transmitted diseases (i.e., gonorrhea, syphilis and chlamydia). We also pro-
pose a more mechanistic modeling framework to study the effects on the spread of IDs
of urbanization-driven inequalities, which are, for instance, reflected in different recovery
periods for infected individuals.
The rapid urbanization taking place across the world, especially in developing coun-
tries, may have significant public-health implications Zhang and Atkinson (2008); Alirol
et al. (2011); Galea (2002); Cohen et al. (2010); Harpham and Molyneux (2001); Leon
(2008); Galea et al. (2005); Bamaiyi (2013); Lo¨nnroth et al. (2009). A century ago around
20% of humans resided in cities. Yet today more than half of the world’s population live in
cities, and by mid-century it is expected that over 60% of the population will live in urban
areas (see Figure 1.1). This explosion of urban dwellers makes it paramount to decipher
how this urbanization transition can be sustainable and beneficial at a global scale. A key
aspect of this challenge is to enhance our understanding of how different IDs spread and
1http://ucatlas.ucsc.edu/cause.php
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evolve in the landscape of cities.
Figure 1.1: Percent Urban in developed and Less developed countries, from 1950 to 2050. Data
Source: United Nations, World Urbanization Prospects: The 2011 Revision
The Issue of Drug Resistance
The evolution of pathogens to escape selective pressures imposed by antimicrobials is not
a recent phenomenon D’Costa et al. (2011), but it is a critical health issue today. Infectious
diseases were a major cause of morbidity and mortality until the introduction of antimicro-
bials. However, the rampant usage of antibiotics in the last seventy years has enhanced the
selective advantage of resistance-conferring genes, allowing the emergence and spread of
pathogens resistant to treatment zur Wiesch et al. (2011). Resistant strains are spreading
rapidly, particularly in diseases such as Tuberculosis, HIV, Malaria and Influenza zur Wi-
esch et al. (2011); Weinstock and Zuccotti (2009). This failure of chemotherapeutic agents
limits treatment options, undermining our ability to fight infectious diseases, making them
potentially untreatable while considerably rising the economic cost of treatment. For the
case of the United States (U.S.), the Center for Disease Control and Prevention (CDC)
conservatively estimates that more than two million people become sick every year with
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antibiotic-resistant infections, leading to at least 23,000 deaths CDC (2013). In terms of
economic cost of antibiotic-resistance to the U.S., it is estimated to be as high as 20 billion
dollars in health care costs, with additional costs to society due to lost productivity as high
as 35 billion dollars a year. As a result, the issue of drug resistance has become a major
concern in public health policy Lipsitch et al. (2007); Wu et al. (2009); CDC (2013).
In the case of Influenza, the rapid development of an effective vaccine against an emerg-
ing novel virus presents considerable challenges. Thus, antiviral agents play a central role
as a first-line defense against emerging epidemics of influenza. The large-scale use of these
drugs could, in turn, select for the evolution of drug-resistant strains Regoes and Bonho-
effer (2006); Weinstock and Zuccotti (2009), making the strategic distribution of antivirals
essential for quelling the spread of drug-resistance while limiting the overall epidemic size.
In the second part of the dissertation we investigate i) the influence of two key param-
eters on the effectiveness of treatment: the relative transmissibility of the drug-resistant
strain, and the frequency of de novo resistance; ii) the impact of contact structure and
stochasticity on the spread of resistance and the selection of treatment strategies; and iii)
the effect of drug-resistance phenotypic heterogeneity on epidemic outcomes and treatment
efficacy.
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Chapter 2
SCALING PATTERNS OF SEXUALLY TRANSMITTED DISEASES IN URBAN
AREAS
2.1 Urbanization and the Spread of Infectious Diseases
The world is becoming increasingly urbanized. For the first time in history, the ma-
jority of people live in urban areas. Most of this urban growth currently takes place in
developing countries, and it is expected that in the next few decades these countries will
also experience the fastest urban growth rates (see Figure 1.1). Rapid urban population
growth and density in these areas, combined with poor living conditions and a precarious
public health infrastructure, may create favorable conditions for the wide spread of certain
infection diseases. As a result, rapid urbanization may have significant public-health impli-
cations Aparicio et al. (2002); Aparicio and Castillo-Chavez (2009); Zhang and Atkinson
(2008); Alirol et al. (2011); Galea (2002); Cohen et al. (2010); Harpham and Molyneux
(2001); Leon (2008); Galea et al. (2005); Bamaiyi (2013); Lo¨nnroth et al. (2009).
The term urbanization can be used to describe the process of modernization, industrial-
ization, and socioeconomic diversification and rationalization. It can also be used to specify
the proportion of a population living in cities, as well as the rate at which this proportion
increases over time. Two common features of urbanization that appear to be most signifi-
cant for disease transmission are population dynamics (e.g., population growth, travel and
migration) and inequalities among individuals (e.g., economic, social, educational, health-
care access) Morens and Fauci (2013); Stephens (1996).
Population dynamics: International travel and migration turn cities into enhancers and
gateways for IDs where all the conditions are present for large outbreaks to occur and
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propagate Morens and Fauci (2013); Alirol et al. (2011), as demonstrated by the global
spread of the human immunodeficiency virus (HIV) and more recent pandemics such as
severe acute respiratory syndrome (SARS) in 2002 Lipsitch et al. (2003); Chowell et al.
(2003) and H1N1 pandemic influenza in 2009 Alirol et al. (2011); Chowell et al. (2011);
Herrera-Valdez et al. (2011). There is also evidence suggesting that the global connectivity
of the world due to international travel can impact the evolution of certain viruses (e.g.,
influenza Vandegrift et al. (2010); Bedford et al. (2012)), and can potentially select for
undesired traits such as increased virulence Eshelman et al. (2010); Kerr et al. (2006);
Read and Keeling (2003a); Boots and Mealor (2007).
Migration affects the transmission and epidemiology of communicable diseases in at
least three ways Alirol et al. (2011); Galea (2002); Clark (2010). First, cities may provide
favorable conditions for the spread of pathogens imported by migrants, to which the resi-
dent population could lack defensive immunity if not previously exposed to the pathogen.
Second, migrants increase the pool of susceptible individuals, facilitating the transmission
of diseases that are already present in the city, more so if many of the newcomers do not
have the specific immunity against the urban germs. Third, an influx of impoverished peo-
ple to a city may tax the existing infrastructure, including transportation, housing, food,
water, sewage, jobs, and health care. Over-taxing of this infrastructure can lead to the
spread of disease and an overall deterioration of public health.
Social inequalities: Urban dwellers enjoy, on average, better health, education and
income 1 (larger weighted means in MSAs, as Figure 2.1 shows) than the population as a
whole, and especially their rural counterparts Alirol et al. (2011); Dye (2008). However,
1Central to the human development approach is the concept of capabilities, which are the equipment one
has to pursue a life of value. Basic capabilities widely valued include: good health, access to knowledge,
and a decent material standard of living. For more information: http://www.measureofamerica.org/human-
development/#human development index.
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these benefits are not evenly distributed across the urban population Dye (2008); Stephens
(1996). In fact, socio-economic disparities (income distribution, educational attainment
and health coverage) are often exacerbated in urban environments (see larger weighted
standard deviations in MSAs in Figure 2.1, and see also Figure 2.3). These disparities can
be expressed in three crucial ways that are determinant for an individual’s health quality:
the social environment (e.g., cultural norms, social networks, socioeconomic status), the
physical environment (e.g., air, water, and noise pollution), and access to health and social
services Alirol et al. (2011); Galea (2002); Leon (2008). Put differently, large disparities in
economic, social, and living conditions often present in urban settings can result in health
inequalities. For example, in the U.S., residents of large central cities within Metropolitan
Statistical Areas (MSAs) fare worse on many health measures compared to residents of the
surrounding suburban areas. Limited access to professional medical attention, vaccination
and medication is a common issue for poorer urban residents Leon (2008), which could
result in the emergence of drug resistance in the urban environment due in part to difficulties
in adhering to complicated and expensive treatment regimes Castillo-Chavez and Song
(2004); Chow et al. (2007).
Another important aspect of urbanization involves both migration and poor living con-
ditions within urban areas. New migrants that settle in low socio-economic status groups
“have lower levels of awareness and/or less power to act on existing knowledge concerning
healthy behavior” and also experience a rapid socio-cultural transition (e.g., relaxation of
traditional cultural norms) that can lead to changes in health behavior patterns (e.g. sexual
activity, alcohol and drug use) Lo¨nnroth et al. (2009), which can in turn affect transmission
risks, especially for sexually transmitted diseases (STDs), with young people particularly
at risk Alirol et al. (2011). For example, there is evidence suggesting that within urban ar-
eas, richer residents have better access to education and mass media, and are more exposed
to campaigns for disease prevention (see Figure 2.4).
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Comparison of Human Development Indicators
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Figure 2.1: Top Panel: Boxplots of Human development indicators in the U.S. in 2011: compar-
ing counties that form MSAs to Rural (non MSA) counties and whole U.S. On average, MSAs have
better levels of human development than their rural counterparts and the country as a whole (com-
pare weighted means). However, the levels of inequality (Gini Index) are slightly higher in MSA, as
well as larger weighted standard deviations in MSAs. Bottom Panel: Comparison of some metrics
that are reflected in the Human Development Indicators. These data also supports the claim that
MSAs enjoy, on average, better levels of education, income and health. The quantities ‘wm’ and
‘wse’ represent the weighted means and standard errors (weighted by county population size) of the
corresponding metrics. Data Source: Measure of America Burd-Sharps and Lewis (2013) and U.S.
Census Bureau.
With regard to sex education, we investigated whether any state-level differences of
STD rates in the U.S. could be attributed to “abstinence only” sex education policy 2 strate-
gies compared to education policies emphasizing preventive measures (e.g., contraceptive
use) against STD infection and pregnancy during sexual activities. We found that the aver-
2Abstinence education is a form of sex education that teaches children abstinence from sex. This type
of sex education promotes sexual abstinence until marriage and avoids discussion of use of contraceptives.
Comprehensive sex education, by contrast, covers the use of contraceptives as well as abstinence, while also
explaining the modes of transmission of STDs and their symptoms (Source: Wikipedia, Abstinence-only sex
education)
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Figure 2.2: Household Income distribution in MSA and non MSA areas of the U.S. in 2011. The
income distribution in MSAs is broader than in non MSAs, suggesting larger income inequalities.
Data Source: U.S. Census Bureau, Current Population Survey, 2012 Annual Social and Economic
Supplement.
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Figure 2.3: Percent of people living in slums within urban areas in different countries. Across
the world, a considerable fraction of urban dwellers live in poor conditions. Each bar represents a
country. The colors represent the region of the world where each country is from. From left (black)
to right (purple): Africa, Latin America, Eastern Mediterranean, Turkey, South-East Asia, Western
Pacific. Data Source: World Health Organization
age incidence rates of chlamydia, syphilis and gonorrhea are consistently higher in states
that enforce the “abstinence-only” policy (see Figure A.1 in the appendix for results). This
suggests that an adequate sexual education at an early age can be instrumental in avoiding
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Figure 2.4: HIV/AIDS transmission dynamics knowledge in urban areas. In all represented coun-
tries, poorer residents within urban areas have less knowledge. Data Source: World Health Organi-
zation.
sexually transmitted infections. Providing incentives for clinicians to screen, counsel and
educate adolescents at risk for, or diagnosed with, an STD could have a tremendous impact
on quelling the spread of an STD epidemic DiClemente et al. (2005).
In contrast to these disease-prone features of urban environments, urban growth can
also trigger the decline of infectious diseases. For example, air and water pollution in
cities often destroys vector habitats, which hinders the growth of vector populations, de-
creasing in turn the prevalence of vector-borne transmitted diseases. Also the deployment
of well-planned and funded strategies for vector control have led to the elimination of
malaria and dengue in some cities Alirol et al. (2011). Improved living conditions and
better accessibility to preventive and curative measures can quell transmission. The case of
tuberculosis (TB) is an interesting one. TB incidence increased in industrialized countries
during the 17th and 18th centuries, with rates being particularly high in urban areas, ar-
guably due to increased population density and crowding, as well as poor nutrition, among
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other risk factors Lo¨nnroth et al. (2009); Aparicio et al. (2002). Then, throughout the
20th century, and even before the introduction of effective chemotherapy, TB incidence
declined steadily in most industrialized countries. Supposedly, poverty reduction and im-
proved living conditions– especially nutrition, which reduces the risk of developing active
(infectious) TB– were the factors that most contributed to this decline in TB, with medical
and public health interventions having a marginal impact. It is important to notice that even
though the aforementioned TB-incidence trends were seen in cities within developed coun-
tries (e.g., U.S., England), we could face a much different scenario in developing countries,
where different socio-economic and cultural structures are present.
2.2 Sexually Transmitted Diseases and their social context: previous findings
Social capital, the idea that social networks have value Putnam (2000), is built on the
concept that the well-being of societies depends on the cohesiveness and cooperation of
their citizens and on their social and civic engagement. It is often defined as a population-
level attribute that measures social relations and connections among people and social
organization of communities. Social capital has been shown to be inversely correlated
with acquired immunodeficiency syndrome (AIDS) case rates, as well as the incidence of
chlamydia, gonorrhea and syphilis among adults DiClemente et al. (2005); Holtgrave and
Crosby (2003); Farley (2006). It has also being found to be inversely correlated with sexual
risk behaviors and positively correlated with protective sexual behaviors among adolescents
Crosby et al. (2003). Despite this evidence of social capital as a key construct in public
health, mechanisms by which social capital may be a positive influence on public health
measures have not been definitely identified, although some proposed mechanisms are: (a)
social isolation linked to poor health present in low social capital; (b) social capital can in-
fluence risk and protective behaviors; and (c) it can influence access to health services and
promote the development of policies that protect all citizens Crosby et al. (2003); Holtgrave
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and Crosby (2003). The directionality of the causal relationship between social capital and
health outcomes will require further examination. Given the cross-sectional nature of the
data, reverse association in which increased STD rates may result in lower levels of social
capital is also possible Semaan et al. (2007).
In fact, Semaan et al. (2007) examined the state-level association between social capital
and rates of gonorrhea and syphilis, controlling for state variation in poverty, income in-
equality and racial composition. The study found that social capital was not associated with
STD rates when state variation in racial composition was accounted for, and that in fact, the
states with a higher proportion of residents who were African-American had higher STD
rates.
In the U.S., the epidemiological pattern of STDs, such as HIV, chlamydia, gonorrhea
and syphilis, shows a disproportionate burden on African-Americans in the Southeastern re-
gion (see Figure 2.5 and, in the Appendix, Figures A.3-A.4). Another clear pattern, shown
in Figure 2.6, is that STD rates are higher in urban areas than in less densely populated
areas.
In terms of the nationwide demographic impact, in 2010 the gonorrhea rate in blacks
was almost 20 times the rate in whites, while the rates of syphilis and chlamydia among
blacks was eight times the rate among whites cdc (2011). Not surprisingly, blacks represent
a far larger proportion of the population in the south than in any other region (see Figure 2.5
(right)). This racial disparity could reflect, beyond socio-economic disparities associated
with race, deep group-level social and environmental factors for which race is a marker.
Previous models have proposed to explain the relationship between race and elevated rates
of STDs in blacks using key factors such as: 1) chronic joblessness, 2) drug and alcohol
marketing, 3) social disorganization (or reduced social capital), and 4) male incarceration
Farley (2006). It is thus clear that a deeper understanding of inter-racial differences in STD
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rates can be obtained from the study of the determinants of the aggregate sexual behavior
of groups.
Rates of partner change and concurrency also play a critical role. A person living in a
social environment where rapid partner change or concurrency is the norm, is at higher rel-
ative risk regardless of his or her individual behavior. Partnership duration and overlapping
has been found to play a significant role in the spread of many diseases, in particular HIV
Morris and Kretzschmar (1995).
Gonorrhea rates per 100,000
<10 10−15 15−20 20−27 27−40 40−63 63−103 103−180 >180
Percent black  indicator
<0.5 0.5−0.8 0.8−1 1−3 3−5 5−9 9−18 18−32 >32
Figure 2.5: Rates of gonorrhea (left) and percent african-american in US counties (right).
Notice the spatial correlation between these two metrics.
2.2.1 Summary of status quo and our way forward
We often find opposing forces in action when studying IDs in urban settings: urban
dwellers have better health on average, but social inequalities and heterogeneities are ex-
acerbated in cities. Also critical is that we expect to see increasing population size and
migration enabling more human interactions, which leads to more innovations and produc-
tion per-capita, on average, Bettencourt and West (2011), but it can also lead to greater
infectious disease incidence. To our knowledge, it is still unclear what the net effect of
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Figure 2.6: Infection rates (per 100,000) for gonorrhea, syphilis and chlamydia from 2007 to 2011.
Comparison between the 50 most populous MSAs (solid lines) versus all US population (dashed
lines). For these three STDs, the rates are higher in MSAs: 1.11 times higher for gonorrhea, 1.40
for syphilis and 1.06 chlamydia. Source: CDC
these contending forces is, and how it is related to the transmission pathways of diseases
(e.g., airborne or sexually transmitted diseases), or the specific socioeconomic environment
in which the disease circulates.
The current literature presents, mostly in a qualitative and post hoc manner, the re-
lationship between urbanization and health outcomes, with special emphasis on chronic
non-communicable diseases such as degenerative cardiovascular diseases, cancers, obesity
and diabetes (so-called “diseases of affluence” given their connection to unhealthy diets,
tobacco and alcohol consumption, and sedentary lifestyles). We consider, nevertheless,
that despite the fact that diseases of the affluence are the most important causes of death
in today’s world, the study and prevention of IDs is as important, if not more. IDs affect
mainly children within poor countries and also, although not as frequently, adults in their
prime, while diseases of the affluence are largely diseases of the later life. Moreover, the
former is, by its nature, preventable in most cases, whereas the latter is often the result of
natural biological degeneration of our bodies.
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A more quantitative and statistical approach has been taken to identify key socio-
economic aspects associated with the spread of STDs. However, the focus in the majority
of these studies have not been on urban areas, but rather countries, states or counties.
Efforts need to be dedicated to the development of more quantitative and mechanis-
tic frameworks to inform how urbanization affects the transmission of IDs. Some of the
reasons for this lack of quantitative and mechanistic understanding, are i) the systematic
collection of health data within and across cities is either scant or non-existent, especially
in developing countries, with many of the studies mainly focusing on comparisons of urban
versus rural health indicators using aggregated data from both contexts; ii) when the data is
available, most studies investigating the relation between rates of STDs and socio-economic
factors have focused on country- and state-level associations; and iii) mechanistic mod-
els are mostly context (city/region) specific and too complex, reducing their mathematical
tractability and our ability to tease out relevant and generalizable insights for public health
policy.
We propose to counteract some of these deficiencies. First, the data used in our sta-
tistical framework include annual cases of disease incidence for syphilis, gonorrhea and
chlamydia, three infectious diseases that have important public health implications given
their long term sequelae, across U.S. cities from 2007 to 2011. Since MSAs are conformed
by collections of counties (see below), these type of data will allow us to go beyond the
rural-urban comparisons, or studying a particular disease in one city at a time Alirol et al.
(2011); Mao and Bian (2010); Gesink et al. (2011), and it will instead take a cross-sectional
look at all metropolitan areas in the U.S. for three diseases of interest. This approach will
make it possible to identify relevant statistical patterns at a systemic level, as well as offer
a conceptual basis for a systematic analysis of the impact of population size of urban areas
on the spread of certain pathogens while identifying socio-economic factors enhance their
transmission.
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Second, we construct theoretical/computational models as a venue to assess the im-
pact of disparity in public health access and living conditions on disease prevalence and
epidemic risks. These models will offer an alternative approach, simple yet generic, to ad-
vance our understanding of how urbanization-driven inequalities can enhance IDs spread,
informing policy and improving our capabilities to quell transmission.
Lastly, most of the studies have explored these issues considering states Semaan et al.
(2007); Holtgrave and Crosby (2003) or entire countries as the unit of analysis Pickett and
Wilkinson (2009); Wilkinson and Pickett (2006). Our approach will compliment and build
upon the existing knowledge by focusing instead on MSAs as the unit of analysis, and to
our knowledge, this is the first study to do so.
So, why MSAs?
An MSA is defined as a core area (i.e., a city) containing a large population nucleus or
core (of at least 50,000 people), along with adjacent suburban counties that share a high
degree of economic and social integration with that core urban area (see Figure 2.7). By
definition, a significant fraction of people (at least 25%) within the boundaries of these
MSAs commute on a regular basis to and from the core population (in order to work or
shop, for instance). These significant levels of commuting within MSAs have relevant im-
plications for diseases dynamics, such that MSAs can be considered highly interconnected
meta-populations containing an urban hub, where diseases can spread relatively faster. This
is the case especially once an infected individual reaches the main urban nucleus and is able
to infect individuals that will commute to the surrounding suburban areas, potentially caus-
ing an epidemic within the MSA (Figure 2.7 (left)). In addition, this epidemic can spread
to other MSAs through long range travels (Figure 2.7 (right)). For these reasons, MSAs are
a suitable unit of analysis for studying disease infection patterns in the landscape of cities.
Moreover, their socioeconomic characteristics make MSAs a widely used unit of analysis
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when studying the properties of economic and social outputs in urban contexts Bettencourt
et al. (2007b,a).
Alternative to this unit of aggregation, one could also consider countries, states or coun-
ties. However, these other scales might not be as suitable for the study of disease contagion
processes. For example, the boundaries of countries and states are largely determined by
political and/or geographical circumstances, and do not necessarily subscribe their defi-
nition to the socio-economic interactions among individuals within their populations, for
which aspects such as commuting patterns represent a good proxy. As a result, a country
or a state, in many cases, could be a unit of analysis too large for its aggregate properties
to be representative of its individuals and their behaviors. Counties on the other hand, are
also defined in a less functional fashion than MSAs are, and given their relatively small
geographical extension, they would likely fail to capture aspects of their environment (such
as interactions with neighboring counties) that are essential to the functioning of their pop-
ulations, and more importantly, to the spread of IDs.
In general, we consider the appropriateness of the unit (scale) of analysis to be depen-
dent on 1) the specific social/biological processes under study, 2) the particular environment
(country or region of the world) and ultimately 3) the nature of the question being asked.
2.3 Materials and Methods
2.3.1 Data Sources
Dependent variables:
• The variables whose variation we are trying to explain in this study are new cases of
chlamydia, gonorrhea and syphilis (primary, secondary and congenital) from 2007
to 2011, in the counties of the 48 contiguous states, as reported by the Centers for
Disease Control and Prevention (2013).
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Figure 2.7: Cartoon of an MSA with its core city and surrounding suburban areas or counties.
These are strongly connected with the core city, and weakly connected among themselves. Center
piece of figure by Alexey Zaitsev. (Left) Infection spreading within an MSA after an initial infection
in the core city. (Right) Infection spreading between MSAs through long range connections after
one MSA got infected.
The surveillance information in this dataset is based on the following sources of data:
(1) notifiable disease reporting from state and local STD programs; (2) projects that
monitor STD positivity and prevalence in various settings, including the National
Job Training Program, the STD Surveillance Network, and the Gonococcal Isolate
Surveillance Project; and (3) other national surveys implemented by federal and pri-
vate organizations for Disease Control and Prevention (2013). Because of incomplete
diagnosis and reporting, the number of STD cases reported to the CDC is less than
the actual number of cases occurring in the U.S. population.
Although most state and local STD programs generally adhere to the national notifi-
able STD case definitions collaboratively developed by the Council of State and Ter-
ritorial Epidemiologists and CDC, differences in policies and systems for collecting
surveillance data may exist. Thus, comparisons of case numbers and rates between
jurisdictions should be interpreted with caution for Disease Control and Prevention
(2013). However, because case definitions and surveillance activities within a given
area remain relatively stable over time, trends should be minimally affected by these
differences.
19
The category of “total syphilis includes primary, secondary, latent and congenital
syphilis.
Covariates:
• The population of the counties, as per the 2010 estimates of the Census Bureau.3
• Percentage in poverty (% Poor). This variable measures the percentage of people in
a county living below the federal poverty level. We used the 2010 estimates from
Census Bureau.
• Income inequality (Gini index): By definition, this variable measures the distribution
of income between different categories making up a population. It ranges from 0 to
1, 0 being the Gini Index for perfect equality. For our analysis, we use data from
Measure of America4 Burd-Sharps and Lewis (2013), although its value is computed
by the Census Bureau.
• Percentage of African-American residents (% Black). The percentage of African-
American residents for each county in 2010 was taken from Census Bureau data for
residents who identified themselves as African-American or Black. This will allow
us to control for racial composition of the population.
• Education index. It is based on two sub-indices: Educational Attainment Index and
Enrollment Index. The former measures the overall level of educational attainment
achieved by the adult population, whereas the latter is based on a net enrollment
calculation that takes into account the total number of students enrolled in school.
For methodological details, see Burd-Sharps and Lewis (2013). Data from Measure
of America.
3Source: http://quickfacts.census.gov/qfd/download data.html
4Source: http://www.measureofamerica.org
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• Income per-capita, as per the 2010 estimates from Census Bureau.
• Percent insured (under 65 years old), as per the 2010 estimates from Census Bureau,
Small Area Health Insurance Estimates.5
• Population density (population per square mile), as per the 2010 estimates from Cen-
sus Bureau.
• U.S. regions. The contiguous states of the four regions of the United States were
based on the Census Bureau’s definition. ‘Region’ is considered as a categorical
variable in the regression analyses in one of the sections.
As explained before, our unit of analysis are MSAs, thus we limit our interpretations to
MSA-level associations, and, for comparison purposes, we show some of the estimates at
the state and county level. There are a total of 381 MSAs in the U.S.,4 belonging to Hawaii
and 2 to Alaska (which are the non-contiguous states). This leaves 375= 381-6 MSAs
within the 48 contiguous states. Our data set has information on 364 of these MSAs. We
used an alpha level of 0.01 to guard against type 1 error. All statistical analyses presented
in this work were performed in the R statistical software package R Core Team (2012).
Constructing MSA data from county data
Our proposed unit of analysis are MSAs. The original STD data obtained from the CDC,
as well as the socio-economic census data, are at the county level for the 48 contiguous
states of the U.S. (i.e. excluding Alaska and Hawaii). Therefore, we construct MSA-level
metrics using county-level data.
Population and total number of STD cases: MSAs are composed of a collection of
counties. Let Mi be the ith MSA, and C ji the jth county within MSA Mi. Then, Mi is the
5Source: http://www.census.gov/did/www/sahie/data/20082012/index.html
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union of its conforming counties: Mi =
⋃
j C ji. The total number of cases in Mi is simply the
sum of cases in counties C ji, and the total population of Mi is also the sum of populations
of counties C ji.
Socio-economic covariates: The value of a socio-economic covariate for MSA Mi is
the average of the covariate values in each county C ji, weighted by county population size.
Formally, let Ekji be the value of the kth socio-economic covariate to be considered, in
county C ji. Then its value at the MSA level, namely Eki , is given by
Eki =
∑ j EkjiPji
∑ j Pji
,
where Pji is the population size of C ji.
2.3.2 The Scaling Framework
We aim to develop an understanding of the conduciveness of urban features to the
spread of diseases. By exploring the transmission dynamics of infectious disease through
a novel scope, we present a data-driven approach to assess how well the variation of epi-
demiological aspects (e.g., disease incidence) can be explained using predictors such as the
population size of urban entities and factors of their socio-economic environments. In a
nutshell, the goal of this study is to better understand and quantify the association of popu-
lation size of urban areas and the transmission dynamics of STDs, and how this association
is related to the socio-economic context of these urban populations.
We approach this issue using a theoretical framework, motivated by the work of Bet-
tencourt et al. (2007b) , where it is proposed that Yi, an urban metric, and Ni, the population
size of an urban area, satisfy the scaling relationship
E[Yi|Ni] = Y0Nαi . (2.1)
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The subscript indexes a city or urban population, Y0 is a baseline value for Y , and the scaling
exponent α measures the average relative change in Y with respect to N. The vertical bar
stands for “given”, as in conditional probability.
Interesting empirical regularities have been discovered through this scaling analysis.
It has been found that population size is a strong predictor of several urban metrics that
measure the socio-economic performance of cities. More specifically, quantities reflecting
interaction processes such as wealth creation, innovation, new HIV cases and violent crime
have a scaling exponent α > 1 (superlinear, increasing returns), whereas those accounting
for a city’s physical infrastructure (i.e., communication, transport and services) display α <
1 (sublinear, economies of scale) Bettencourt et al. (2007b,a); Bettencourt and West (2011,
2010); Bettencourt (2013); Gomez-Lievano et al. (2012). This allometric approach has also
been used in biology, where empirical evidence indicates that host body size significantly
predicts metabolic rates West et al. (1997), and that pathogenicity (measured as time to
symptom onset and death) is controlled by the scaling of host metabolism Cable et al.
(2007). These lines of evidence suggest, compellingly, that the size of urban entities may
influence to a great extent the rate at which infectious diseases spread in them.
An informative interpretation of α in the context of infectious diseases is as follows.
Let Yi and Ni be, respectively, the number of infected cases and the population of MSA
i. Dividing both sides of Eq. (2.1) by Ni yields Yi/Ni = Y0Nα−1i . Here Yi/Ni = fi is the
fraction of the population that became infected, or more specifically, the likelihood that, in
a homogeneous population, any given person got infected. It is then clear that when α > 1,
f (N) =Y0Nα−1 is an increasing function of N. In other words, when the allometric relation
is superlinear, the disease case rates and the likelihood of any given individual becoming
infected increases for larger populations.
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Assuming that the error term εi in Eq. (2.1) is a lognormally distributed random vari-
able6 (r.v.) with mean one, such scaling relationship can be transformed, by removing the
expectation operator and taking logs 7 in both sides, into
log(Yi| log(Ni)) = log(Y0)+α log(Ni)+ log(εi). (2.2)
Taking the expectation in both sides renders
E[log(Yi| log(Ni))] = E[log(Y0)+α log(Ni)]+E[log(εi)] (2.3)
=⇒ E[log(Yi| log(Ni))] = log(Y0)+α log(Ni) (2.4)
Note that E[log(εi)] = 0 (given that εi is assumed to be a lognormally distributed ran-
dom variable with mean one) allows the transfromation (2.3) to (2.4).
What do we want to know?
Using this allometric framework, we address a series of questions. 1) Is the relationship
between city size and incidence superlinear, or sublinear? Put differently, will the burden
of STDs be reduced or magnified as the populations in which they circulate become more
urbanized (i.e., larger)? One interpretation of these results is that, for those diseases for
which α > 1, the per-capita rate of infections will increase as urban populations grow.
To approach question 1) we use expression (2.2) and regress data on log(Y ) versus
log(N). The slope of the estimated regression line will yield α , the scaling parameter. Thus,
letting k = {gonorrhea,syphilis,chlamydia}, we can regress log(Yk) versus the predictor
log(N), yielding different scaling exponents αk for each disease. We also assess whether
these scaling features are significantly different for the three diseases under study, providing
statistical evidence to support or reject the conjecture that the scaling patterns of IDs in
6A log-normally distributed R.V. is one whose logarithm is normally distributed.
7Throughout this manuscript we will adhere to the following notation: “ log” refers to base 10 logarithm,
whereas “ ln” refers to base e logarithm.
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MSAs depend on the general characteristics of the disease’s life history (e.g., the timing of
symptoms, virulence, transmission, and host recovery).
Two common features of urbanization that appear to be most significant for disease
transmission are i) population dynamics and ii) social inequalities. We then ask: 2) For
a given disease circulating in different environments, how does the scaling exponent α de-
pend on the demographic contexts (e.g., racial makeup) and the socioeconomic landscapes
(e.g., poverty rates, income inequality)?
To address question 2) we run a series of categorical and multivariate regression analy-
ses in order to explain the variance in the STD incidence per MSA. We use the following
covariates: population size in 2010, poverty rates, per capita income, percent of the popu-
lation that is African-American, percent of the population that is insured (under 65 years of
age), Gini Index and education Index. Since income inequalities within societies have been
linked to worse health outcomes Wilkinson (1997); Pickett and Wilkinson (2009); Wilkin-
son and Pickett (2006), we assess whether incidence rates are greater for those counties
with larger levels of inequality. We also assess the hypothesis that the scaling patterns for
the same diseases varies from one region of the country to another based on their aggregate
socio-economic status.
2.3.3 Poisson Regression
The most straightforward way to regress model (2.2) consist of using ordinary-least-
squares (OLS) regression Kutner et al. (2005). However, the appropriateness of this model,
which assumes that the dependent variable is continous, is disputable given that Yi are
counts of STD cases. As an alternative, one could make use of the Central Limit Theorem
and assume that for large counts (and conditional on population size), the data follow ap-
proximately a Normal distribution with non-constant variance. Under this assumption, we
could perform a weighted OLS regression (see Appendix for details on this). Arguably, this
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regression method could still be inappropriate for the data at hand, especially since there
is a considerable number of MSAs with few counts (10 or less) in the case of Syphilis,
yielding the assumption of large counts invalid.
A parsimonious way to model count data is to assume that the counts are Poisson dis-
tributed Ross (2006). Poisson distributed data have a probability density function
h(y;µ) = P[Y = yi] =
exp(−µ)µyi
yi!
,
with mean and variance E[Y ] =Var[Y ] = µ .
In poisson regression, the canonical link function8 is g(µ) = θ0+θ1X , with θ0 and θ1
parameters, and where
g(µ) = ln(µ). (2.5)
This implies that µ = E[Z|X ] = exp(θ0+θ1X). In order to assess the superscaling hypoth-
esis using the Poisson regression link function (2.5), we propose the following model
E[Y | log(N)] = exp(log(Y ∗0 )+α∗ log(N)) (2.6)
where log is the base 10 logarithm operator. Taking logs in both side yields
log(E[Y | log(N)]) = log(Y
∗
0 )
ln(10)
+
α∗
ln(10)
log(N) = log(Y0)+α log(N). (2.7)
Notice that the linear model in (2.7) is basically equivalent to the original allometric model
in (2.4).Thus, as in the previous framework, if α > 1 then we are in the presence of super-
linear scaling.
2.3.4 Negative Binomial Regression
Negative binomial regression can be used for over-dispersed count data, that is, when
the conditional variance exceeds the conditional mean (conditional on the levels of the
8the link function relates the linear predictor X with the mean response Kutner et al. (2005)
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predictor variable) Ismail and Jemain (2007). It can be considered as a generalization of
Poisson regression since it has the same mean structure as Poisson regression and it has
an extra parameter to model the over-dispersion. If the conditional distribution of the out-
come variable is over-dispersed, the confidence intervals for negative binomial regression
are likely to be larger as compared to those from a Poisson regression. That is, the disper-
sion parameter in negative binomial regression does not significantly affect the expected
counts, but it does affect the estimated variance of the expected counts, providing more
conservative confidence intervals.
In negative binomial regression, the distribution is specified in terms of its mean, λ ,
which is often related to explanatory variables, as in other regression frameworks. The
probability mass function of negative binomial r.v. X is
P[X = k] =
Γ(r+ k)
k!Γ(r)
(
r
r+λ
)r( λ
r+λ
)k
, (2.8)
where k = 0,1,2..., and r is the dispersion parameter 9. The variance of X can be written
as λ +
λ 2
r
. When r→ ∞, the negative binomial approximates a Poisson distribution with
mean λ and variance also λ . If r is in the vicinity of 1, then the variance is much larger
than the expected under the Poisson regime.
2.4 Results
2.4.1 Scaling Patterns I
For the scaling analysis we use the data, at the county level, of annual cases for chlamy-
dia, gonorrhea and syphilis for the 48 contiguous states of the United States (i.e. excluding
Alaska and Hawaii). Here we investigate the scaling patterns of these data, aggregated by
MSAs, for the most recent years (2007-2011) in the dataset. That is, in the regression anal-
9The negative binomial models the probability that a given number of successes happen in a sequence of
Bernoulli trials before a specified number of failures, denoted by r, occur.
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ysis, the dependent variable will be the total number of cases reported from 2007 to 2011.
The scaling exponents for each year separately are reported in the Appendix, Figure A.8.
No major departure was observed from the mean behavior that we present in what follows.
The results of the Poisson regression are shown in Figure 2.8 and more comprehensively
in Table 2.1. (The format in some of the tables presented are based on a format by Hlavac
(2014).) For all diseases, the scaling exponent estimates are significantly greater than one
(as per a Chi-square test), suggesting a superlinear scaling pattern. However, before moving
on with a more detailed analysis and discussion of these patterns, the appropriateness of
the model needs to be assessed.
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Figure 2.8: Scaling of STD incidence with MSA population with Poisson regression for Chlamy-
dia (left), Gonorrhea (center) and Syphilis (right) using model (2.6). Cases are the sum of reported
cases between 2007 and 2011.
Adequacy of the Poisson model
The Poisson maximum likelihood estimator (MLE) has robustness to distributional mis-
specification so that the Poisson MLE estimate is consistent even if Yi are not Poisson
distributed. However, the usual Poisson MLE standard errors and t-statistics need to be
adjusted: unless count data are equidispersed (equal mean and variance), the usual Poisson
MLE standard errors are wrong.
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Table 2.1: Poisson Regression Results using model in (2.6)
Chlamydia Gonorrhea Syphilis
α̂ 1.0173∗∗∗ 1.0028∗∗∗ 1.2454∗∗∗
(SE) (0.0003) (0.0006) (0.0029)
log(Ŷ0) −1.780∗∗∗ −2.265∗∗∗ −5.157∗∗∗
(SE) (0.0017) (0.0034) (0.0191)
Observations 364 364 364
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Thus, the assumption that the conditional variance is equal to the conditional mean
should be checked. If the count mean and variance are very different (equivalent in a
Poisson distribution) then the model is likely to be over-dispersed. In fact, the data in our
study are over-dispersed (see Figure 2.9).
Another way to perform a goodness of fit test for the model is using the the residual
deviance, which is the difference between the deviance of the current model and the maxi-
mum deviance of the ideal model where the predicted values are identical to the observed.
A quick test of the adequacy of a Poisson model is to divide the residual deviance by its
degrees of freedom (this ratio is Chi-square distributed) and see if the result is close to 1.
If the ratio is much larger than 1 we call the data over-dispersed. In our case, we found
that this ratio is indeed much greater than 1 in all three cases. These observations led us to
employ the Negative Binomial regression instead.
2.4.2 Scaling Patterns II
The results of the Negative Binomial regression are shown in Figure 2.10 and more
comprehensively in Table 2.2. The estimates from this methodology are similar to the ones
yielded by the Poisson regression, but more importantly, the standard errors in the Negative
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Figure 2.9: Mean vs. variance. Since the blue line has a slope greater than 1 (gray line) in all three
cases, the data are over-dispersed.
Binomial case are much more conservative (i.e., wider) when compared to those from the
Poisson regression (see Table 2.1), as well as if compared to the results from the weighted
OLS and the quasi-Poisson regressions (see Tables A.1 and A.2). This estimation “conser-
vatism”, along with the discrete nature of the data and the issue of overdispersion, led us
to employ the negative binomial regression scheme over the other alternatives. Statistical
patterns that are significant under the negative binomial regression scheme, should not only
capture a more realistic and informative representation of the process, but should also be
significant in other less conservative schemes.
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Figure 2.10: Scaling of STD incidence with MSA population with Negative Binomial regression
for Chlamydia (left), Gonorrhea (center) and Syphilis (right) using model (2.6). Incidence is the
sum of reported cases between 2007 and 2011.
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Table 2.2: Negative Binomial Regression Results using model (2.6)
Chlamydia Gonorrhea Syphilis
α̂ 1.0450∗∗∗ 1.1002∗∗∗ 1.2940∗∗∗
(SE) (0.0189) (0.0397) (0.0507)
log(Ŷ0) −1.940∗∗∗ −2.835∗∗∗ −5.456∗∗∗
(SE) (0.105) (0.219) (0.280)
Observations 364 364 364
r (dispersion) 6.627∗∗∗(0.481) 1.505∗∗∗(0.102) 0.956∗∗∗(0.067)
Yet another evidence that can be used to reject the Poisson-distributed counts hypothe-
sis, while also assessing the appropriateness of the Negative Binomial model, is by simu-
lating the counts under the Poisson regime, and under a more flexible regime in which the
mean and the variance do not have to coincide, e.g., Negative Binomial. For simulating
the counts we use the scaling relationship that relate the expected counts and population
size: E[Y |N] = µ = Y0Nα . Simulations in Figure 2.11 use the same populations sizes of
the 364 MSAs in the real data, and the estimates for each of the three diseases in Tables
2.1 and 2.2. Thus, for each MSA i, for each disease d and for each regression method
m ∈ (Poisson,Neg.Binonmial), the expected mean of counts is µ̂idm = 10log(Ŷ0idm)Nα̂idmi .
Then we generate 364 random numbers from the Poisson distribution, each with mean
µ̂idP, as well as 364 random numbers generated from the Negative Binomial distribution
with mean µ̂idNB, and dispersion parameter ridNB.
Note in the bottom panel of Figure 2.11 how as r becomes smaller (left to right), the
variation in the data increases. More importantly, note that the Poisson simulated counts
do not resemble that of the STD data, mainly due to small variance, whereas the Negative
Binomial simulated data is strikingly similar (compare with Figure 2.10).
31
Poisson− Chlamydia
4 5 6 7
0
1
2
3
4
5
6
Lo
g 
Si
m
u
la
te
d 
Co
un
ts
Poisson− Gonorrhea
4 5 6 7
0
1
2
3
4
5
6
Poisson− Syphilis
4 5 6 7
0
1
2
3
4
5
6
N. Binomial− Chlamydia
4 5 6 7
0
1
2
3
4
5
6
Log Population
Lo
g 
Si
m
u
la
te
d 
Co
un
ts
N. Binomial− Gonorrhea
4 5 6 7
0
1
2
3
4
5
6
Log Population
N. Binomial− Syphilis
4 5 6 7
0
1
2
3
4
5
6
Log Population
Figure 2.11: Simulated counts generated from Poisson and Negative Binomial distributions using
the estimates obtained from the Poisson and Negative Binomial regressions in Tables 2.1 and 2.2.
Note similarities of the lower panel to the data in Figure 2.10.
Are the scaling patterns significantly different from each other?
We ask whether the scaling exponents are significantly different for each disease. The
null hypothesis is that the scaling exponents are not significantly different. To assess this
hypothesis we use the z-statistics for the exponent estimate for each disease d, namely α̂d ,
given by
zd =
α̂d− α¯
ŜEd
where α¯ = (1/3)∑3d=1 α̂d is the mean of the estimates. The statistics
X =
3
∑
d=1
(zd)2
follows a χ2 distribution with 2 degrees of freedom Kutner et al. (2005). If the correspond-
ing (one-sided) p-values P[X > χ2(2)] are less than a significance level of 0.01, the null can
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be rejected. Using the results in Table 2.2 we obtain that X = 39.9 with p-value 0.01.
Therefore, we can conclude that the scaling patterns for these three STDs in MSAs are
different from each other, and possibly, this difference is partly determined by how these
pathogens differ in their life history traits, such as symptomatology and virulence.
In fact, we believe that understanding the reasons why the scaling properties are dif-
ferent for these three STDs would be also be a step forward in interpreting the statistical
regularities found herein in ways that can inform public health policy.
Are the scaling patterns significantly superlinear?
The results show that, as expected, MSA population size is a good predictor of incidence
for all three diseases. However, we are not only interested in whether population size is a
good predictor of disease burden, but more importantly, we want to assess, in the statistical
sense, whether in fact the scaling parameter α for each disease is significantly larger than
one.
The null hypothesis for each disease is H0 : α ≤ 1, with alternative Ha : α > 1. We use
the one-sided t-test to check whether or not the null can be rejected. The t statistic in this
case is given by
t∗ =
α̂−1
ŜE
(2.9)
where α̂ and ŜE are the estimated regression coefficient and its standard error. The p-value
of this test is p = 1−T (t∗,d f ), with T being the cumulative t distribution, and d f = n− p
are the degrees of freedom of the t distribution.
For the case of chlamydia, α̂C = 1.0450, ŜEC = 0.0189 and d f = 364−2 = 362. The
p-value in this case is pC = 0.009 < 0.01. Thus, we can reject the hypothesis that αC ≤ 1.
In the case of gonorrhea and syphilis we obtain respectively pG < 0.01 and pS  0.01.
These results indicate that scaling exponents are significantly greater than one, providing
statistical evidence suggesting that all three diseases feature superlinear scaling. Put dif-
ferently, these findings indicate that as the population size of MSAs increases so does the
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per-capita burden of these STDs. Thus, larger urban areas seem to be conducive of in-
creased per-capita levels of sexually transmitted infections.
Quantitative interpretation of scaling exponents
It is easy to show from (2.6) that differentiating the expected value of Y with respect to
population size yields
dE[Y | log(N)]
dN
=
α∗
N ln(10)
E[Y | log(N)] = α
N
E[Y | log(N)], (2.10)
which implies, simplifying the notation, that
dE[Y ]
E[Y ]
= α
dN
N
. (2.11)
More specifically, for the case of chlamydia, if we change population size by one per-
cent, the expected number of new chlamydia infections will change by αC = 1.05% with
95% confidence interval [1.01, 1.08], holding everything else constant. For gonorrhea and
syphilis, a 1% change in population size will be related to a 1.10% [1.02, 1.18] and 1.29%
[1.19, 1.39] change in the expected cases of gonorrhea and syphilis, respectively.
Scaling Properties of STDs at different units of analysis
Are the STD scaling patterns different at different scales of aggregation? To answer this
we compare the results of the negative binomial regression analysis at the MSA level of
analysis, with those obtained for the 48 contiguous states and for the rural (non MSA)
counties as the units of analysis. Results are shown in Table 2.3.
The results at alternative levels of analysis are not strikingly different from the ones
obtained using MSAs as the unit of analysis, but some differences are interesting. For
instance, the scaling at the Rural Counties level yields scaling patterns of STD incidence
that are significantly more superlinear than the case of MSAs or States levels (both of
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Table 2.3: Scaling results at different units of analysis using Negative Binomial fit with
model (2.6).
Chlamydia Gonorrhea Syphilis
Unit of Analysis α̂ (SE) α̂ (SE) α̂ (SE)
MSAs 1.045 (0.019) 1.1 (0.040) 1.294(0.051)
Rural Counties 1.186 (0.016) 1.329 (0.028) 1.305 (0.048)
States 0.994 (0.046) 1.137 (0.104) 1.123 (0.122)
which are more similar, in a statistical sense). This evidence suggest that, although STD
rates in cities increase with population size, these rates increase at an even faster pace in
rural areas. If this is indeed the case, population size in urban areas are less associated with
an increase in the transmission of STDs than in rural areas.
This apparent benefit of living in cities– in the sense that population size has less of a
negative impact on STD transmission– is counteracted by the fact that STD rates in urban
areas are consistently higher than in non urban areas, as Figure 2.12 shows.
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Figure 2.12: Comparison of STD rates (cases per 105) at different units of analysis: MSAs, rural
(non MSA) counties and States. The value on top of each boxplot are, respectively, the weighted
man and standard error, weighted by population size.
2.4.3 The impact of socio-economic variables on the scaling properties of STDs
In this section we further investigate the issue of scaling properties of STD cases by
categorizing MSAs based on certain economic and demographic indicators. Accounting
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for these indicators will enhance not only the explanatory power of the model, but also
our understanding of the key urban features that drive the infection patterns. In contrast
from previous models on socio-economic inequality and health disparities where the unit
of analysis were states Semaan et al. (2007); Crosby et al. (2003) or countries Pickett and
Wilkinson (2009); Wilkinson and Pickett (2006), our approach is new in that it focuses
instead on MSAs.
To recall, the six covariates explored, other than population size of MSAs, are: 1)
percent poor, 2) percent black, 3) Gini index, 4) education index, 5) income per-capita,
6) percent insured. Noteworthy, we also analyzed covariates such as medium household
income, income index and migration rates, but these did not add significant explanatory
power to the analysis.
Defining MSA classes based on quantiles of each covariate
Do the scaling features of STDs with population size of MSAs depend on what “type”
of MSAs we focus on? For instance, are the scaling properties of MSAs presenting higher
levels of income disparities different from that of MSAs showing less income disparity? To
address this question, let us categorize MSAs into different classes based on their respective
level for a given characteristic (i.e., covariate), say, Gini coefficient. We can then test
whether the scaling exponent α and the intercept Y0 will vary across these classes of MSAs.
For each covariate of interest, all MSAs are categorized into 10 different classes or
quantiles, i.e., 1-10%,11-20%... ,91-100%. For example, all MSAs whose Gini coefficient
is within the 1-10% quantile of the Gini Index distribution, is placed in class c = 1, and so
on. Then, 10 different regressions are performed to each of these MSA classes. That is, for
each class c, with c= {1,2...10}, the scaling exponent αc and the intercept Y0c are obtained
from a negative binomial regression of the model in (2.1):
E[Yic|Nic] = Y0c(Nic)αc (2.12)
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where Yic is the number of cases in MSA “i” which belongs to class c, and Nic the population
of that MSA. The ten estimates for the scaling exponents and intercepts can be stored in
two vectors, namely α̂c and Ŷ0c.
For each quantile of a given covariate ν j, j = 1,2...6, we find the average of that co-
variate within each of the quantiles. This will yield a vector of size ten, namely ν¯ jc, with
an entry for each of the ten classes c.
To assess whether the scaling features change across MSA classes defined by the quan-
tiles of covariate ν j, once the ten regressions for this covariate are performed and the vector
ν¯ jc has been determined, we linearly regress the models
α̂c = σ0α +σα ν¯ jc and Ŷ0c = σ0Y0 +σY0 ν¯ jc (2.13)
using weighted OLS with weights given by 1/SE for each α̂c and Ŷ0c. Therefore, testing
whether the scaling features change across MSA classes is equivalent to testing whether
the slope of these regressions are significantly different from zero. Let these slopes for the
exponents and intercepts be, respectively, σα and σY0 .
For each disease, the results for the six covariates of interest are given, in Figure 2.13
(only for the case of σα ) and more extensively in Table 2.4. The results from a similar anal-
ysis using the alternative regression procedures to obtain the vectors α̂c and Ŷ0c are shown
in the Appendix Tables A.3, A.4 and A.5. As before, the negative binomial approach yields
the most conservative results. Under this regression scheme, only the % Black covariate is
found to significantly affect the scaling properties (as suggested by small p values), whereas
for the other schemes the Gini covariate is also found to considerably change the scaling
patterns.
Effect size, that is, the magnitude and relative importance of an effect, is as impor-
tant as the significance level of the corresponding estimate. Put differently, the important
question is not only whether the effect is significant or not, but whether it is of practical
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Figure 2.13: Scaling exponents for each quan-
tile. Purple line represents the regression line
obtained from regressing the vector of α̂c and
the vector of the average of the covariate ν¯c in
each quantile, using model in (2.13).
relevance Nuzzo (2014). If we focus on the sign of σα and σY0 for both % black and Gini,
we find that, since σα < 0, for MSAs that belong to classes with a higher percentage of
black people and larger income disparities, the scaling exponent is smaller compared to
the corresponding exponents in MSAs with a reduced fraction of blacks and more income
equality. Complementarily, we also observe that since σY0 < 0, for MSAs that belong to
classes with a higher percentage of black people and larger income disparities, the intercept
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Table 2.4: Regression estimates and corresponding p-values using models in (2.13). We
have highlighted in red the variable that significantly affects the scaling (p-value ≤ 0.01).
Chlamydia Gonorrhea Syphilis
Covariates σα {p} σY0 {p} σα {p} σY0 {p} σα {p} σY0 {p}
%Poor 0.001 {0.93} 0.015 {0.73} -0.01 {0.61} 0.10 {0.33} -0.04 {0.11} 0.28 {0.05}
% Black -0.003 {0.04} 0.03 {0.01} -0.003 {0.21} 0.04 {0.04} -0.015 {0.01} 0.11 {0.004}
Gini -1.63 {0.12} 10.9 {0.08} -4.1 {0.19} 26.3 {0.15} -5.9 {0.12} 41.8 {0.07}
Education -0.01 {0.63} 0.03 {0.84} 0.06 {0.5} -0.42 {0.4} 0.04 {0.7} -0.3 {0.54}
P. Income 0 {0.34} 0 {0.6} 0 {0.82} 0 {0.88} 0 {0.84} 0 {0.97}
Insured 0.006 {0.06} -0.037 {0.04} 0.008 {0.16} -0.06 {0.13} 0.013 {0.12} -0.1 {0.08}
is larger compared to those corresponding intercepts in MSAs with a reduced fraction of
blacks and more income equality.
In combination, these observations suggest that: 1) the relative effect of population size
on the number of STD cases is lower in MSAs with a high percentage of black people
and larger income disparities, and 2) these MSAs also have larger rates of STDs in the
less populated MSAs. In fact, a closer inspection of Figure 2.13 reveals that for MSAs
with low percentage of blacks and low income inequality, the scaling pattern is superlinear
(e.g., max(αc) ∼ 1.7 for syphilis), whereas for MSAs belonging to high percentage of
blacks and low income inequality classes, the scaling is sublinear (e.g., min(αc) ∼ 0.87
for syphilis, a 50% decrease). Put more concretely, the sublinear scaling suggests that, on
average, for cities belonging to a class of high percentage of blacks and/or high levels of
income inequalities, highly populated areas have lower rates of STDs than less populated
areas within that same class.
To make this idea more tangible, in Figure 2.14, we have selected the MSAs belonging
to the lowest quintile (20th percentile) (blue) and the highest quintile (gray), based on %
Black (top panel) and Gini (low panel). MSAs within the class with the highest percent
of blacks or highest income inequality show sublinear scaling (except for syphilis in the
Gini case). This sublinear scaling pattern suggests that, the most populated urban areas
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that belong to this class of MSA suffer from lower rates of STDs as compared with the
less populated areas. Thus, the process of urbanization (i.e., increasing population) in this
type of cities could have a positive impact in terms of reducing the per-capita prevalence of
STDs.
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
5
6
L o
g  
C a
s e
s  
p e
r  M
S A
Log MSA Population
Chlamydia
α^sub = 0.942(0.0258)
α^super = 1.03(0.0589)
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
5
Log MSA Population
Gonorrhea
α^sub = 0.912(0.0356)
α^super = 1.138(0.111)
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
Log MSA Population
Syphilis
α^sub = 0.97(0.0796)
α^super = 1.592(0.1652)
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
5
6
L o
g  
C a
s e
s  
p e
r  M
S A
Log MSA Population
Chlamydia
α^sub = 0.966(0.0411)
α^super = 1.131(0.0629)
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
5
Log MSA Population
Gonorrhea
α^sub = 0.93(0.0807)
α^super = 1.211(0.1271)
4.5 5 5.5 6 6.5 7 7.5
0
1
2
3
4
Log MSA Population
Syphilis
α^sub = 1.118(0.0993)
α^super = 1.453(0.1135)
Figure 2.14: Sublinear scaling versus superlinear scaling in different classes of MSAs. MSAs
belong to either the lowest quintile (%20 percentile) (blue) or the highest quintile (gray) of % Black
(top panel) and Gini (low panel).
At first glance, these observations seem paradoxical. But, as we will see in the next
section, % Black and Gini are correlated with one another, and also with poverty levels,
low educational index and low medical coverage. All of these factors exacerbate the risk
factors associated with STD infection and hence, their incidence rates. Our main claim is
that population size of urban centers is just one aspect associated with the transmissibility
of STDs, and that its marginal impact depends on the socio-economic contexts of urban
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areas, becoming more important in areas with low intrinsic transmissibility risk, i.e., areas
with higher aggregated socio-economic status.
The scaling properties of African-Americans in cities
The % Black appears to be the covariate most significantly affecting the scaling features of
STD cases within MSAs. This finding raises the question: what are the scaling properties
of the number of blacks in cities?
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Figure 2.15: (left) Scaling features of the number of blacks in all MSAs, and (right) in different
classes of MSAs based on the percent black that resides in them (belonging to either the lowest
quintile, i.e., lowest %20 percentile (blue) or the highest quintile (gray) of % Black. For comparison
purposes, we note that the scaling pattern of ‘whites’ is sublinear, with α̂ = 0.911, SE=0.014. These
results are also obtained using the same Negative Binomial model structure as in (2.6).
Figure 2.15 shows that the scaling of blacks in MSA populations is, in general, su-
perlinear, but that when MSAs are divided into different classes based on the percent of
the residents that are African-American, their scaling is significantly different. As we will
show in the next section, the % Black covariate is an excellent predictor of STD rates,
specially gonorrhea case rates in MSAs (and also in the general population). Notice in
Figure 2.15 (right panel), how the scaling features of the number of blacks are in excellent
agreement with those found in gonorrhea in Figure 2.14 (top middle panel).
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This finding suggests that one of the features of urbanization in the U.S. is an increased
percentage of African-American residents in larger cities, resulting in superlinear scaling
patterns of STDs that are largely determined by the population’s racial composition.
2.4.4 The impact of socio-economic covariates on Disease Rates
In the previous section, the scaling features of STD cases with MSA population size
were studied, concluding that population size is an excellent predictor of STD cases, and
also, arguably more interestingly, that STD cases scale superlinearly with population size.
However, the effect size of this superscaling was found to be relatively small in the case
of chlamydia and, arguably, gonorrhea. We also determined what socio-economic aspects
affect these scaling characteristics, realizing that % Black and, arguably, Gini Index were
the most significant covariates affecting the scaling properties of STD in cities. Importantly,
we found evidence indicating that the higher the fraction of black residents and the more
unequal economic conditions are in MSAs, the less impactful their population size is on
transmissibility.
Complementing those results, this section will serve to determine what socio-economic
covariates better explain the variability in the transmission of STDs. In an attempt to elim-
inate the effect of population size in the transmission process, we now focus on STD rates
rather than cases. Rates (namely R) are computed as the number of cases in the MSAs
divided by the MSA population, and then multiplied by 100,000, a standard practice when
calculating STD rates. As in previous studies Semaan et al. (2007), we use in the regres-
sion analyses a logarithmic transformation of the rates to accommodate the assumption of
normally distributed errors, and also a logarithmic transformation of % Black to satisfy the
assumption of linearity between this variable and the dependent variables, as indicated by
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diagnostic tests in Figure A.9. As a result, the proposed statistical model is
log(Rd|~ν) =C0+
6
∑
j 6=2
Ci×ν j +C2× logν2 (2.14)
where the log function relates the expected mean of the rates with the linear regressor. In
this model, ~ν j represents a vector containing each of the six covariates, that is, percent
poor ( j = 1), percent black ( j = 2), Gini index ( j = 3), education index ( j = 4), income
per-capita ( j = 5) and percent insured ( j = 6).
The fact that logarithmically transforming the rates and the percent black allowed for
the model to be consistent with the OLS assumptions resulted interesting to us. At first
glance, this hints for another scaling law relation between the rates and the percent black:
R∼ ναν22 . (2.15)
We decided to explore this claim further and found that in fact, the log of percent black
explained a significant amount of the variance in the log of STD rates, especially gonorrhea.
Table 2.5 shows the results using model (2.15) within the OLS regression framework. In
the three cases, the scaling is sublinear, implying that a percent increase in the percent of
blacks in the population will be associated, on average, with an increase of less than 1% in
the rates (see expression 2.11). Also, for the three STDs, the amount of variance explained
by the percent black in the population is considerably large. We consider that these findings
are interesting on its own and deserve further attention.
Table 2.5: Scaling analysis of STD rates and % Black using model (2.15) within the OLS
regression framework.
Disease Estimates α̂ν2 (SE) Adjusted R
2
Chlamydia 0.24 (0.01) 0.45
Gonorrhea 0.74 (0.02) 0.75
Syphilis 0.60 (0.036) 0.44
The issue of multicollinearity
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Before regressing the model 2.14, we first explore the issue of multicollinearity. Mul-
ticollinearity is present when some of the explanatory variables are not independent, but
instead correlated. If multicollinearity is present, the regression coefficients become im-
precise, in the sense that it becomes difficult to assign the change in the dependent variable
precisely to one or the other of the explanatory variables Kutner et al. (2005). Therefore
our analysis should start with the estimation of the correlation coefficients between all the
variables to be included in the model. One can check for multicollinearity by means of the
correlation matrix. In such matrix, if the correlation coefficient between two explanatory
variables is above 0.8 one needs to be aware of possible collinearity.
In addition to addressing the issue of multicollinearity, this bivariate analysis allows
us to examine the (Spearman) correlations between the predictor variables, helping our
understanding of the interrelations between these covariates.
We added a new covariate of potential interest in the process of spread of STDs: popu-
lation density. Population density is, in general, an enhancer of social interactions among
individuals, and arguably, could also modify social norms and behaviors associated with
infection risk. Thus, population density could play an important role in how certain dis-
eases spread, especially those that require close proximity for transmission events to occur,
such as STDs and diseases carried by airborne pathogens.
The results are given in Figure 2.16. Note that population size of MSAs is strongly
correlated with population density (corr = 0.84 ). In fact, we find that population density
is a good predictor of the number of STD cases in MSAs, but in all three cases, population
size significantly outperforms population density in terms of the amount of variability it
explained. Thus, given its redundancy and less strong predictive power, we decided to drop
the covariate population density from our analysis.
In terms of collinearities among the socio-economic covariates, as expected, MSAs
with higher levels of poverty are the ones where individuals make, on average, less money
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(corr = −0.71). Also, correlated with poorer MSAs are those with lower education index
(corr =−0.31), and lower medical insurance coverage (corr =−0.56).
A covariate of great importance in this study given the findings in the previous section,
% Black in MSAs, is associated with higher levels of poverty (corr = 0.25) and more in-
come inequality (corr = 0.26). Gini, as a proxy of economic inequalities, is also important
in this analysis, and we find that more economically unequal MSAs are associated with
those with higher poverty rates (corr =−0.51), MSAs with a higher percentage of blacks
(corr = 0.26) and lower medical insurance (corr =−0.41).
Two other interesting yet unsurprising associations are urban areas with higher edu-
cation index and areas with higher income per-capita (corr = 0.65) and medical cover-
age (corr = 0.51). All of these correlations are statistically significant (df=362, p value
< 0.001, testing the null hypothesis that the observed value comes from a sample in which
corr = 0).
In short, this correlation matrix describes a picture in which most covariates expected
to be associated with transmissibility of STDs, are also intertwined among themselves,
making it difficult to determine their individual effect on the spread of STDs. In addition,
MSAs with higher levels of income inequality and percentage of blacks, also suffer, on
average, from higher poverty rates and lower medical coverage. Both these aspects limit
accessibility to health care facilities, medication and preventive care.
What socio-economic covariates are more important in the transmission of STDs?
Here we consider the general regression model (2.14) in which all of the six indicator
covariates are considered. To account for the issue of multicolinearity we use the stepAIC
algorithm (a primitive of R, using ‘both’ forward and backward selection) to determine
the most parsimonious model that better explains the incidence variability. This model
selection procedure starts with the model including all explanatory variables and uses the
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Figure 2.16: Correlation matrix of covariates used in the factor regression analysis. For 364
observations (362 degrees of freedom), any correlation whose absolute value is greater than 0.1 is
significant, with p-value less than 0.05.
AIC (Akaike Information Criterion) to exclude some of the covariates. For this criteria, the
preferred model is the one with the minimum AIC value. AIC not only rewards goodness
of fit, but also includes a penalty that is an increasing function of the number of estimated
parameters Kutner et al. (2005).
The results are given, for each disease, in Tables 2.6, 2.7 and 2.8. In all cases, the
covariates selected by the stepwise algorithm explain a considerable fraction of the vari-
ability. Tables 2.6, 2.7 and 2.8 show that % Black and % Poor are present in all models,
while Gini is only significant in the chlamydia model. The % Black is also the most signif-
icant covariate, sensu the magnitude of its estimation divided by its standard error, leading
to the smallest p value in the estimation. Moreover, comparing the adjusted R2 in Table
2.5 with the ones obtained here, it is easy to conclude that the % Black covariate explains
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most of the variation in the data for all three diseases. Interestingly, this same covariate is
the one that seems to affect more significantly the scaling features of diseases cases with
population size of MSAs.
Table 2.6: Reduced Model, Estimates and Standard Errors obtained from the AIC model
selection criteria applied to the general model in (2.14) for Chlamydia Rates.
Covariates (Coefficient) Estimates (SE)
% Poor (C1) 0.021∗∗∗(0.004)
log % Black (C2) 0.224∗∗∗(0.013)
Gini (C3) −1.03∗∗(0.455)
Education index (C4) −0.023∗∗∗(0.01)
Per-capita income (C5) 0.00001∗∗∗(0)
% Insured (C6) 0.004∗(0.002)
Adjusted R2 0.77
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table 2.7: Reduced Model, Estimates and Standard Errors obtained from the AIC model
selection criteria applied to the general model in (2.14) for Gonorrhea Rates.
Covariates Estimates (SE)
% Poor (C1) 0.013∗∗∗(0.003)
log % Black (C2) 0.722∗∗∗(0.022)
Adjusted R2 0.77
At this point it is worthwhile recalling that in the case of gonorrhea, the scaling patterns
of incidence, as well as the rates, were significantly explained by the scaling of % Black in
urban areas. Notice, however, how this is not the case for chlamydia and syphilis, as the
predictive power of the covariate % Black is much lower for both the scaling patterns and
rates. This indicates that the socio-economic determinants of case incidence for chlamydia
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Table 2.8: Reduced Model, Estimates and Standard Errors obtained from the AIC model
selection criteria applied to the general model in (2.14) for Syphilis Rates.
Covariates Estimates (SE)
% Poor (C1) 0.027∗∗∗(0.006)
log % Black (C2) 0.563∗∗∗(0.033)
Per-capita Income (C5) 0.00004∗∗∗(0)
% Insured (C6) −0.015∗(0.004)
Adjusted R2 0.53
and syphilis may be more complex than for gonorrhea. Tables 2.6, 2.7 and 2.8 show indeed
that in the case of chlamydia and syphilis, more covariates are significant in explaining the
variance, as compared to the case of gonorrhea.
Interpretation of estimates
The interpretation of the covariates estimates when the independent variable has been log-
arithmically transformed is not as simple as in the case of regular OLS regression. To
quantify the effect of a unit change in covariate νk, let R̂k be the resulting expected rate
after increasing νk (with k 6= 2) by one unit. Then
log(R̂k)− log(R̂) = Ĉ0+∑
j 6=k
Ĉiν j +Ĉk(νk +1)−
[
Ĉ0+∑
j 6=k
Ĉiν j +Ĉkνk
]
=Ck. (2.16)
Thus, the Ck represents the expected “logs difference” of the disease rates when νk changes
by one unit. For the case of C2, the coefficient for the % Black covariate, we adopt the in-
terpretation in 2.11:
dE[R]
E[R]
=C2
dν2
ν2
. That is, a percent change in ν2 produces, on average,
a C2 percent change in R.
In terms of effect size of each of the covariates, note that the effect of covariates should
not be compared under the same scale. For instance, a unit increase in Gini (which ranges
from approximately 0.2 to 0.6) is a much higher change relative to a unit change in per-
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capita income (which ranges from approximately 7× 103 to 60× 103). Thus, to extract
more useful information from the regression results, the units of each covariate should be
independently defined (i.e., rescaled). For % Poor, % Black and % Insured, the unit of
analysis would be 1 percentage. For Gini, a unitless quantity, the unit would be 0.1. For
educational index, also a unitless quantity ranging from 0 to 10, it would be 1. Finally, for
per-capita income, the unit would be $1000. As a result, two of the coefficient estimates
Ĉ j need to be rescaled to Ĉ∗j as follows: Ĉ∗3 = 10×Ĉ3, Ĉ∗5 = 10−3×Ĉ5.
% Poor: This covariate was found significant in all models, with increased poverty be-
ing associated with higher rates of STDs. In the case of chlamydia, a percent increase in
the poor population of an urban area is associated with expected logs difference of 0.021
of cases per 105, on average, when all other covariates are held constant; whereas for gon-
orrhea and syphilis, the log cases is expected to increase by 0.013 and 0.027, respectively.
% Black: In the case of chlamydia, a percent increase in the black population of an
urban area is associated with a 0.22 % increase in the cases per 105, on average, when all
other covariates are held constant. For gonorrhea and syphilis, the effect is even higher in
comparison, with an average increase of 0.72% and 0.56% in the cases per 105, respec-
tively. Notice again that the relative increase for gonorrhea is much larger in comparison.
Gini: This covariate was selected for the chlamydia model only. However, this case
is interesting in the sense that, when Gini is the only regressor in the model, all the es-
timates are significant and positive, suggesting that more income inequality is associated
with elevated levels of STD rates. However, when all other variables are accounted for,
Gini is either not significant or negative, a possible sign of strong colinearity with the other
regressors (e.g., with % Black, corr = 0.26). Thus, we suspend the interpretation of this
covariate.
The other covariates, when significant, explained a small fraction of the variability of
the data, thus any information gained from their analysis should be interpreted with caution.
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A few observations are worth mentioning, though. The first one is that Education Index is
negatively associated with chlamydia rates, suggesting that MSAs that are more educated
on the aggregate, present, on average, lower incidence rates of this STD
Second, % Insured, present in the chlamydia model is positively associated with levels
of disease rates. This seemingly contradictory association could be the result of the asymp-
tomatic nature of this disease. Chlamydia is known as a “silent” disease since most people
who have chlamydia have no symptoms CDC (2014a). Although a considerable fraction
of women with gonorrhea are asymptomatic, as well as some infected men (5-10%) HH
et al. (1974); Hethcote and Yorke (1984) CDC (2014b), the symptomatology of the dis-
ease is more clinically obvious both in men and women 10. Syphilis, on the other extreme,
is usually asymptomatic only in its latent (later) stage. In fact, bivariate analysis show a
negative association between rates and insurance coverage for the cases of gonorrhea and
syphilis. An explanation for these dichotomous findings is the following. Since asymp-
tomatic cases can easily go unnoticed, they are often unreported to the health care system.
This is more likely the case in infected individuals who have limited access to medical care
and are unable to get regularly screened for these infections. As a result, a larger fraction
of the asymptomatic (and also symptomatic) cases will be unreported in places with lower
levels of medical insurance coverage, compared to places with higher coverage. In fact, the
substantial rise in chlamydia case reports (see Figure A.6) is arguably a reflection of the
continued increase in screening efforts for this STD. More specifically, changes in diagnos-
tic methods and improvements in reporting practices enhances the detection of infections,
which in turn contributes to more reported cases, and thus are not solely attributed to an
increase in the actual number of cases. Our finding that % Insured positively correlates
with levels of asymptomatic STD rates supports this claim.
10It is estimated that a large fraction of the prevalence is composed by asymptomatic cases that do not seek
treatment and are therefore responsible for most the infections Hethcote and Yorke (1984).
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Finally, it is interesting to note how the Per-capita Income covariate did not have a
significant effect on the scaling features of STDs across MSAs, nor in disease rates. This
is in line with previous work Wilkinson (1997); Pickett and Wilkinson (2009); Wilkinson
and Pickett (2006) where evidence shows that some health metrics, such as life expectancy,
are more influenced by relative rather than absolute living standards. Similarly, the spread
of STDs is conceivably enhanced based on how different different an individual’s living
conditions are relative to those around them, rather than their actual living conditions. We
further explore this issue in the next chapter.
2.4.5 Scaling Features and Incidence Distribution by Region of the U.S.
In the previous two sections we have presented evidence suggesting that the scaling
properties of STDs in urban areas are context-dependent. In fact, the transmissibility of the
pathogen can differ substantially in different geographies or populations according to the
presence of disease-control infrastructure (e.g., STD prevention campaigns, testing policies
and accessibility) and differing contact patterns determined by aspects such as crowding as
well as population demographic and socioeconomic structure Fisman et al. (2014).
To test this idea, we explore the scaling features of STDs in cities that belong to one
of the four regions of the U.S., as defined by the Census Bureau (see Figure 2.17). These
regions present, in the aggregate, different socio-economic characteristics (see Figure 2.18).
Thus, they represent a suitable framework for testing our main claim that STD scaling
features depend on the socio-economic properties of the cities. Arguably, this analysis
would be akin to one that compares the scaling characteristics of four different countries
that present different socio-economic profiles.
Figure 2.19 presents the most recent trends in the three STDs under study. Note that
in most cases, the incidence rates are on the rise. Clearly, the South region has the highest
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Northeast Midwest South West
Figure 2.17: Regions of the U.S. per Census Bureau definition.
levels of STD incidence, whereas the relative levels of STD incidence in other regions
depends on the disease at hand.
In Figure 2.18 we compare these regions in terms of some socio-economic metrics of
interest. It is noteworthy that, the South region presents the worse scenarios for all these
metrics, with the lowest education, income and health standings, as well as the largest levels
of inequality. Importantly, it also features the highest percentage of African-Americans in
their populations. In contrast, the North East region shows the opposite scenario with the
best education, income and health status, while the levels of inequality are relatively similar
to the other regions.
To examine whether the scaling relationships will vary across regions with relatively
different socio-economic makeup, we performed the regression analysis, this time dividing
MSAs based on the U.S. region they belong to. The results are presented in Table 2.9
(for results using the alternative regression models, see Appendix Tables A.6 – A.8). In
all cases, the explanatory power– as measured by the AIC – of the model increases when
compared to the simpler model that did not include the geographical regions.
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Comparison of Socio−economic Indicators per US Region
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Figure 2.18: Comparison of different socio-economic indicators in the four main US regions.
Figure 2.19: Infection rates (per 100,000) for chlamydia, gonorrhea and syphilis from 2007 to
2011, by U.S. regions. Source: CDC
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Figure 2.20: Scaling of chlamydia.
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Figure 2.21: Distribution of chlamydia rates.
Gonorrhea
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Figure 2.22: Scaling of gonorrhea incidence.
Gonorrhea
Northeast
0 500 1000 1500 20000
. 0
0 0
0
0 .
0 0
1 0
0 .
0 0
2 0
Rates per 105
D
e n
s i
t y
mean=288.54
 std. error=29.07
Midwest
0 500 1000 1500 20000
. 0
0 0
0
0 .
0 0
0 5
0 .
0 0
1 0
0 .
0 0
1 5
Rates per 105
D
e n
s i
t y
mean=540.16
 std. error=34.14
South
0 500 1000 1500 20000
. 0
0 0
0
0 .
0 0
0 4
0 .
0 0
0 8
0 .
0 0
1 2
Rates per 105
D
e n
s i
t y
mean=745.65
 std. error=36.4
West
0 500 1000 1500 20000
. 0
0 0
0
0 .
0 0
1 0
0 .
0 0
2 0
0 .
0 0
3 0
Rates per 105
D
e n
s i
t y
mean=192.54
 std. error=16.61
Figure 2.23: Distribution of gonorrhea rates.
Do the scaling features differ in different U.S. regions?
The null hypothesis of this test is that the scaling exponents are not significantly different.
To assess this we use the z-statistics for each exponent estimate in region r, namely α̂r,
given by
zr =
α̂r− α¯
ŜEr
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Figure 2.24: Scaling of syphilis incidence.
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Figure 2.25: Distribution of syphilis rates.
Table 2.9: Negative Binomial Regression Results by Region
Chlamydia Gonorrhea Syphilis
Regions α̂ (SE) Ŷ0 (SE) α̂ (SE) Ŷ0 (SE) α̂ (SE) Ŷ0 (SE)
Northeast 1.13 ( 0.04 ) -2.58 ( 0.2 ) 1.21 ( 0.08 ) -3.75 ( 0.46 ) 1.34 ( 0.06 ) -6.07 ( 0.37 )
Midwest 1.12 ( 0.03) -2.33 ( 0.17 ) 1.23 ( 0.06 ) -3.54 ( 0.34 ) 1.57 ( 0.07 ) -7.32 ( 0.36 )
West 1.06 ( 0.03 ) -2.07 ( 0.18 ) 1.34 ( 0.06 ) -4.64 ( 0.35 ) 1.6 ( 0.07 ) -7.4 ( 0.39 )
South 1.04 ( 0.03 ) -1.88 ( 0.18 ) 1.08 ( 0.05 ) -2.54 ( 0.28 ) 1.21 ( 0.08 ) -4.72 ( 0.43 )
where α¯ = (1/4)∑4r=1 α̂r is the mean of the estimates. The statistics
X =
4
∑
r=1
(zr)2
follows a χ2 distribution with 3 degrees of freedom Kutner et al. (2005). If the correspond-
ing (one-sided) p-values P[X > χ2(3)] are less than the significance level of 0.01, the null
can be rejected. Using the results in Table 2.9 we obtain, for each disease, the Chi square
statistics and its corresponding p-value: XC = 5.09, pC = 0.165; XG = 11.76 pG < 0.01;
and XS = 20.49, pS 0.001. Thus, we find that for two of the three diseases (gonorrhea
and syphilis), the scaling features of the four regions of the U.S. are significantly different.
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How do the scaling features of U.S. regions depend on their socio-economic contexts?
Motivated by our findings in the previous sections, we ask: is population size less impactful
on STD incidence for the U.S. regions with the worse socio-economic conditions? Further-
more, are STD rates higher in those regions where the population size is less influential?
We find that indeed, the answer to both questions is affirmative. As noticed before, the
South has the worse socio-economic standards. Note that the scaling exponents estimates
(α̂) are always lowest in the South region, whereas the intercept Ŷ0 is always larger for the
South compared to the other regions. This scaling properties indicate that population size
of urban areas in the South is the least impactful in the number of STD cases.
In addition, the South region has the more right-skewed distribution on STD rates (see
Figures 2.21, 2.23 and 2.25). This pattern could be explained by the existence of MSAs
with relatively low populations yet presenting a relatively high number of cases. If this
is correct, then it would imply that in the south, there exists an infection saturation (i.e.,
a relative depletion of the pool of susceptibles) for small cities due to high transmission
rates. In these places, the marginal effect of population size on transmission rates is less
significant than in areas where this saturation effect is not present 11.
2.4.6 Simple epidemic models that generate different scaling behaviors
In this section we show how a simple epidemic model can generate features observed in
the STD data, such as superscaling and different scaling profiles based on risk of infection.
11 In Hethcote and Yorke (1984), the authors observed that the ‘preemption effect’, the fact that an infection
can only occur if one of the interactors is not infected, is the only possible saturation factor, that is, a factor
which limits the prevalence of a disease. They also note that in the ‘core group’, composed of very sexually
active individuals, there is a significant preemption effect. Our results indicate that populations with large
fractions of high-risk individuals and where, as a result, this preemptive factor is present, population size has
less of an impact on the transmissibility of the pathogen.
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This will also serve as a simple illustrative example to help us consolidate the ideas exposed
in the previous sections.
The SIS epidemic model
The SIS model (Susceptible-Infected-Susceptible) is widely used to study the dynam-
ics of many sexually transmitted diseases in homogeneous Keeling and Rohani (2008a);
Castillo-Chavez et al. (1996) and heterogeneously mixed populations, Castillo-Chavez
et al. (1997); Li et al. (2003); Castillo-Chavez et al. (1999), where following pathogen
clearance from the host, due to treatment or immune response, an infectious individual
recovers but is once again susceptible to infection. Therefore, this modeling approach, al-
beit simplistic, could be suitable for explaining the underlying dynamics that can lead to
superlinear scaling patterns observed in data.
In this framework, individuals are classified based on their infectious status as suscep-
tible (S) or infected (I). Individuals become infected at rate β and recover at rate γ , where
1/γ is the expected time a typical individual takes to recover. The transmission rate is
defined as the per-capita contact rate, c, multiplied by the probability a contact with an in-
fectious individual actually leads to an infection, p. That is β = c× p. Intuitively, it is clear
that the number of contacts experienced by a random individual in a population depends on
the size of the population, N, that is, c = c(N); and moreover, arguably c should increase
with population size.
Without making any assumptions about the functionality of β (N) = c(N)× p, and consid-
ering a relatively short modeling time frame we can neglect demographic aspects such as
births and deaths, the system describing the disease dynamics is
dS
dt
= −β (N)SI/N+ γI (2.17)
dI
dt
= β (N)SI/N− γI. (2.18)
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This system has a basic reproductive number Chowell and Brauer (2009) given by
R0(N) = β (N)/γ , and the endemic equilibrium can be found by solving dI/dt = 0, yielding
I∗(N) = N[1−1/R0(N)]. (2.19)
Then, what is the relation of c with N? For small populations, it is often hypothesized
that the number of contacts made by a typical individual grows linearly with the population
size, that is, c ∼ N (mass action). For large populations, however, the number of contacts
made by a typical individual is assumed to be independent of the population size, that is,
c = constant (standard incidence). Implicit in this scheme is that as a person can only have
a finite number of contacts per unit time, the number of contacts reaches– or approximates–
a maximum number, cmax, at a given population size Sattenspiel (2009). Nevertheless, it is
not clear what that population size is and how it depends on the type of disease and host
population structure.
In the simplest case, we can assume that population size is very large, so that c is
constant, and therefore R0(N) = R0. In this scenario, I∗(N) is a linear function of N. That
is, plotting log(I∗) versus log(N) yields a line with slope 1, not superscaling.
At this point it seems appropriate to make a clarifying comment. The data we are
working with are new cases of STD, that is, it is measuring the incidence, namely Inc.
The simple model proposed herein is tracking disease prevalence, namely I. These two
quantities are different in general. The expression that relates them in this model is
Inc(τ1,τ2) =
∫ τ2
τ1
βS(t)
I(t)
N
dt =
∫ τ2
τ1
(
dI
dt
+ γI(t)
)
dt, (2.20)
where τ1 and τ2,τ2 ≥ τ1, are two given times. At equilibrium dIdt = 0 and I(t) = I
∗ (con-
stant). Therefore, expression (2.20) becomes Inc(τ1,τ2) = γ(τ2−τ1)I∗. That is, if the time
interval is fixed, the two magnitudes are related by a constant. Hence, if we assume that the
system under study has reached its equilibrium (a somewhat fair assumption for the STD
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data, at least within a one year period), then the scaling properties of prevalence and inci-
dence will be identical. As a result, any findings in terms of prevalence (as in the model)
can be transferred to incidence (as in the data).
Different types of cities, different scaling profiles
Suppose there are two types of cities, type A and type B. These two types of cities can
have a diversity of population sizes. In addition, suppose type A cities have worse socio-
economic (S-E) status than type B. Based on our findings and previous work, we can safely
assume that worse socio-economic status is positively associated with higher risk of STD
transmission. Let us then suppose that the S-E context affects the probability, p, that a
contact with an infectious individual actually leads to an infection. Thus, type A cities have
a probability pA, and type B have pB, with pA > pB.
Regardless of the type of city, we also assume that larger population sizes enable more
human interactions Bettencourt and West (2011), and therefore increase the (sexual) con-
tact rate among individuals. In fact, let us propose that the contact rate, c(N), is a function
of population size N, described by
c(N) = bNa (2.21)
where a and b and positive constants, and they are the same for both types of cities (in the
Appendix we explore other functionalities for c(N), see Figure A.10). That is, the marginal
effect of population size in increasing the contact rate is independent of city type.
Therefore, the expression of the transmission rate, β = c× p, has one component which
is affected by population size, i.e., c, and one that is affected by the S-E context, i.e., p. It
is also clear, however, that the S-E context can affect the recovery rate parameter γ . For
instance, higher income is associated with better access to health care and treatment, both
of which are critical in determining the speed of recovery. In fact, improved S-E conditions
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will reduce 1/γ . Thus, better S-E conditions will both decrease p and 1/γ , albeit in different
ways. Aiming for simplicity and clarity, we can construct a new parameter ω = p/γ , which
will be a decreasing function of S-E conditions.
Substituting expression (2.21) into I∗ in expression (2.19) yields
I∗(p,N) = N
[
1− 1
ωbNa
]
.
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Figure 2.26: Disease prevalence versus population size, in type A cities (blue), type B cities (gray),
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Figure 2.26 shows the plot of the two curves corresponding to the two types of cities,
that is, I∗(pA,N) (gray) and I∗(pB,N) (blue). The city with the better S-E conditions (blue)
has a higher slope and lower intercept than that of the city with worse conditions (gray), as
already shown in the data. The phenomenon of saturation is also clear in this figure. Notice
how the gray curve (worse S-E) has a slope slightly greater than 1. This implies that, even
though population size has the same marginal effect on transmission rates, in cities with
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worse S-E situations population size has less of an effective impact than cities with better
S-E conditions, and moreover, population size has almost no effective impact on disease
rates, i.e., I∗(N)/N is approximately constant across populations.
MSAs for which the scaling exponent is less than one could indicate that S-E condi-
tions improve as population size increases, outmatching the negative effect that population
size has on transmissibility. This can be shown with this simple model by making ω a de-
creasing function of N. In fact, if ω(N) is such that ω(N)Na = 1, then the scaling is linear
(log(I∗) = log(N)(1−1/b)). We then propose ω(N) = bωNaω , with aω < 0. To determine
the values of bω and aω , it is assumed that ω(Nmax) = ωmin and ω(Nmin) = ωmax, where
ωmax > ωmin and Nmax > Nmin. As a result,
aω =
log(ωmin/ωmax)
log(Nmax/Nmin)
and bω = ωmax/Naωmin.
The red curve in Figure 2.26 shows that indeed, when S-E conditions improve with
population size (in the same functional form as population size increases interactions), we
obtain a sublinear scaling behavior. Since the data shows a sublinear scaling pattern in the
South region, the argument that S-E conditions improve with population size can explain,
at least partially, the South region pattern.
In short, by assuming that the contact rates increase with population size as a power
law, and that population size is also related to the S-E conditions through a power law, this
model offers a possible explanation for the different scaling patterns observed in the data.
2.5 Discussion
The quantification of certain socio-economical aspects on the spread of STDs in cities
may offer venues to better confront its challenges. The sustainability of an STD in a host
population can be characterized by its reproductive number, which is in turn determined
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by three factors: 1) the infectivity of the pathogen, partly driven by individual behavior
(e.g., frequency of condom and/or drug use) and partly by the nature of the pathogen itself
(e.g., virulence); 2) the rate of sexual partner exchange and the aggregate risk behavior
in the pool of potential sexual partners (e.g., concurrency and disease prevalence); and 3)
the duration of infection (often affected by access to health care services). These factors
are modifiable through interventions efforts. However, to determine successful ways of
deploying these efforts, one must first identify and quantify, within the social and physical
environment, the most prominent elements driving the spread of the disease; such that “if
the major determinants of health are social, so must be the remedies” DiClemente et al.
(2005).
In this chapter we have shown that annual incidence of chlamydia, gonorrhea and
syphilis across U.S. metropolitan areas follow a superlinear scaling pattern, indicating
that the rates of STDs grow with the population size of MSAs. Put differently, living in
larger urban areas increases the likelihood of becoming infected with any of these STDs.
This is an unfortunate finding given the current and expected increase in the fraction of the
population living in urban areas, especially in developing countries. We also showed, how-
ever, that these scaling features vary within MSAs that belong to different socio-economic
classes. MSAs that have higher percentages of African-Americans in their populations and
present more income inequalities, show sublinear scaling patterns. This suggests that in
these types of urban areas, population size has a reduced effective impact (or association)
on the transmission dynamics. Insights from a simple mathematical model indicate that
such sublinear patterns can be the result of MSAs, which present socio-economic condi-
tions that are more favorable for the spread of STDs, actually improving these conditions
as their population sizes grow.
In combination, these observations lead to an important insight: the ingredient of larger
populations (as a potential enabler of more interactions) has a smaller effective role on
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transmission rates in places with already high-risk settings due to other factors, such as a
relatively large fraction of the population forming densely connected sexual networks of
individuals with risk-prone behaviors, in addition to limited access to health care services
and population-wide income inequality, that is, populations with a large ‘core group’ Het-
hcote and Yorke (1984). Arguably the high levels of inequalities in these urban areas aid in
the formation and maintenance of social barriers that frame these relatively isolated sexual
networks. In contrast, the negative role of population size becomes more important in areas
with low intrinsic transmissibility, i.e., areas with higher aggregated socio-economic status.
It seems to be a feature of urbanization in the U.S. that the percentage of African-
Americans living in urban areas consistently increases as population size grows, revealing
a superlinear scaling pattern of the African-Americans populations in cities. Furthermore,
our analyses showed that the scaling properties of African-American in cities can be dif-
ferent for MSAs with different racial composition. These discernments, could explain, at
least partially, the different scaling patterns we found in the incidence of STDs, especially
for the case of gonorrhea.
Our findings suggest that the percentage of African-Americans in the population was
the most significant and influential variable affecting the features of the scaling patterns, in
addition to explaining most of the variability in the levels of STD rates in cities. An obvious
reason why MSAs with higher percent of African-American residents are associated with
higher STD rates is because disease rates have remained highest among this demographic
group. In 2010, the gonorrhea rates in blacks were almost 20 times the rates in whites,
while the rates of syphilis and chlamydia among blacks were eight times the rates among
whites cdc (2011). Supporting these results, we found that in terms of regional differences,
the South region, where socio-economic levels are lowest and the percentage of African-
Americans is highest, also show the lowest scaling exponents, while featuring the largest
rates of STDs, as compared to all other regions.
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The issue then becomes: why do blacks suffer from higher prevalence rates of STDs?
Other authors have weighted on this problem Farley (2006); DiClemente et al. (2005);
Marmot (2005), suggesting, for instance, that higher rates of STDs in African-American
adolescents can be traced back to a greater proportion of African-Americans living in geo-
graphic clusters that are characterized by low educational attainment, compromised family
structures and lower socio-economic status DiClemente et al. (2005). Nevertheless, the
issue of high rates of STDs in African-American populations goes beyond socio-economic
indicators, as suggested by recent work (see Farley (2006) and citations therein). Studies
in two cities of the U.S. showed that, even within the same socio-economic strata, blacks
had gonorrhea incidence rates that were 30 times that of whites.
Farley (2006) proposes a socio-historical conceptual model that describes the possible
causal routes that might explain high STD rates in blacks (see Figure 2.27). First, the model
proposes that 1) chronic joblessness leads to both social disorganization and drug market-
ing; 2) that drug marketing increases drug use; 3) that social disorganization and drug
use increases the instability of marriage and other long-term relationships, and thereby
increases the likelihood of casual sex; 4) that drug use and marketing leads to higher incar-
ceration rates, further weakening, in turn, the stability of relationships; and 5) that lack of
access to health care, by allowing STD infections to go untreated, increases the likelihood
of their transmission.
Our own analysis showed that, indeed, the % Black predictor was associated with 1)
poverty rates; 2) living in MSAs with large economic disparities, and, although not so
strongly; 3) less income; 4) less medical insurance coverage; and 5) lower education levels
(see Figure 2.16).
Since rates of incarceration have been associated with rates of gonorrhea and chlamydia
infection Farley (2006), we decided to compile data on imprisonment rates in the U.S. for
2011 Carson and Sabol (2012). Among males– who accounted for 93% of the sentenced
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Figure 2.27: Socio-historical model to explain elevated rates of sexually transmitted diseases in
African-Americans. Modified from Farley (2006).
prison population– black prisoners were generally younger than white prisoners. Of rel-
evance for STD transmission is the fact that about 63% of black prisoners are age 39 or
younger, i.e., individuals are at their sexual peak. In fact, between 6.6% and 7.5% of all
black males in the population ages 25 to 39 were incarcerated. As Figure 2.28 demon-
strates, imprisonment rates were much higher within the black population compared to
hispanic and whites, and in line with the regional patterns found in this study, the rates of
imprisonment in the general population were higher in the South.
Larger imprisonment rates can affect the mixing structure of the general population by
placing a stress on long-term interpersonal relationships, promoting unstable partnerships
and casual sex, which is further enhanced in drug/alcohol users due to their disinhibitory
effects. In addition, individuals in correctional facilities are exposed to an environment
with high infection rates of STDs, and as a result they often carry these diseases over to the
general population, creating a positive feedback loop that allows the maintenance of high
levels of STD prevalence within these populations Farley (2006).
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These observations indicate that a potentially interesting covariate to investigate is the
imprisonment rates per MSAs. We can then study the effects of this covariate on the scaling
properties and rates of STD. For example, we suspect that MSAs with larger rates of im-
prisonment will be positively correlated with STD rates. In fact, this opens new venues for
theoretical approaches to model the effects of imprisonment rates in the population dynam-
ics of STDs in populations composed by two interacting groups: those in prison and those
outside of prison. This perspective could be useful for testing certain hypothesis about the
impact of STD rates and sexual behavior of inmates on the incidence of these diseases in
the general population.
Serial parenting or multiple-partner fertility (MPF), a term that describes women who
have children with multiple parents, can be taken as a proxy for the mixing structure in
the network of sexual partners. A recent study based on a longitudinal survey of American
women Dorius (2011), showed that women with MPF were three times more likely to be
African-American than white. In addition, and quite relevant to the spread of STDs, it was
found that women with MPF 1) spend, on average, about three times as much of their adult
life in poverty compared to those who have children with a single man; 2) spend about 12%
less of their adult life employed; 3) report less educational attainment; and 4) tend to have
more relationship formations and disruptions.
A the limitation of this study, relevant to the applicability of its insights, is the fact that
variables, such as race/ethnicity and age structure of the population, are immutable, that
is, less amenable to public health action. Farley (2006). In fact, any public health policy
action to be taken should be cautious about not further stigmatizing African-American
populations. This limitation means that it is likely that significant racial disparities in STD
rates will continue for some time.
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Figure 2.28: (left) Estimated imprisonment rate of male sentenced prisoners under state and fed-
eral jurisdiction by race and age, December 31, 2011. Data Source: U.S. Department of Justice
Carson and Sabol (2012). (Right) Imprisonment rate per region 2008 Sabol et al. (2010)
Control efforts should still rely on traditional methods of control such as clinical ser-
vices, screening, partner notification, condom distribution, and promotion of safer sex-
ual behaviors. However, the existence of a high-risk groups (i.e., ‘core groups’) suggest
that methods especially designed to identify these groups (particularly within African-
American populations) while targeting these efforts on them, might be a more fruitful way
to prevent infections in from occurring in the first place Hethcote and Yorke (1984). Even
though sexual networks tend to be segregated by race, they are far from entirely separate,
thus policies and interventions that help reduce STDs in African-Americans will also ben-
efit the population as a whole Farley (2006).
From a technical point of view, our findings can be also limited by several factors.
Foremost, the number of cases of the STDs under study herein could have been subject to
biases or inaccurate reporting, especially given the asymptomatic nature of some of these
etiologies (particularly in chlamydia and women infected with gonorrhea). Any systematic
under or over reporting may have influenced the observed scaling patterns and correlations
of these counts with the other socio-economic covariates. This is especially an issue if
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underreporting is not homogeneous across different counties and states (e.g., some states
could have different reporting policies and practices), or if the underreporting is somewhat
tied in to the ethnicity of those infected that were not notified to the health authorities.
These potential problems could significantly bias some of the estimates and scaling pat-
terns we report herein.
Finally, it is worthwhile mentioning that, although not as significantly as the % Black,
the covariate Gini was also found to alter the scaling patterns of STDs (higher levels of
Gini were associated to lower scaling exponents). However, its explanatory power was sig-
nificantly reduced once the % Black covariate was included in the analysis, suggesting that
inequality may not be the driver of higher rates, but just a confounding factor in the rela-
tionship between % Black and the incidence of STDs. This situation is also similar to the
one reported in Semaan et al. (2007), where social capital was found to be a confounding
factor in the state-level association between racial composition and rates of gonorrhea and
syphilis.
In combination with the existing literature, our analyses incline us to conjecture that
several of the socio-economic aspects we observe to affect the patterns of STD incidence
and rates, are probably confounding factors in the actual association between the fraction of
African-Americans in the population and STD incidence. And as reflected above, increas-
ing fractions of African-Americans in larger cities of the U.S. seems to be a key aspect of
urbanization in the U.S., which in turn drives the patterns of STD incidence.
In essence, our message in this study is that population growth could be one of the key
features of urban areas around the world governing the spread of STDs. Larger popula-
tions can be associated with environments that promote an increase in human interactions,
which in consequence can also modify norms and behaviors. It is our impression that it is
still unclear how this population-size effect depends on the nature of the interactions (e.g.,
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sexual, social) and the aggregate characteristics of the population itself. Thus, this study
aimed to quantify the association between urban population sizes and disease transmission,
while identifying important socio-economic aspects that drive these patterns; and to our
knowledge it is the first to take this particular approach. First, we find that STD incidence
features superlinear scaling with the size of urban populations, suggesting that STD rates
are, on average, higher the larger the urban area is. Second, our analyses indicate that these
scaling patterns can significantly differ in populations with an inherent high risk/rate of
transmission as compared to those with lower risks/rates, which is in turn closely related to
the percent African-American in the population. In high-risk urban areas, population size
has less of an effective impact on transmissibility than in lower-risk ones.
The finding that populations (i.e., cities) with different ethnic makeups present different
statistical patterns underscores the importance of heterogeneity in sexual risk behaviors
within different groups in the population. This in turn indicates that, when modeling the
spread of STDs, dividing the population into groups with different risk behaviors (i.e., the
concept of ‘core groups’ where a small fraction of the population causes a large fraction of
the infections due to their high levels of sexual activity and risky behaviors Hethcote and
Yorke (1984); Castillo-Chavez and Huang (2002)) is key for the usefulness of the model in
devising effective disease management strategies.
The study of the population dynamics of STDs is an imperative yet challenging task.
A myriad of factors conflate in the transmission dynamics of these pathogens, including
the growth of cities, mass transportation and international travel, the development and de-
ployment of antimicrobial agents, changes in norms and values that are in part driven by the
constant clash of cultures that the processes of urbanization and globalization, together with
new forms of mass media, bring about Castillo-Chavez and Huang (2002). The statistical
regularities presented in this work are but a small step in deciphering the epidemiological
impact of each of these factors. In fact, we consider that for our findings to have clear
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and direct relevance into public health policy much work is left to be done. For example,
it is still unclear to us what exactly does superlinear scaling, or the fact that the scaling
properties are different for each STD, implies about the transmission dynamics of STDs,
the life history of the pathogens, or the properties of the underlying sexual network (e.g.,
size distribution of ‘core groups’ in the population). All of these are interesting and po-
tentially relevant issues that the present work leaves unanswered. A crucial limitation in
further deepening our interpretation of these statistical associations is the nature of the data
at hand. Due to privacy issues, the data provided to us by the CDC, did not contain any
information regarding the gender, age or race of those infected. As a result we had to rely
on county-level data of these and other covariates to try and infer relevant associations.
Also important is to remark that given the cross-sectional nature of our statistical anal-
ysis, we can only assert and assess association between STD incidence and other socio-
economic covariates. Causality, the ‘holy grail’ of epidemiological studies, given its im-
portance in policy making and clinical study designs, will be hard to establish without
additional information on those infected, as well as a temporal analysis of STD incidence
and its possible socio-economic drivers.
Statistical associations, however, can guide the design of theoretical models that can be
used to test hypothesis regarding underlying mechanisms or processes that gave rise to the
observed patterns, akin to the approach in reverse engineering (or the inductive method).
This knowledge could then be then used to “control” the system. For example, we showed
that if the population mixes and behaves in a homogeneous way, for interesting scaling
patterns to emerge, the parameters of the model need to be related to the population size.
The flip side of this insight is that the presence of super or sublinear scaling patterns are
likely the result of certain heterogeneities in the population (e.g., behavioral, economical,
biological and sexual activity levels) and/or the presence of a non-trivial network of inter-
actions between individuals. Moreover, these heterogeneities can in turn be linked to the
70
population size in complex ways (e.g., population size can change norms and behaviors,
and also the contact structure of sexual the network).
We hope that this study motivates further investigation of scaling patterns in other set-
tings –especially developing countries where urbanization is unfolding at a faster pace–
while also focusing on different pathogens whose mode of transmission is less related to
the socio-economic and racial makeup of the host populations. For example, since we
found that the aspect of urbanization in the U.S. that most affect patterns of STD trans-
mission is the increasing percentage of Africa-americans living in larger cities, it would be
interesting to reveal what aspects of urbanization, in other countries with different racial
makeup, drive these patterns. It would also be informative to examine what are the scaling
patterns of the incidence of airborne transmitted diseases, such as influenza.
This work offers a conceptual basis for studying and quantifying the role of population
size, in combination with socio-economic covariates, in the spread of STDs. We expect
the knowledge gained from this study to complement that obtained using more traditional
frameworks in mathematical and computational epidemiology, unveiling a more complete
and holistic description of ID dynamics in the context of cities. We consider this task to be
of chief importance for society writ large, particularly for developing countries suffering
from large disparities in health care access, where conditions may be favorable for the
large-scale spread of certain IDs.
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Chapter 3
MODELING THE INTERPLAY BETWEEN INEQUALITIES IN HEALTH CARE
ACCESS AND EPIDEMIC OUTCOMES
In a meta-analysis of 155 papers (168 analyses in total), which assessed the associ-
ation between income distribution and population health, a large majority (70%) of the
studies suggested that health outcomes are worse in societies with larger income differ-
ences Wilkinson and Pickett (2006). This issue gathers special importance because, in
many countries, inequalities in health have been increasing Marmot (2005); Pickett and
Wilkinson (2009). In most of these studies, however, the term ‘health’ referred to ‘life ex-
pectancy’, not particularly addressing the case of infectious diseases (IDs). In addition, this
review lacked mechanistic (causal) pathways to explain the statistical findings: “rather than
suggesting any new causal processes... it is more parsimonious to suggest that [income] in-
equality is related to health...[because these two arise through] the same processes... that
are responsible for class differences in health” Wilkinson and Pickett (2006).
These observations raise an interesting question: why is income inequality (measured,
for example, by the Gini index), rather than income per-capita, the factor associated with
worse health outcomes? In fact, the results of the previous chapter support this view. We
found that the Per-capita Income covariate did not have a significant effect on the scaling
features of STDs across MSAs, nor in disease rates, especially compared to the relatively
larger effect of the Gini Index covariate.
Based on country-level analyses, Wilkinson (1997) states that “mortality in developed
countries is affected more by relative than absolute living standards,” suggesting that gra-
dients in health are associated with socioeconomic gradients in the population, while high-
lighting the potential importance of psychosocial pathways in these processes. The author
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goes on to say: “it would be difficult to understand why, despite having a median income
four times as high, life expectancy among black men in the U.S. was nine years shorter
than for men in Costa Rica.” He states, however, that raising the absolute living standards
continues to be of great importance in developing countries.
The fact that low income is found to provide, at best, an incomplete explanation of
differences in mortality among countries Marmot (2005), may be partly an issue of how one
measures income. For instance, many studies of this kind measure gross national product
(GNP) per person as a proxy for income. But ‘income’ is a relative measure since it depends
on the acquisitive power of money, which can vary from country to country. Poverty, on
the other hand, is less of a subjective indicator since the poverty line is defined locally and
therefore applies better to each specific place. This could be a reason why income does not
appears to be an issue.
From a public policy view, this issue is critical because when devising and implement-
ing social policies aimed at relieving poverty, we should ask whether their impact is not
only reflected in increasing average incomes, but also in reducing the variance in the in-
come distribution, for example, by targeting the poorest people Marmot (2005).
From a more mathematical perspective, and focusing on the spread of IDs, the claim
that relative living conditions are more significant than absolute living conditions is simi-
lar to stating that the variance rather than the mean of the relevant metric in the population
(e.g., access to health care, susceptibility to a disease) is the factor that more strongly deter-
mines epidemic outcomes. As a thought experiment, take ‘time from infection to treatment’
as the metric we are measuring in the population, while keeping in mind that social condi-
tions powerfully influence both the onset and response to treatment of the major infectious
diseases Marmot (2005). Why would low mean and variance (that is, a homogeneously
poor population with low access to treatment and health care) be better than higher mean
and variance (that is, a heterogeneous population with both very poor and very rich indi-
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viduals, leading to substantial differences in health care access, but with better access, on
average)?
Marmot has an interesting take on this quandary. He observes that “where material
deprivation is severe, a social gradient in mortality could arise from degrees of absolute
deprivation. In rich countries with low levels of material deprivation the gradient changes
the focus from absolute to relative deprivation” Marmot (2005).
Translating this statement to a mathematical framework would imply that only when the
mean of the relevant metric is relatively high, the variance (inequalities) begins to matter.
We would like to assess the validity of this conjecture through the scope of mathematical
models while testing different mechanistic explanations for the observed patterns in the
data. With this work we intend to reveal a causal link (or lack of thereof) between inequali-
ties and worse health outcomes, which is hard to establish using a cross-sectional statistical
frameworks that at best provide the insight of relevant associations.
3.1 Deterministic Modeling Formulation
We first approach this question is through the construction of a simple SIS-type epi-
demiological model Hethcote and Yorke (1984); Allen (2003); Keeling and Rohani (2008b);
Brauer and Castillo-Chavez (2012), where individuals are categorized based on their re-
spective infectious periods. One group has better access to health care services– sym-
bolized by a larger recovery rate once infected. For the sake of clarity and simplicity of
argument, here we neglect difference in susceptibility, although we recognize its important
role in disease spread. Also for our purposes, the reasons why some people recover faster
than others are not relevant. We do know, however, that the time from infection to treatment
is significantly determined by individual socio-economic aspects such as income, educa-
tion and access to health care services. These aspects are in turn subject to different levels
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of inequalities in the population, reflecting back these inequalities into variables such as
time to receive treatment and therefore, time to recover.
The scenario we model has two homogeneously mixed groups that share a geographic
location (i.e., we are not dealing with a metapopulation model), with different recovery
rates, characterizing health care, economic and education inequalities between the two
populations. In group i, with population Ni, with i ∈ {1,2}, susceptible individuals be-
come infected at a common rate β , but once infected, they recover at different per-capita
rates γ1 and γ2, returning to the susceptible class. Since group ‘1’ people recover at a faster
rate, we assume that γ1 ≥ γ2, and let ∆γ = γ1− γ2. Thus, the levels of inequality between
the two population classes are implicitly represented in this difference in recovery rates.
The larger these are, the larger the extent of inequality.
Within this framework, we would like to understand the effect of ∆γ in the endemic
levels of infectious disease. We also study how disease outcomes change when the ma-
jority of the population recovers faster or vice versa. Understanding how the proportion
of the population that is unhealthy affects disease outcome is important in a world where
many societies are conformed by a healthy (i.e., healthier) minority. And the question of
what would happen if the majority became healthier is of particular interest in order to
understand the benefits of having a healthier population as a whole and better assess the
worthiness of efforts to achieve those social improvements. Thus, we expect this simple
model to yield insights into the epidemiological impact of inequalities in order to aid public
health policy decision making.
3.1.1 The model
Assume there are two types of individuals (or two groups) in the population that mix
homogeneously. Suppose type 1 recovers at rate γ1 and the other type at rate γ2, with γ1 ≥
γ2. Both types of individuals are equally susceptible to the circulating disease, becoming
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infected at a rate proportional to the transmission rate β and the frequency of interactions
with infected individuals from the entire population. Also consider that the population is
closed and no vital dynamics occurs in it, thus we assume N1 +N2 = N is constant, and
for simplicity we set N = 1. Finally, type 1 individuals represent a fraction f of the entire
population, while type 2 represents the complement fraction 1− f .
The SIS model can be completely specified by the equations related to infected stages
only, and it is given by
dI1
dt
= β ( f − I1)(I1+ I2)− γ1I1 (3.1)
dI2
dt
= β [(1− f )− I2](I1+ I2)− γ2I2, (3.2)
with the temporal evolution of susceptibles given by Si(t) = 1− Ii(t), i ∈ {1,2}. Using
the Next Generation Operator algorithm Van den Driessche and Watmough (2002), we can
show that the system has a basic reproduction number given by:
R0 = β
(
f
γ1
+
1− f
γ2
)
(3.3)
The basic reproductive number, defined as the expected number of secondary infectious
cases generated by a typical infectious case in an entirely susceptible population, is crucial
in determining i) the potential for an infectious agent to start an outbreak, ii) the extent of
transmission in the absence of control measures, and iii) our ability of control measures to
reduce spread Lipsitch et al. (2003).
The stability of the disease-free equilibrium (DFE) {I1, I2} = {0,0}, can be character-
ized by the trace and determinant of the matrix of the linearized system at the DFE Strogatz
(1994),
L =
 β f − γ1 β f
β (1− f ) β (1− f )− γ2
 (3.4)
with trace and determinant given by
Tr(L ) = β − γ1− γ2 Det(L ) =−β (1− f )γ1−β f γ2+ γ1γ2 (3.5)
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For the DFE to be locally stable, the trace has to be negative and the determinant positive.
These two conditions yield
Tr(L )< 0 =⇒ β
γ1+ γ2
< 1 Det(L )> 0 =⇒ R0 < 1. (3.6)
The second of these two conditions is stronger given thatR0 >
β
γ1+ γ2
. Thus, we conclude
that the DFE is stable whenR0 < 1.
Conditions for the Existence and Stability of the Endemic Equilibrium
The endemic equilibrium of system (3.2) can be found by simultaneously satisfying
dI1
dt
= 0 and
dI2
dt
= 0. These conditions yield the equilibria I∗1 and I
∗
2 . Now, let λ =
β (I1+ I2). Then I∗1 and I
∗
2 can be written as
I∗1 =
λ f
λ + γ1
I∗2 =
λ (1− f )
λ + γ2
.
Substituting back into the expression for λ yields the following second-degree polynomial
in λ
λ 2−λTr(L )− γ1γ2β (R0−1) = 0,
with solutions given by
λ1,2 =
Tr(L )±
√
((Tr(L ))2+4γ1γ2β (R0−1)
2
Since Tr(L )> 0 =⇒ R0 > 1 (for which λ1 > 0andλ2 < 0) andR0 < 1 =⇒ Tr(L )< 0
(for which λ1,2 < 0), the endemic equilibrium is unique and biologically significant when
R0 > 1. Since the DFE is stable only when R0 < 1, the endemic equilibrium is stable for
R0 > 1.
Inequalities in recovery rates and disease persistence
The simplest setting in which to assess the impact of inequality in recovery rates on disease
outcome is by assuming the average of the rates to be constant and investigate the role of
77
the gap between the ‘healthy’ and the ‘unhealthy’. For this reason, we define two new pa-
rameters: µγ and ∆γ . Let the levels of inequality between the two populations be explicitly
represented by two parameters related to the recovery rates: µγ = (γ1+ γ2)/2 (unweighted
mean) and ∆γ = γ1− γ2 > 0 (difference). Since we intend to focus on the effect of inequal-
ity on disease outcome (i.e., R0 and prevalence), we fix the average and redefine recovery
rates as follows
γ1 = µγ +
∆γ
2
, γ2 = µγ − ∆γ2 . (3.7)
For these expressions to make realistic sense, i.e., γ2 > 0, it is required that µγ −∆γ/2 > 0.
The larger ∆γ , the larger the extent of inequalities, with ∆γ = 0 signifying complete equality
between the groups.
The expression ofR0 can already provide some useful insights into the role of inequal-
ities in recovery rates and the persistence of disease. Using the new terms in (3.7), the
reproduction numberR0 can be rewritten as
R0 = β
[
f
µγ +∆γ/2
+
1− f
µγ −∆γ/2
]
(3.8)
For the rest of this section we will slightly change the nomenclature from ∆γ/2 to
simply ∆. Lets first analyze the case f = 0.5, that is, when exactly half the population
recovers faster than the other half. It is easy to show that R0( f = 0.5) =
βµγ
µ2γ −∆2
, and
since µγ > ∆, increasing ∆ also increases the reproduction number. In other words, when
the population is divided equally between those that recover faster and those that do so
slowly, increasing the levels of recovery-rate inequalities also increases the transmission
potential of the pathogen, leading in turn to larger endemic disease levels.
For the more general case when f ∈ [0,1], we take partial derivatives ofR0 with respect
to ∆ to investigate the role of ∆ in disease persistence, yielding
∂R0
∂∆
= β
(
1− f
(µγ −∆)2 −
f
(µγ +∆)2
)
. (3.9)
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Solving for ∆ from this expression, results in
∆1,2 = µγ
1±2√(1− f ) f
2 f −1 . (3.10)
Since the maximum of
√
(1− f ) f is 0.5, the numerator in always non-negative. Thus, the
sign of these roots is determined by the sign of 2 f − 1. Hence, the roots change sign at
f = 0.5. For f < 0.5, the roots are negative, for f > 0.5 the roots are positive, whereas for
f = 0.5 the roots are indeterminate. Only the smaller root (the one with the negative sign in
±) is relevant to us, given that the larger root is always larger than µγ . Thus, to determine
the nature of the fixed point ∆2 , we have to know the sign of the second derivative of R0
with respect to ∆ evaluated at ∆2 . We find that
∂ 2R0
∂∆2
(∆ = ∆2) =
β (1−2 f )4F2 (2F−1)
4µγ (2F2−F)3
=
β (1−2 f )4 (−2F +1)
4µγF (−2F +1)3
,
where we have defined, for tractability purposes, F =
√
f (1− f )≥ 0. All the terms in the
last expression above are positive. Therefore, ∂
2R0
∂∆2 (∆ = ∆2) is positive, and ∆2 is a local
minimum.
We can then conclude that in the neighborhood of ∆2 , when ∆ < ∆2 , the reproduction
number R0 decreases with ∆, whereas when ∆ > ∆2 , R0 increases with ∆. Recalling that
f < 0.5 implies that ∆2 < 0, and as a resultR0 increases with ∆, and since f > 0.5 implies
that ∆2 > 0, thenR0 decreases with ∆ when ∆ ∈ [0,∆2) and increases when ∆ ∈ (∆2 ,µγ).
Figure 3.1 depicts what we have learned from this analysis. We can conclude that when
the majority of the population recovers at a slower pace ( f ≤ 0.5, red and blue), increasing
inequality levels always increases the basic reproduction number of the disease. In contrast,
when most individuals recover at faster rates ( f > 0.5), then larger inequality levels could
be detrimental to the disease’s transmission potential only for relatively small levels of
inequality (small ∆γ ), but it could benefit the disease for larger inequality levels.
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Figure 3.1: Reproduction number as a function of inequalities, for different populations structures:
f = 0.1 (red), f = 0.5 (blue) and f = 0.9 (black). Other parameters: β = 0.3, µγ = 1/7.
Through this simple approach, we would also like to understand the role of the mean
of the recovery rates, namely µγ , in the impact of inequalities on epidemic persistence and
size. In other words, we would like to know when do inequalities matter most?
Expression (3.10) indicates that, when ∆2 > 0, as µγ increases so does ∆2, thus enlarg-
ing the range (0,∆2) in which the reproduction number decreases with larger inequalities.
More generally, from Figure 3.2 we can infer that the smaller µγ , the more impactful it is
any change in ∆ on R0. In other words, the slower individuals recover, on average, the
more impactful are any changes in inequalities between the two groups on the transmission
potential of the disease. As noticed before, when the majority recovers slowly ( f < 0.5)
increasing inequalities leads to higher reproduction numbers, whereas if the majority recov-
ers at a larger rate ( f > 0.5), the effect of increasing inequalities depends on the magnitude
of the inequalities themselves: increasing inequalities when these are relatively low will
keep decreasing them, but if inequalities are relatively large, further increasing them can in
fact improve the transmission potential of the pathogen.
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Figure 3.2: Reproduction number as a function of µγ and ∆. Other parameters: β = 0.3 and
f = 0.1 (left) and f = 0.9 (right).
What is the role of inequalities in recovery rates on prevalence levels?
The total fraction infected at the endemic equilibrium, given by I∗T = f I∗1 +(1− f )I∗2 ,
can be written in terms of µγ and ∆γ as
I∗T =
∆γ
(√
(β +∆γ)2−4β∆γ f −2µγ
)
+2(2 f −1)µγ
√
(β +∆γ)2−4β∆γ f
4β∆γ
+
+
β{∆γ [8( f −1) f +3]−4 fµγ +2µγ}+∆2γ(1−2 f )
4β∆γ
. (3.11)
So, how does the extent of inequality in the recovery rates, that is ∆γ , affects the endemic
levels of the disease?
Figure 3.3 shows that, as for the case of R0, the effect of inequalities depends on the
fraction f . For f ≤ 0.5, the case where most individuals recover at smaller rates, increasing
the difference ∆γ– while keeping the mean µγ fixed– also increases the prevalence, whereas
for larger f , increasing ∆ actually reduces the overall prevalence. A rather surprising fea-
ture of Figure 3.3 is that when f ≈ 0.5, that is, when about half of the population recovers
faster, the prevalence is substantially reduced for lower levels of µγ .
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Figure 3.3: Prevalence as a function of µγ and ∆ = ∆γ/2. Other parameters: β = 0.3, f = 0.1
(left), f = 0.5 (center) and f = 0.9 (right).
Analysis in terms of Mean and Variance
The approach taken so far is useful for modeling two groups. More generally, when indi-
viduals form part of G “recovery” groups, one would need G−1 fractions fi, i= {1,G−1},
to fully determine the “recovery” structure of the population. In these cases, quantifying
inequalities in terms of the variance, instead of differences ∆γi between each consecutive
pair of groups, could be more informative and, arguably, easier.
In fact, in the next section we will explore the issue of inequalities and epidemic out-
comes from an agent-based perspective– where each individual is assigned a time to recover
drawn from a particular distribution– and assessing the impact of inequalities employing
the variance of such distribution seems the most conducive approach. Hence, investigating
these issues in the deterministic context in terms of the variance allows to draw fair and
consistent comparisons between the two modeling perspectives.
Formally, the mean (µ) and the variance (ν) of the recovery rates in this two-group
population are given by
µ = f γ1+(1− f )γ2, ν = f (γ1−µ)2+(1− f )(γ2−µ)2
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Isolating γ1 and γ2 from these two expressions yields:
γ1 = µ+
√
(1− f )ν
f
, γ2 = µ−
√
fν
(1− f ) . (3.12)
For the mean and variance to make realistic sense, that is, condition γ2 > 0 must hold,
the variance must satisfy ν < µ2(1− f )/ f = νmax.
Reproduction number in terms of Mean and Variance
Substituting the expressions in (3.12) intoR0 in (3.3) renders
R0 = β
 f
µ+
√
(1− f )ν
f
+
1− f
µ−
√
fν
(1− f )
 . (3.13)
We then ask: What is the effect of increasing the variance ν on R0? To find that out
we computed ∂R0∂ν
1. The equation ∂R0∂ν = 0 has a positive root, namely ν0. To find out
the nature of this fixed point, we need to know the sign of the second partial derivative
evaluated at ν0, which turned out to be quite difficult to analyze. Thus, we employed a
graphical alternative.
Recalling that ν must be smaller than νmax, from extensive graphical examination, we
inferred that the fixed point ν0 is not a local extreme when ν0 < νmax, but an inflection
point, and moreover, ∂R0∂ν > 0 when ν ∈ [0,νmax). Contrarily, when ν0 > νmax, ν0 does
become a local maximum (although this is irrelevant to our analysis).
In conclusion, the graphical method suggests that the derivative is positive for the rel-
evant values of ν , hence, increasing the variance increases the reproduction number of the
disease. Figure 3.4 shows that indeedR0 always increases with ν (whenever it is relevant),
regardless of µ or f , and, furthermore, that when µ is smaller, increasing ν has a larger
1It is prudent to remark that the change in ν(γ1,γ2, f ) in this partial derivative can only be due to changes
in γ1 and γ2, not in f , given that f is held constant in the rest of the expression forR0.
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impact onR0. That is, the variance matters more the slower individuals recover on average.
Figure 3.4: Reproduction number as a function of mean and variance. Other parameters: β =
0.3, f = 0.5.
Prevalence in terms of Mean and Variance
Substituting expressions (3.12) into (3.11) renders the endemic prevalence as a function
of the mean and the variance
I∗T (µ,ν) =
S1S(2 fµ−µ+2S1)−β
{
(1−2 f )µS1−6S21+2ν
}−µν
2βν
, (3.14)
where
S =
√
β 2(1− f ) f +2β (1−2 f )S1+ v
(1− f ) f and S1 =
√
(1− f ) f v.
Figure 3.5 shows that increasing the variance will, as expected, increase the total preva-
lence. Interestingly, however, the impact of the variance on the prevalence seems to be
larger when the mean is higher. That is, when focusing on the prevalence, inequalities mat-
ter more when, on average, individuals recover faster, supporting statements put forward in
Marmot (2005), but contrary to what we found for theR0.
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In Figure 3.5 we can also see the surprising feature already observed in Figure 3.3, that
is, when f ≈ 0.5, the prevalence is substantially reduced for lower levels of µ .
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Figure 3.5: Prevalence as a function of mean and variance. Other parameters: β = 0.3, f = 0.1
(left), f = 0.5 (center) and f = 0.9 (right).
In conclusion, our analyses suggest that larger levels of inequality, as measured by the
variance ν , lead to higher larger reproduction numbers, and accordingly, larger endemic
levels of the disease. Hence, the evidence from this modeling approach support the claims
in Pickett and Wilkinson (2009) that larger inequalities are associated with worse health
outcomes.
Also interesting is that the conclusions derived from the analyses that used the differ-
ence ∆γ to quantify inequalities were slightly different from those obtained when using the
variance ν instead. In the former approach, for large values of f , increasing inequalities
(i.e., ∆γ ) could either increase of decrease the transmission potential of the disease, whereas
in the latter approach, increasing inequalities (i.e., ν) always increased the transmission po-
tential.
Adding Mixing Structure between the groups
An important aspect that has been neglected so far is the mixing between the two types of
populations. We have assumed that both populations mix homogeneously, but this is not
likely to be the case in reality.
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In a study that examined the patterns of sexual mixing in American adolescents Ford
et al. (2002), it was found that relationships with persons of different ethnicity were more
common among Latinos (42%) than among white (14%) and black (15%) respondents.
Similar patterns of partnerships between different ethnicities have been found elsewhere
Ford and Norris (1997). Thus if we assume a population of two groups with different
aggregate socio-economic status, for instance, whites and blacks, then the levels of mixing
between these two groups would not be as high as the homogeneous mixing assumption
dictates.
At this point it is useful to note that, in addition to structural heterogeneities associated
with the contact process (e.g., spatial clustering of contacts), behavioral heterogeneities are
especially important in the spread of STDs Sattenspiel (2009). For instance, infections are
often concentrated in high-risk groups (formed by individuals with large number of part-
ners or with risky sexual behavior), enhancing the likelihood of the persistence of infection
in these groups, while promoting the rapid spread of disease but lower endemic states in
the whole population, as compared to random mixing Garnett and Anderson (1996). In
addition, heterogeneity in susceptibility or sexual behavior can allow for the coexistence of
multiple strains Castillo-Chavez et al. (1997, 1999).
Formulation of mixing pattern
Mixing matrices can be used to describe interactions among groups in mathematical models
that feature heterogeneity in population structure Blower and McLean (1991). Let Ni be
the number of individuals in group i ∈ {1,2}. The entries mi j of the mixing matrix M,
are the fraction of those contacts made by infectious individuals in group j that are with
individuals of group i Sattenspiel (2009). The contact rate between groups is given by
ci j = a jmi j, where a j is the activity level or contact rate of individuals in group j. Since
we are interested in investigating the epidemiological effects of differences in recovery
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times, and not the impact of sexual behavior heterogeneity, in our model we assume that
a j = ai = a, although this is certainly not the case for groups with different sexual behaviors
(see for example Garnett and Anderson (1996)). The columns of matrix M must sum up to
1, that is, mii +m ji = 1, for i ∈ {1,2}. An additional constraint is necessary to ensure the
fact that the number of contacts made by individuals in group i with those of j must equal
the number of contacts made by individuals in group j with those of i. Hence, Nic ji =N jci j.
The model with mixing structure
Assume again two types of individuals (or two groups) in the population. Type 1 individu-
als represent a fraction f of the entire population, while type 2 represents the complement
fraction 1− f , while their respective populations are N1 and N2. Suppose type 1 recov-
ers at rate γ1 and the other type at rate γ2, with γ1 ≥ γ2. Both types of individuals are
equally susceptible to the circulating disease, becoming infected at a rate proportional to
the transmission rate β = a× p (where p is the transmission probability given a contact)
and the frequency of interactions with infected individuals from the entire population. Also
consider that the population is closed and no vital dynamics occurs in it, thus the total pop-
ulation is kept constant, and for simplicity we set to 1.
To include heterogeneous mixing between these groups, lets suppose matrix M, con-
taining the entries mi j as defined above, describes the mixing structure in the population.
Since Ni = Si(t)+ Ii(t), i ∈ {1,2}, the SIS model is fully determined by the equations re-
lated to infected stages only, and it is given by
dI1
dt
= β (N1− I1)
[
m11
I1
N1
+m21
I2
N2
]
− γ1I1 (3.15)
dI2
dt
= β (N2− I2)
[
m12
I1
N1
+m22
I2
N2
]
− γ2I2. (3.16)
The aforementioned constrains in this context are:
m11 = 1−m21, m22 = 1−m12, m12N2 = m21N1.
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These three conditions allow for the mixing matrix to be completely defined by one of the
matrix’s entries, namely, m21, like this:
m11 = 1−m21, m12 = m21 N1N2 , m22 = 1−m21
N1
N2
.
For simplicity, we will refer to m21 as m. Moreover, since N1 +N2 = N = 1, then N1 = f
and N2 = (1− f ), we can rewrite the system of ODEs as
dI1
dt
= β ( f − I1)
[
(1−m) I1
f
+m
I2
(1− f )
]
− γ1I1 (3.17)
dI2
dt
= β [(1− f )− I2]
[(
m
f
(1− f )
)
I1
f
+
(
1−m f
(1− f )
)
I2
(1− f )
]
− γ2I2.
Special cases: The homogeneous mixing framework is obtained from this model by as-
suming that mi j =
Ni
N1+N2
, with j ∈ {1,2}. That is, m = N2
N1+N2
= (1− f ). Complete
assortative mixing, that is, mixing that occurs only with members of an individual’s own
group, yields a scenario in which the two populations are uncoupled and the disease dy-
namics in one group becomes independent of the dynamics in the other group. This case
is achieved by making M an identity matrix, i.e., m = 0. On the other extreme, disas-
sortative mixing (like with unlike), in which those of one group never form relationships
with those of the opposite group, is given by m = 1. Assortativity decreases the epidemic
threshold, having an advantage in low transmission scenarios, but for larger transmissibil-
ity, random mixing has higher prevalence. The reason being that in the assortative case,
the disease remains within a group and does not reach the entire population Garnett and
Anderson (1996). Other types of mixing, such as preferred mixing, used in the study of
AIDS, leads to interesting dynamics such as the existence of multiple endemic equilib-
ria Castillo-Chavez et al. (1989a); while models of proportionate mixing suggest that the
interplay between cross-immunity and age-specific demographics may underlie observed
oscillations in influenza Castillo-Chavez et al. (1989b).
Like in the previous section, we employ the terms ∆γ = γ1 − γ2 > 0, and the (un-
weighted) mean µγ = (γ1 + γ2)/2 to represent the health-related inequalities between the
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two populations. Since we intend to focus on the effect of inequality on disease outcome
(i.e., prevalence), we fix the average and redefine recovery rates as follows,
γ1 = µγ +
∆γ
2
, γ2 = µγ − ∆γ2 .
Within this framework, we would like to understand the effect of ∆γ (inequalities) and
m (mixing) in the endemic levels of infectious disease.
Reproduction Number
The reproduction number of the system with mixing structure was determined using the
Next Generation Operator, and the largest eigenvalue is given by
R0m =
β
(
−B+√B2+4AC
)
2A
with
A = (1− f )γ1γ2, B = γ1( f m+ f −1)+(1− f )γ2(m−1), C = ( f +m−1).
Figure 3.6 helps to better understand the role of different population mixing scenarios
on the reproduction number. In addition, this figure shows how this dependance is in turn
affected by different inequality levels. The first clear observation is that increasing the
mixing reduces the reproduction number. As observed before, larger inequalities increment
the reproduction number (thus the larger R0m in the right panel of Figure 3.6), and when
inequalities are high, the detrimental effect of the mixing between the two groups is more
pronounced. In addition, the larger the fraction of ‘Healthy’ individuals in the population,
also the more influential is the mixing in decreasing the reproduction number.
In summary, mixing always decreases the infection potential of the disease, and more-
over, when inequality levels and the fraction of the population that recovers faster are large,
increasing the mixing between the two populations significantly decreases the transmission
potential of the disease.
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Figure 3.6: Reproduction number as a function of mixing. Other parameters: β = 0.1,γ1 = 0.1,
and ∆γ = 0.01 (left) and ∆γ = 0.05 (right).
A more informative interpretation of the parameter m is as a measure of how assorta-
tive the nature of contacts is, instead of representing the mixing structure of the population.
Thus, higher m values leading to lower reproduction numbers and larger epidemic thresh-
old is the result of contacts being more dissassortative. For large m, individuals that are
infected for longer, mix more often with those that recover faster, diluting the cluster of
more infectious individuals, and hence reducing the transmission potential of the disease,
especially for low transmission rates.
Numerical Integrations
For the numerical integrations, we define disease prevalence as Ii(τ) for i ∈ {1,2} and τ
a large enough time for the system to have reached its endemic equilibrium state (here
τ = 103 days).
In order to explore more comprehensively the role of mixing in the endemic dynamics
of system 3.17, we numerically integrate the system for all possible values of m. In the
following figures we employ the following notation: ‘Unhealthy’ stands for I2, ‘Healthy’
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for I1 and ‘All’ for IT = f I1+(1− f )I2. In these block of simulations the “transmissibility”
of the disease is determined by r0 = β/µγ , where µγ = 1/7.
Healthy majority, f=0.9: Figure 3.7 shows that since the majority of people recover
faster, larger levels of inequalities– that is, the majority of people recovering very fast–
yields smaller levels of prevalence. The lowest levels of prevalence are achieved for larger
values of m, i.e., the case of disassortative mixing, whereas for homogeneous mixing (m =
1− f = 0.1) results in relatively larger endemic levels (notice a peak for m ≈ 0.1 in the
‘Healthy’ panel). This observation is in agreement with what we found in Figure 3.6:
larger m decreases the reproduction number. One possible reason for why disassortative
mixing yields the lowest levels of prevalence is that most of the population belongs to one
category, and this type of mixing pattern would lead to smaller contact rates.
Finally, we note that the overall behavior does not depend on the transmissibility levels.
Unhealthy majority, f=0.1: Figure 3.8 shows that when the majority recovers slowly,
the prevalence levels in this group does not depend strongly on the mixing structure (no-
tice the horizontal contour lines in that panel), and as expected, increase monotonously
with inequalities. However, the overall behavior of the ‘Healthy’ group depends strongly
on the transmissibility levels– notice, though, that the prevalence levels do not change
dramatically, with a maximum level of 5%. Regardless of the transmissibility, the lower
endemic levels are achieved for high inequality and and for low levels of mixing (with
higher mixing levels contributing to more effective transmissibility), contrary to the re-
sults in the case of ‘Healthy’ majority. The maximum prevalence levels correspond to high
levels of mixing, which is expected given the ‘Unhealthy’ majority condition. In terms of
levels of inequality, the worse endemic levels are achieved for high levels of inequality– for
low transmissibility– and lower inequality– for higher transmissibility. The highest levels
of inequality in the ‘Healthy’ group correspond to high transmissibility and disassortative
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Figure 3.7: Disease prevalence in a healthy-dominated population in different mixing scenarios
and different levels of recovery inequality (∆γ ), with r0 = 1.1,1.5 and 2, µγ = 1/7,β = r0×µγ and
τ = 103(days).
mixing, regardless of inequalities.
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Figure 3.8: Disease prevalence in an unhealthy-dominated population in different mixing scenar-
ios and different levels of recovery inequality (∆γ ), with r0 = 1.1,1.5 and 2, µγ = 1/7,β = r0×µγ
and τ = 103(days).
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3.2 Stochastic Modeling Framework
In this section we take an individual-based approach, where instead of having two
groups of individuals characterized by two different recovery rates, each individual is as-
signed an infectious period. The infectious period of each individual is sampled from
distributions with different properties, allowing us to assess how these properties affect
disease outcome.
The empirical evidence supports the claim that larger income inequality is associated
with worse health outcomes Pickett and Wilkinson (2009). Evidence has shown that some
health metrics, such as mortality, are more affected by relative rather than absolute living
standards Wilkinson (1997). Put differently, in terms of health outcomes, how different
your living conditions are compared to those around you is more influential than your
actual living conditions. For example, mortality is more closely related to relative income
within countries than to differences in absolute income between them. That is, mortality is
lower in more egalitarian societies.
Focused on IDs and in a particular inequality profile (that is, symmetric), our model-
ing framework tests a especial case of this broader claim: given that the distribution of
inequalities in the population is symmetric and its mean is fixed, does larger variance (i.e.,
inequality) yields larger levels of disease?
Largely, the findings shown in Pickett and Wilkinson (2009); Wilkinson (1997); Wilkin-
son and Pickett (2006) are statistical correlates between different metric of well being and
health (mostly mortality rates), with little attention dedicated to IDs, and, importantly, a
noticeable lack of causal explanations for these patterns. In the present section we investi-
gate the validity of the claims put forward in Pickett and Wilkinson (2009), while offering a
more mechanistic framework to explore the effects of health-care access inequalities in the
spread of infectious diseases, while testing a possible causal pathway for the associations
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reported in Pickett and Wilkinson (2009) and references therein. We measure these effects
using metrics such as the likelihood of epidemics and the distribution of the prevalence
levels in endemic scenarios, and also the scaling properties of infection rates with popu-
lation size. Thus, we investigate the role of the variance– taken as a proxy for the extent
of inequalities and heterogeneities– in the spread of infectious diseases and their scaling
properties with population size.
Previous findings
Other models have already shown the importance of this individual-based heterogeneity
Lloyd-Smith et al. (2005); Fisman et al. (2014), and the implications for disease dynamics
due to the inclusion of more realistic infectious period distribution Keeling and Grenfell
(1998); Lloyd (2001b,a). For example, in Lloyd (2001a), it was found that for the stochas-
tic version of the model, less dispersed infectious periods destabilize it, leading to larger
stochastic fluctuations around the endemic equilibrium. Also, constant infectious periods
had a destabilizing effect on the global dynamics leading more often to extinction). The
consequences of non realistic or inadequate modeling choices could provide biased results
and hence orient towards inappropriate recommendations.
In Lloyd-Smith et al. (2005), where the authors considered, in the case of SIR-type
framework, three candidate models for the offspring distribution (number of new infections
per infected case), and analyzed how the heterogeneity embodied in these distributions
affected disease outcomes. The authors found that model predictions accounting for the
variability in number of new infections differ significantly from average-based approaches,
with disease extinction more likely and outbreaks rarer but more explosive. implying that
the initial rate of growth of the epidemic in these scenarios is faster than scenarios with less
variation. Furthermore, they demonstrate how these type of models can provide a better
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assessment of the impact of outbreak containment measures, emphasizing the usefulness
of these models when devising control policies.
In the context of SARS, Lipsitch et al. (2003) showed that if there is large variation
in the number of secondary cases generated by each index case, the probability of a large
epidemic is lessened as compared to the cases with less variation. Thus, larger variance in
the distribution of secondary cases (offspring distribution) decreases the risk of an outbreak
significantly.
Findings of a recent work studying the efficacy of vaccine protection in heterogeneous
host populations Gomes et al. (2014) suggest that the impact of protection appears to in-
crease with increased heterogeneity of vaccine effects:“the more homogeneously a vaccine
acts, the lower its impact on disease transmission.” Worded with our terminology, when het-
erogeneity is larger, endemic levels are lower. It must be noted that in the case of Gomes
et al. (2014), population heterogeneity is related to susceptibility after vaccination, but we
suspect the effects of heterogeneity in their case and ours should be qualitatively similar.
Focusing on the generation interval2 distribution in an SIR class of epidemic models,
the authors in Wallinga and Lipsitch (2007) show that, all else equal, epidemics without
variation in generation interval will grow at higher reproductive numbers, than epidemics
with variation in the duration of their generation intervals. Even though this result was
obtained in the context of diseases that induce immunity upon recovery (SIR-type model),
its implications also support the claim that larger variance in recovery periods lead to lower
prevalence.
Finally, in a recent work Morin (2013), using an SIR epidemic model with differential
susceptibility of its individuals, it was found that the most infection is produced when the
2The mean duration between time of infection of a secondary infectee and the time of infection of its
primary infector; a quantity akin to the infectious period
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distribution of susceptibilities is given by the delta distribution, that is, a distribution with
zero variance representing a homogeneously susceptible population.
As one can see, most of these model address the epidemiological impact of heterogene-
ity in the framework of SIR epidemic models. To explore these issues in the case of cur-
able STDs (e.g., gonorrhea) we propose an stochastic agent-based SIS-type (Susceptible-
Infected-Susceptible) epidemiological model, where agents of the population mix ran-
domly and, if infected, recover at different times. In reality, the time to recover can be
affected by the living conditions (e.g., sanitation and nutrition), the specific nature of the
host-pathogen interaction (e.g., host partial immunity due to prior exposure, development
of drug resistance), and the accessibility of health care facilities and treatment, which are
in turn determined by a myriad of other social, cultural and economic aspects that are dif-
ficult to measure Galea (2002); Harpham and Molyneux (2001). These aspects will not
be explicitly considered in the model; we instead postulate that their net outcome is repre-
sented by a single parameter: the infectious/infected period. Thus, the distribution of this
parameter characterizes the health-related inequalities, a measure of variability across the
population. This variability could be important to how diseases propagate, as demonstrated
in previous works Keeling and Grenfell (1998); Lloyd (2001b,a); Garnett and Anderson
(1996); Lipsitch et al. (2003); Gomes et al. (2014); Wallinga and Lipsitch (2007); Morin
(2013).
In short, within this modeling framework we aim to gain understanding into i) how
health disparities affect epidemic outcome (e.g., extinction probability and epidemic bur-
den), and ii) how host population size affect the interplay between health disparities and
epidemic outcome. We would also like to explore these question in the context of dis-
eases with different transmission potential (different R0). A key quantity to determine is
the endemic levels of infection– and in this probabilistic setting, its distribution. Another
important quantity is the likelihood of an epidemic. One of the interesting aspects of this
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model is that both of these quantities need to be related to the shape of the recovery-rates
distribution, that is, to the structure of inequalities in the population. Thus, a simple ques-
tion would be: when large inequalities exist, are epidemics less frequent and larger? And,
how is this related to population size?
3.2.1 The model
In this model, a susceptible individual becomes infected at a rate proportional to the
frequency of interactions with infected individuals, and the transmission rate β .
By assuming that the transition processes from one class to another is a homogeneous
Poisson process Ross (2006), the probability a susceptible individual becomes infected
between time t and t+dt, namely PI(t) 3, can be given by
PI(t) = 1− exp(−β I(t)dt/N), (3.18)
where the other parameters in the transition rate are I(t), the number of infected at time t,
and N, the size of the population.
When infected, individuals recover in different times, moving back to the susceptible
class. We define the infection period as the time spent in the infectious class, and model this
quantity as a random variable (r.v.) T , measured in days. Let TM and Tm be the maximum
and minimum number of days in which infected individuals recover, that is, maximum
and minimum infectious periods. Thus the interval [Tm,TM] is the support of T . Let also
∆T = TM−Tm. Finally, let T = g(X) = ∆T X +Tm. Here X is a Beta distributed r.v. with
probability density function given by fB(x,a,b)with parameters a and b. Since the function
g is monotonic, then the density function for the r.v. T , with random realization τ , is given
3Here we are using a discrete-time model, however, the probabilities of infection are computed as if there
was an underlying continuos Poisson process. At each time step, all susceptibles are equally likely to become
infected.
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by4
fT (τ) =
∣∣∣∣ ddτ (g−1(τ))
∣∣∣∣ · fB(g−1(τ)) = 1∆T fB
(
τ−Tm
∆T
,a,b
)
, (3.19)
where g−1 denotes the inverse function. Thus, the probability that an individual infected at
time t0, recovers between time t0+ τ and t0+(τ+dτ) is
P[T ∈ (τ,τ+dτ)] = fT (τ,a,b)dτ. (3.20)
Using the Beta distribution as a kernel for the recovery times T , allows for the shape
of this distribution to be considered a descriptive proxy for the structure of inequalities in
the population. Different inequality profiles– that is, distribution profiles– can be easily ob-
tained by calibrating the parameters in the distribution, making this theoretical framework
quite flexible to test the effects of different inequality profiles on epidemic outcomes and
scaling patterns.
An important clarification is in order here. Since the time to recover for each individual
is fixed and sampled from a distribution with a kernel Beta, we are not modeling exponen-
tially distributed recovery times. The reason for this decision is that we want to test the
impact of distribution profiles of measurable quantities, such as the time from infection to
recovery or treatment administration. Inferring recovery rates from data (necessary to deter-
mine the exponential distribution), on the other hand, is dependent on the very assumption
that recovery times are exponentially distributed, which albeit a convenient assumption, is
not very realistic.
The Beta distribution and Inequalities
Let the random variable X follow a Beta distribution, with 0≤ X ≤ 1, and shape parameters
a > 0 and b > 0. Its probability density function (pdf) is given as
P[X ∈ (x,x+dx)] = fB(x,a,b)dx = Γ(a+b)Γ(a)Γ(b)x
a−1(1− x)b−1dx, (3.21)
4wikipedia.org/wiki/Probability density function#Dependent variables and change of variables
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with mean and variance given, respectively, by
µB =
a
a+b
, σB =
ab
(a+b)2(a+b+1)
. (3.22)
Fixing the mean
Suppose µB is fixed at a constant value m. Then the two-parameter pdf drops one degree
of freedom, and its variance can be calibrated with only one of the parameters, say a.
Deriving b(µB) = a(1+1/µB) from the expression of the mean in (3.22), and substituting
in the expression for the variance, we get
σB(a|µB = m) = (m−1)m
2
a+m
(3.23)
To determine the effect of increasing a on the value of the variance, we find the partial
derivative of the expression above, yielding
∂σB(a|µB = m)
∂a
=
(m−1)m2
(a+m)2
. (3.24)
Since m∈ [0,1], then we can conclude that ∂σB/∂a< 0 for all a. In other words, increasing
the parameter a when the mean is fixed decreases the variance of the distribution. This can
be easily seen in Figure 3.9, where µB is fixed at 0.5. As a grows, the pdf becomes narrower.
Figures 3.9 and 3.10 show the conduciveness of this distribution for testing different
inequalities scenarios. For a = 0.1 we would be modeling extreme inequality, where most
individuals either recover rapidly or very slowly. Stated simply, some individuals have
excellent access to health care resources, while the rest lacks complete access.
Mean and Variance of recovery periods
Let X be a Beta distributed r.v., T be the r.v. representing the recovery periods in the
population, and TM and Tm the maximum and minimum recovery times. As stated before,
T = g(X) = ∆T X +Tm. Therefore, the mean and the variance of T are given by
µT = E[T ] =
∫
g(x) f (x,a,b)dx = ∆T
∫
x f (x,a,b)dx+Tm = ∆TµB+Tm, (3.25)
σT = V[T ] = V[∆T X +Tm] = (∆T )2V[X ] = (∆T )2σB. (3.26)
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Figure 3.9: Beta distribution for µB = 0.5. As parameter a increases, the variance is reduced.
Inequalities and recovery periods
a=0.1
10 30 50
0
10
00
20
00
30
00
40
00
Fr
eq
ue
nc
y
Recovery Periods
a=1
10 30 50
0
20
0
40
0
60
0
80
0
10
00
Recovery Periods
a=100
30 35 40
0
50
0
10
00
15
00
20
00
Recovery Periods
Figure 3.10: Sampling 10000 r.v. from fT with maximum recovery period of TM = 60 days
and minimum of Tm = 7 days, and µB = 0.5. The parameter a controls the variance of the Beta
distribution.
3.2.2 Simulations
The simulations were set up as follows. The maximum recovery period is TM = 60 days,
and minimum Tm = 7 days. The variance of the recovery period distribution is controlled
by parameter a, which takes values 0.1 (extreme inequality), 1 (medium inequality), and
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100 (low inequality), as shown in Figure 3.10. That is, as a increases, the heterogeneities
in the population decrease.
To explore the role of pathogen transmissibility, the transmission rate β is also varied,
taking up values 0.03, 0.05 and 0.08. We can consider that the corresponding mean-field
model has reproduction number given by RMF0 = β × µT , with µT = (TM − Tm)/2+ Tm
being the mean of the recovery periods in a symmetric distribution (see expression (3.25));
then the corresponding RMF0 values for each β are 1.01, 1.68 and 2.68. Finally, the host
population size ranges from N = 103 to N = 50×103.
For each parameter combination, 100 iterations were run for three years, with dt = 0.1.
At the beginning of each run, 5 individuals were infected. The infectious period of each
agent was assigned at the start of each simulation run (even for those individuals that never
got infected). These infectious periods were sampled from the corresponding distributions
determined by parameters a,TM, Tm, and µT (the mean was fixed in order to yield symmetric
distributions).
When each iteration (simulation run) ends, the prevalence is computed as the mean of
the prevalence values during the last year of simulations. That is, we allow for a ‘burn-in’
time of two years for stochastic fluctuations to ameliorate or for the epidemic to die out.
The mean of the endemic prevalences for each parameter value is just the average over
the 100 iterations. However, it is more appropriate to take this average conditional on non
extinction. That is, we take averages over those iterations that led to endemic levels of the
disease, discarding the epidemic die-outs.
Since population size does not change, we set N = 1 in each case and therefore the
prevalences are numbers between 0 and 1.
The code to for the simulations was written in C++, and these were run using the
Saguaro computing cluster at the ASU Advanced Computing Center (A2C2).
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Results
Of primary interest is the quantification of the probability of stochastic extinction, that is,
the probability that after the introduction of a small number of infected individuals, the
epidemic invasion dies out. Figure 3.11 shows that when the transmissibility levels are rel-
atively small, β = 0.03 (i.e., close to the mean-field threshold), the probability of epidemic
persistence is similar for all inequality cases. However, for larger values of pathogen infec-
tivity, β =0.05 and 0.08, the likelihood of disease extinction (that is, one minus epidemic
probability) is larger for the scenarios with larger inequalities. In other words, scenarios
in which there is more infectious-period heterogeneity in the population, lead to more fre-
quent epidemic die-outs. This observation suggests that recovery-period inequalities could
be detrimental for pathogen’s persistence in the host population, as compared to scenarios
with more recovery-period homogeneity, especially when its transmissibility is at interme-
diate levels.
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Figure 3.11: Probability of endemic state versus population size for different inequality and trans-
missibility scenarios. This probability is computed as the number of iterations with prevalence
greater than zero, over the total number of iterations (i.e., 100). The 95% confidence intervals
were computed as follows. Let Z be a Binomially distributed random variable, with parameters
p and n, which quantifies the number of epidemics that did not die out at a sufficiently large
time (3 years). That is, for each of the n independent epidemic runs (trials), these survive with
probability p. Thus, the expected non-extinction probability is given by p̂ = z/n, with variance
Var(p) = Var(Z)/n2 = np(1− p)/n2 = p(1− p)/n. Hence, the estimated standard error of p is
given by ŜEp = ŜDp/
√
n =
√
p̂(1− p̂)/n/√n =√p̂(1− p̂)/n, where ŜDp is the standard devia-
tion of p. The 95% confidence intervals (CI) are then given by CI± = p̂±1.96× ŜEp.
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Figure 3.12 shows that, holding the mean constant, larger variance (i.e., larger levels of
inequalities) led to lower endemic levels of disease. A possible explanation for this finding
is that when inequalities are large, a considerable number of individuals recover relatively
faster, constraining the bulk of the epidemic to the fraction of the population that has very
long recovery periods. Notice that RMF0 is much less than 1 for individuals recovering in the
shortest possible time: min(RMF0 ) = β × 7 = 0.21,0.35 and 0.56 for each of the β values
considered.
Contrary to the case of high inequalities (heterogeneities), when inequalities are low,
most individuals recover in times large enough as to be able to infect at least another person,
and thus, the epidemic persists at higher levels.
What makes these findings somewhat perplexing is that, in conditions of extreme in-
equality, a large fraction of the population is also capable of infecting a large number of
individuals: max(RMF0 ) = β ×60 = 1.8,3.0 and 4.8. The simulations suggest that in these
cases of extreme inequality, the group that recovers faster sets off the long infectious peri-
ods of the group that recovers slower, but it does so in such a way that the resulting endemic
levels are lower than in the cases of less heterogeneity.
We assessed the veracity of this finding by challenging the most controversial assump-
tion of the model: modeling inequalities using a Beta distribution kernel. As an alternative,
we considered that recovery times were Gamma distributed, which is arguably a more re-
alistic assumption, as a large fraction of infected individuals recover relatively faster, thus
the recovery time distribution is right-skewed, instead of symmetric, as we have assumed
so far (see Figure A.11 in the Appendix). Under the Gamma distribution assumption, we
also obtain that decreasing the variance of the recovery times also yields larger prevalence
levels (see results in Figure A.12 in the Appendix). Thus, the insight that larger variance
(i.e., larger inequalities) results in lower prevalence levels appears to be robust to these
choices two of recovery time distributions.
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Lastly, notice that increasing the transmission rate from 0.05 to 0.08, even though it has
the expected absolute increase in prevalence, it does not significantly affect the relative lev-
els of prevalence for different inequality scenarios. In other words, the transmissibility of
the pathogen (when it is sufficiently high) does not affect the relative impact of inequalities
on disease prevalence.
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Figure 3.12: Mean endemic behavior (conditional on non extinction) versus population size for
different inequality and transmissibility scenarios. The 95% confidence intervals bands are also
depicted, where uncertainties are larger for smaller population sizes.
As pointed out before, the expected prevalence under the mean-field assumption is
given by I∗MF = N(1− 1/RMF0 ), and for RMF0 =1.01, 1.68 and 2.68, the corresponding
prevalences are I∗MF = 0.01, 0.41 and 0.63. Note in Figure 3.12 that for a = 100, that
is, the most homogeneous scenario, the prevalence levels from the stochastic agent-based
model completely agree with the mean-field predictions, not surprisingly so.
The first clear message from Figure 3.13 is that, for high levels of transmissibility,
the scaling of prevalence (or incidence) and population size is linear. In other words, the
extent of inequalities does not seem to affect the linear relationship between prevalence and
population size, a feature of simpler mean-field models, where I∗MF = N(1−1/RMF0 ) =⇒
I∗ ∼ N. We argue that the reason is that none of the parameters in our agent-based model
depend on population size. In contrast, we showed in the previous chapter that when aspects
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such as contact rates, transmissibility and/or infectious periods depend on population size,
then a variety of scaling scenarios are possible.
The insight from these results is the following. Host heterogeneities that are not tied in
to the size of the population will likely yield a linear relationship between disease incidence
and population size. The data presented in Chapter 2 showed that in the real world this is
not the case, and that in fact, the scaling properties can range from sublinear to superlinear
depending on socio-economic aspects of the populations. What this simple agent-based
model suggest is that, for non-linear scalings to be present (i.e., α 6= 1), the individual-
level heterogeneities have to be somewhat associated to the size of the population in which
these individuals live.
Lastly, notice that for β = 0.03 (near the epidemic threshold), the scaling properties are
non-trivial. This suggest that there might be interesting scaling properties at the epidemic
threshold. Hence we considered this issue worthy of further investigations.
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Figure 3.13: Scaling properties of prevalence levels for different inequality and transmissibility
scenarios. The α estimates are found using OLS regression on the linear model given by log〈I∗i 〉=
α0i+αi logN, with 〈I∗i 〉 being the mean of the prevalences in the 100 iterations and i = {1,2,3} for
the three a values of the Beta distribution parameter.
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Increasing the gap between the well-off and the worse-off.
By modifying the parameter a we are changing the variance by changing the structure
of the population (determined by the variance of Beta kernel, σB), not the support, i.e.,
∆T = TM − Tm is kept fixed. In other words, changing the a parameter redistributes the
recovery times in the population.
Note in expression (3.26) that σT = (∆T )2σB, indicating that the variance of the recov-
ery time distribution can be changed either by changing the variance of the Beta kernel,
σB, or the range ∆T . Figure 3.14 shows the consequences of modifying ∆T while fixing
σB (that is, fixing a and the mean µB). Results show that increasing inequalities through
the term ∆T (the absolute gap between the healthier and the less healthy), also yields lower
levels of prevalence, especially when the kernel variance, σB, is larger (i.e., lower a). These
results are contrary to what we observed in the deterministic framework.
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Figure 3.14: Mean prevalence with 95% CI (too small to show) for different levels of ∆T and
different inequality profiles a = 0.1,1,100. More specifically, TM1 = 37,Tm1 = 30,∆T1 = 7 (square);
TM2 = 47,Tm2 = 20,∆T2 = 27 (triangle); TM3 = 60,Tm3 = 7,∆T3 = 53 (rhombus). In all cases µT =
33.5. Other parameters, N = 20000, β = 0.05.
In fact, note in Figure 3.14 that when ∆T is smaller, the kernel variance (determined by
a) becomes irrelevant, i.e., mean prevalence is approximately 0.4 for all a. In addition, the
case of lower kernel variance, a = 100, shows no sensitivity to changes in ∆T . In this case,
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since the distribution in peaked around the mean, the vast majority of recovery times are
concentrated around the mean, regardless of the distribution’s support ∆T . In combination,
these observations suggest that the variance of the kernel distribution, σB, matters more the
larger the effective range of the recovery time distribution is (that is, where most recovery
times lie).
Complementing this insight, we must also point out that since the distribution is sym-
metric in all cases, and given that we observe that wider distributions always yield the
lower levels of inequality, it seems that healthier individuals (those that recover faster than
the mean) have a larger (reducing) effect on the disease’s transmission potential than the
(increasing) effect of the less healthy individuals. In other words, individuals that recover
faster have a larger (positive) impact on disease outcomes than those that recover slower.
Is better to have 20 healthy individuals and 20 unhealthy ones, than 10 of each.
In short, the three main isights from Figure 3.14 are: i) larger effective range of the
recovery time distribution yield lower endemic levels, ii) the larger the effective range is,
the more influential becomes the kernel variance (shape) on prevalence, and iii) healthier
individuals have a larger (positive) impact on epidemic outcomes than less healthy ones.
When do inequalities matter most?
Lastly, we are interested in quantifying what is the effect in the average prevalence of
increasing the mean recovery time in different inequality profiles. To this end, we shifted
the range of the recovery time distributions as to vary the mean while keeping ∆T constant,
and determined the average prevalence for the different scenarios, as shown in Figure 3.15.
As expected, when the distribution mean increases, so do the average prevalence.
To determine the relative effect of increasing the variance in distributions with different
means, we also computed the ratio between the prevalences in two inequality scenarios
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Figure 3.15: Mean prevalence with 95% CI (too small to show) for different inequality profiles
a= 0.1,1,100 and different means of µT . More specifically, TM1 = 55,Tm1 = 2,µT1 = 28.5 (square);
TM2 = 60,Tm2 = 7,µT2 = 33.5 (triangle); TM3 = 70,Tm3 = 17,µT3 = 43.5 (rhombus). In all cases
∆T = 53. Other parameters, N = 20,000, β = 0.05.
under the same mean. That is,
rti =
〈IµTtai+1〉
〈IµTtai 〉
.
For example, the ratio between the mean prevalences at a= 0.1 and a= 1, when µT = µT1 ,
is r11 = 〈I28.51 〉/〈I28.50.1 〉 = 1.35. The other ratios are r12 = 1.23,r21 = 1.25,r22 = 1.14,r31 =
1.11,r32 = 1.06. The fact that the ratios decrease when the mean increases, that is, r
t
i > r
t+1
i ,
indicates that as the mean recovery increases, the effect of the increasing the variance de-
creases, or equivalently, the slope of the lines joining the points decreases as µT increases.
In other words, the inequalities in recovery rates matters most when the average recovery
times are smaller. Put differently, inequalities in health care access have the highest (neg-
ative) impact on prevalence in places where health care access is better, on average. This
observation is in agreement with those made in Marmot (2005); Pickett and Wilkinson
(2009).
A more hopeful way to interpret this result is by realizing that a public health policy
aimed at reducing inequalities in health care access will have a greater epidemiological
impact in societies (populations) that enjoy, on average, high health standards. This insight
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emphasizes the importance of well-planned public health interventions and policy in re-
ducing disease prevalence, not only within poor cities and countries (which is obvious), but
also within rich cities where residents are, on average, better off.
3.3 Discussion
Mathematical models of transmission dynamics of STDs are key in helping us to under-
stand the role of biological, social, and behavioral factors in the incidence or prevalence of
infection Garnett and Anderson (1996). Our model examined heterogeneity in infectious
periods to determine how individual variation influences epidemiological pattern within a
population, enhancing our ability to quantitatively assess the relative contribution of one of
the many factors that dictate the observed patterns of STDs. More specifically, we aimed
to understand how inequalities in recovery times affect i) the likelihood of persisting epi-
demics, ii) the toll of these on the population, and iii) the scaling properties of prevalence
versus population size. Also, we are interested in figuring out when varying the levels of
inequalities matters most. Our ultimate goal is to contribute with frameworks that can lead
to a better understanding of how best to control the spread of disease. In addition, new
theoretical frameworks can indicate the aspects that need to be measured in order to better
understand and control the dynamics under study, while stimulating further epidemiologi-
cal studies Garnett and Anderson (1996).
What did we learn from the deterministic modeling approach?
When the population is segregated into two groups with different recovery rates and that
mix homogeneously, we find that increasing the levels of inequality (variance in recovery
rates between the groups) can have important implications for epidemics risk and size.
Numerical investigations suggested that increasing the variance of the recovery rates
leads to a worsening of epidemic outcomes by increasing the transmission potential of the
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disease, regardless of the mean µ and the population structure f . This provides supportive
evidence to the claims that larger inequalities are associated with worth health outcomes
Pickett and Wilkinson (2009).
Hence, the analyses using different ways to quantify inequalities rendered slightly dif-
ferent conclusions: one where increasing inequalities, under certain conditions, could either
increase of decrease the transmission potential of the disease, and another where increasing
inequalities always increased the transmission potential.
Motivated by real-world data suggesting that populations of different ethnicities do
not mix as often as a homogeneous mixing model supposes, we built upon the previous
model and add a mixing structure between the two populations. A clear observation from
this approach is that increasing the mixing between the two groups decreases the infection
potential of the disease, especially when inequality levels and the fraction of the population
that recovers faster are large. The explanation we put forward for these observations is
that, in our modeling framework, higher levels of mixing indicate that contacts are more
disassortative, implying in turn that individuals that are infectious for longer, mix more
often with those that recover faster, diluting the cluster of more infectious individuals, and
hence reducing the transmission potential of the disease, especially for low transmission
rates.
What did we learn from the stochastic modeling approach?
Results from the stochastic approach indicate that larger variance in the recovery period
distribution is associated with greater probability of epidemic extinction, especially for
intermediate values of transmissibility. Other authors have found similar results supporting
this finding Lipsitch et al. (2003); Lloyd-Smith et al. (2005).
An important insight from our analysis is that larger inequalities in infectious periods
(i.e., larger variance) yield lower endemic levels of disease, holding the mean constant.
This insight is not exactly suitable for implementation as a public health policy, but it could
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open the door to further investigations of these issues. However, other authors have found
evidence to support this observation Gomes et al. (2014); Wallinga and Lipsitch (2007);
Morin (2013).
Our results, in combination with the previous work, suggest that the way heterogeneities
(in recovery times or susceptibility) are distributed among individuals could be a major
determinant in the population-level impact of a disease, and thus should be carefully con-
sidered when predicting future epidemic scenarios or the efficacy of interventions.
Finally, we show that different sampling distributions of infectious periods do not yield
different scaling patterns, as observed in the real data. Thus, this simple model does not
provide a framework to infer the profile of the inequalities present in the populations from
which the data was extracted. However, insights gained from this study can improve our
understanding of the key processes and features of urban environments that drive the exist-
ing infection patterns. For example, it provides evidence to put forward the hypothesis that
for non-linear scalings of disease incidence to exist, heterogeneities at the individual level
have to be somewhat linked to the size of the population in which they live.
Comparing insights from the Deterministic and Stochastic Models
Our results indicate that the deterministic model fails to capture a key feature of the
agent-based stochastic framework: smaller variance (i.e., inequalities) in recovery periods
yields worse epidemic outcomes. The reason for this discrepancy is still not entirely clear
to us. We investigated two possible reasons for this discrepancy: 1) the discretization of
the stochastic implementation; and 2) the fact that the two modeling frameworks are not
comparable to each other (i.e., we are not comparing apples to apples).
1) Strictly speaking, the discretization used in the computational algorithm (determined
by the length of the time step dt) is not consistent with the assumptions of the SIS model
since it imposes an artificial recovery period (of duration dt = 0.1 days) that isn’t present
in the ODE models. To test whether this nuance is important or not to the validity of our
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claims, we repeated the simulations using a smaller and larger time steps (i.e., dt = 0.05
and dt = 0.5) and checked if these changes affected the equilibrium prevalence in each
inequality (variance) scenario. Let Idta be the equilibrium prevalence for discretization dt
and inequality given by a. The results were the following, I0.050.1 = 0.282, I
0.1
0.1 = 0.284,
I0.50.1 = 0.295; I
0.05
1 = 0.352, I
0.1
1 = 0.353, I
0.5
1 = 0.363, I
0.05
100 = 0.403, I
0.1
100 = 0.403, I
0.5
100 =
0.410. As we can see, the changes are minimal, with, arguably, a systematic increase in the
respective prevalences as dt increases. More importantly, the effect of the variance on the
equilibrium prevalences is not affected: larger variance leads to lower endemic levels.
2) Another reason could be that in the deterministic case individuals recover at fixed
rates and with exponentially distributed times, whereas in the stochastic framework agents
recover in fixed times, Beta (or Gamma) distributed. To compare the deterministic model
with its stochastic equivalent, we simulated an SIS type epidemic in a population composed
by a fraction f of individuals that recover in exponentially distributed times, with rates γ1,
and the other fraction 1− f at rate γ2. These rates were assigned to each agent before the
start of each simulation, and did not change during the simulation. The infection process
was identical as the one used in the original stochastic model (see Ee.(3.18)). In order to
incorporate the idea of a fixed mean and a varying variance of the recovery rates, we used
expressions (3.12) to define the recovery rates in terms of their weighted mean and variance.
Simulations suggests that increasing the variance, while holding the mean constant, leads
to higher prevalence, as in the deterministic case. Thus, the deterministic model and its
stochastic equivalent are in line with their qualitative predictions.
However, the discrepancy between the results obtained from the “mixed-exponential”
stochastic model and those obtained from the Beta (or Gamma) distributed recovery times
still remains. Then, the discrepancy might be a result of i) the variance of the distribution is
not being enough to explain the effect of heterogeneities on epidemic outcomes, but the ac-
tual shape of the distribution is important, and/or ii) the fact that in the mixed-exponential
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model individuals recover at given rates, whereas in the Beta and Gamma models, indi-
viduals recover within given times. To test argument ii) we modified the model with the
mixed-exponential so that each individual recovers at a fixed time (like in the Beta and
Gamma case) drawn from its respective exponential distribution (with rate γ1 with prob-
ability f and rate γ2 with probability 1− f ). Simulations again demonstrate that when
individuals recover in exponentially distributed times, the pattern of “larger variance leads
to larger prevalence” is maintained. Therefore, since the discrepancy between the two mod-
eling frameworks still remains, we can be more confident that it is partly due to point i):
the significantly differing shape of the corresponding distributions.
The discrepant nature of the insights obtained from the two-group with exponential re-
covery times and the agent-based with Beta-distributed recovery times models indicate that
the impact of health-care access inequalities on disease outbreaks and prevalence patterns
cannot be fully understood if individual variation in infectiousness period is neglected, and
moreover, that the shape of the distribution describing this variation (shape of inequali-
ties), not just its mean and variance, are important when assessing the impact of inequality
scenarios.This is particularly interesting because different diseases may have different re-
covery period distributions, although these are not very well know empirically.
Possible limitations and future work
The socio-economic context of individuals not only affects the speed of recovery, but it
is also tied in to the likelihood of becoming infected in the first place, which would reflected
in the transmission rate β . However, for the sake of clarity, herein we assume that social
inequalities only result in heterogeneities of recovery rates. A more realistic version of the
model would add heterogeneity of transmission/susceptibility, but then we would have to
arbitrarily relate functionally both levels of heterogeneities (e.g., people that recover faster
are less susceptible to infection, on average). At this point it is uncertain what would be the
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empirical basis to determine such relation, thus imposing one would both make the system
more intractable and ad hoc.
To add more realism to the model, we could also consider an SIRS framework, instead
of SIS, where individuals remain immune to the disease for a certain period of time. The
reason being that infected individuals undergoing treatment will both cease to be infectious
while gaining protective immunity against reinfection for a period of time that depends
on the rate at which the drug is metabolized. Also, we consider that understanding how
inequalities affect public health interventions such as isolation and reactive treatment, is
worth the effort in future works.
Due to time and computational constraints we could not run more iterations for each pa-
rameter value combination. However, we believe the nature of the insights obtained herein
will not be subject to significant modifications through more extensive simulations. Also
for future investigations, we would like to study other interesting scenarios. For example,
the idea that larger (i.e., more urbanized) populations present greater levels of inequali-
ties, can be readily modeled in this framework by assuming that the variance of the Beta
distribution– a proxy for the extent of inequalities– increases with N. Formally, the idea
would be to fix the mean (constraining shape parameter b) and vary a as a function of N
such that as N grows, the variance also grows.
The claim put forward in Pickett and Wilkinson (2009) that relative living conditons
matter more than absolute living conditions has not been completely assessed here. We
have limited ourselves to study the effect of inequalities on disease outcomes, not having
compared which aspect, the mean or the variance, has a larger impact. To further investigate
this issue it would be convenient to make use of approaches such as sensitivity analysis.
Our goal is to understand and control the spread of IDs. With these modeling ap-
proaches, both deterministic and agent-based stochastic, we have aimed not to predict how
an epidemic will unfold, but rather gain insights of how different social settings affect
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possible epidemic scenarios, and plan accordingly. To our knowledge, the issue of how
heterogeneities in time-to-recover impact the prevalence of STD has received little atten-
tion in the literature, especially from a mechanistic point of view, and therefore it is not
fully understood.
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Chapter 4
OPTIMIZING TREATMENT EFFICACY TO REDUCE DRUG RESISTANCE IN
INFLUENZA
4.1 Introduction
Rapid antigenic evolution in the influenza virus increases the likelihood of emergence of
novel strains against which little to no immunity may exist in the host population Morens
and Fauci (2013); Ferguson et al. (2003); Bedford et al. (2012); Ferguson et al. (2005);
Nelson and Holmes (2007). In this scenario, if vaccines are not yet available or non-
pharmaceutical interventions have limited impact on disease containment, antiviral treat-
ment plays a crucial role in the control of epidemics Ferguson et al. (2005); Jaberi-Douraki
et al. (2012); Moghadas (2008); Alexander et al. (2007). A critical constraint in the de-
ployment of antivirals agents (e.g., M2 inhibitors and neuraminidase inhibitors such as
oseltamivir Regoes and Bonhoeffer (2006))1 is the evolution of highly transmissible drug-
resistant mutants Weinstock and Zuccotti (2009). In fact, the large-scale use of antivi-
rals during influenza pandemics poses a significant selection pressure for drug-resistant
pathogens to emerge and spread in a population Weinstock and Zuccotti (2009). The
evidence is extensive. For example, during normal influenza seasons, resistant viruses
can develop in a considerable fraction of individuals (especially children) who receive os-
eltamivir treatment Kiso et al. (2004). In the case of seasonal H1N1, oseltamivir resistant
strains were on the rise during the 2007-2008 season WHO (2008) in countries such as
1The two main classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as
zanamivir and oseltamivir, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. Four
licensed influenza antiviral agents are available in the United States: amantadine, rimantadine, zanamivir,
and oseltamivir.
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the U.S. Dharan et al. (2009) Japan Ujike et al. (2010) France Casalegno et al. (2010)
and Norway Hauge et al. (2009). Although to a lesser extent, oseltamivir-resistant strains
have also arisen in treated hosts infected with the pandemic H1N1 strains Renaud et al.
(2011); Graitcer et al. (2011) , (and the CDC). Moreover, oseltamivir-resistant strains have
also appeared in treated hosts infected with avian strains of influenza A/H5N1 de Jong
et al. (2005); Le et al. (2005) in Asia. More recently, mutations conferring resistance to
oseltamivir, peramivir and partially to zanamivir, have been found in some H7N9 clinical
isolates Hai et al. (2013). Even more concerning is that, compared to their drug-sensitive
conterparts, H7N9 resistant mutants showed similar viral replication and pathogenicity in
experimental models.
The implications of drug resistance are myriad. Drug resistance decreases the effec-
tiveness of chemotherapy in infected patients, prolonging recovery or leading to outright
treatment failure Levin et al. (1999). Epidemics of untreatable strains have the potential
to cause major morbidity and mortality Lipsitch et al. (2012); Herfst et al. (2012); Russell
et al. (2012); Imai et al. (2012), with significant economic costs for both the individual
and for society writ large Althouse et al. (2010). Consequently, public health policy has a
growing need to understand the key factors that lead to the rise and spread of resistance.
In addition, treatment strategies need to be tailored to both amplify the effectiveness of ex-
isting drugs, while halting the emergence and spread of resistance Ferguson et al. (2006);
Lipsitch et al. (2007); Wu et al. (2009); zur Wiesch et al. (2011).
In addition to important precautionary measures, such as improvement of hospital counter-
infection methods and regulation of antiviral use, mathematical models can be used to
explore plausible competition scenarios between sensitive and resistant strains and the im-
pact of treatment strategies on these dynamics Lipsitch et al. (2000); Keeling and Rohani
(2008a); Lipsitch et al. (2007); zur Wiesch et al. (2011); Althouse et al. (2013b); Chow
et al. (2007, 2011); Ortiz et al. (2010). Previous models of the development of resistance
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of influenza to antiviral agents have focused on efforts to minimize the fraction of drug-
resistant infections during an epidemic outbreak Lipsitch et al. (2007); Jaberi-Douraki et al.
(2012); Moghadas (2008); Alexander et al. (2007) and to give recommendations that in-
form policy Schwartz et al. (1997); Regoes and Bonhoeffer (2006); Althouse et al. (2010);
Wu et al. (2009); WHO (2006); Fiore et al. (2011). However, the study of the long-term
(endemic) dynamics of drug-resistance has received less attention, except for instance Qiu
and Feng (2010).
In the work proposed here, which was recently published Patterson-Lomba et al. (2013),
we intend to assess the effectiveness of treatment at minimizing the total number of in-
fections while halting the spread of drug-resistance, both from an endemic and a single-
epidemic perspective. We focus our attention on two points: i) the relative transmissi-
bility of the drug-resistant strain with respect to the wild-type (drug-sensitive) strain, and
ii) the frequency of de novo resistance. Point i) is related to the fitness cost associated
with the evolution of drug resistance, reflected in a reduced transmissibility of the drug-
resistant pathogen relative to its wild-type counterpart Lipsitch (2001); Regoes and Bon-
hoeffer (2006). Recent evidence has demonstrated, however, that this reduction in fitness
may be questionable and could also be limited due to compensatory mutations which can
restore fitness without loss of resistance-conferring genes Handel et al. (2006); Weinstock
and Zuccotti (2009); Casalegno et al. (2010); Hai et al. (2013). Point ii) represents the prob-
ability that treatment leads to resistance within the treated host (de novo). Both quantities
are crucial in the population dynamics of drug-resistance, especially due to their variabil-
ity within different epidemiological settings Regoes and Bonhoeffer (2006). Nonetheless,
their combined effect on the effectiveness of treatment regimes during influenza pandemics
is not fully understood Jaberi-Douraki et al. (2012).
We build on a previous model Lipsitch et al. (2007) to examine these issues in the long-
term (endemic disease prevalence) as well as in the short-term (single-epidemic). Lipsitch
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et al. Lipsitch et al. (2007) observed that intermediate levels of antiviral use are indicated
to reduce the attack rate during an influenza pandemic. Figure 4.1 shows the existence of
this “optimal” level of treatment for which the total final epidemic size (FS) is minimized,
where the FS is defined as the proportion of the population infected during the epidemic.
We can readily see this minimum is a function of the likelihood of de novo resistance,
namely c. As c increases, the dip in the combined FS curve vanishes. Furthermore, for large
c the treatment regimes that minimize the total FS, are not optimal in terms of avoiding the
emergence of resistance, featuring a trade-off: treatment regimes that minimize total attack
rates, allow for drug resistance to spread widely. This raises questions as to whether or
not the treatment fraction that will minimize the overall attack rate is indeed the optimal
treatment strategy. In fact, we argue that the answer to this question is not absolute, and
instead depends on the values of c and the fitness cost of resistance, namely φ .
In this work, we address this idea in the endemic case, as well as from a single epidemic
perspective, and propose treatment strategies that would be most beneficial in each setting.
In the next chapter, we extend the model in Lipsitch et al. (2007) to include stochasticity
and population structure (i.e., heterogeneity in the contact structure), and explore the impact
of these important features on the emergence and spread of resistance.
4.2 Model Formulation
We extend a version of the model in Lipsitch et al. (2007) to include demography (see
Figure 4.2). Whereas they considered both prophylactic and therapeutic treatment in well-
mixed, homogenous populations, we consider only therapeutic treatment. We limit our
exploration to treatment because current guidelines suggest limiting prophylactic use of
antivirals to individuals at high risk Fiore et al. (2011). Let N be the total population size,
which is divided into five mutually exclusive subclasses: susceptible (X), infected effec-
tively treated (Yt), untreated infected (Yu), infected resistant to treatment (Yr) and recovered
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Figure 4.1: Final epidemic size of both strains vs. Treatment Fraction for two different
frequencies of de novo resistance. Note that ρmin is effective in halting the spread of the overall
epidemic, but not in reducing resistance, which more obvious for larger c. Simulation obtained
using model given by system (4.8) - (4.12) with parameters: βu = 0.6,φ = 0.8, N = 106,m= 0.34,
γr=γu=0.2, τ=0.1, Ir(0)= It(0)=0 and Iu(0)=1
(Z). Susceptible hosts enter the population at a constant rate Λ, and all individuals die at a
per-capita rate µ . We assume no disease-induced mortality and that the pathogen induces
sterilizing immunity Anderson and May (1992); Keeling and Rohani (2008a). Susceptible
individuals can be infected by pathogens either sensitive or resistant to the available antivi-
ral. Moreover, this model does not include superinfection with both strains. A fraction ρ
of patients infected with the wild-type strain are treated and a fraction c of those treated
develop resistance de novo. Therefore, individuals infected with the wild-type strain are
either untreated (Yu), effectively treated (Yt), or resistant to treatment (Yr). Infection with a
resistant strain is either developed de novo or acquired from another resistant-infected in-
dividual. Susceptible individuals become infected at a rate proportional to the densities of
susceptible and infected individuals, and to the transmission rates of each class, βu, βt , and
βr, respectively. Untreated, treated, and resistant infected individuals recover at per-capita
rates γu,γt , and γr, respectively.
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The relative transmissibility of the resistant strain is defined as φ =βr/βu ≥ 0. Suc-
cessfully treated individuals: 1) are not more infectious: βt =mβu, where m ∈ [0,1] is the
reduction in viral shedding Ferguson et al. (2006); Lee et al. (2009); Ling et al. (2010), and
2) recover faster: γt = γu+ τ , where τ > 0 is the increase in recovery rate Nicholson et al.
(2000); Ferguson et al. (2006); Regoes and Bonhoeffer (2006).
The ordinary differential equation (ODE) model describing these dynamics is
dX
dt
= Λ− (θw+θr +µ)X (4.1)
dYt
dt
= θwXρ(1− c)− (γu+ τ+µ)Yt (4.2)
dYu
dt
= θwX(1−ρ)− (γu+µ)Yu (4.3)
dYr
dt
= θrX +θwXρc− (γr +µ)Yr (4.4)
dZ
dt
= (γu+ τ)Yt + γuYu+ γrYr−µZ (4.5)
with forces of infection
θw =
βuYu+mβuYt
N
and θr =
φβuYr
N
.
The total population size N = X +Yt +Yu+Yr +Z satisfies the relation
dN(t)
dt
= Λ−µN(t). (4.6)
It is easy to obtain that N(t)→ Λ/µ as t → ∞. For our analysis we will assume that the
total population size has already stabilized to Λ/µ .
If N = Λ/µ , then we can define a new set of variables as
S =
X
N
, It =
Yt
N
, Iu =
Yu
N
, Ir =
Yr
N
, R =
Z
N
, N =
Λ
µ
, (4.7)
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and system (4.1)-(4.5) is equivalent to
dS
dt
= µ− (Θw+Θr +µ)S (4.8)
dIt
dt
= ΘwSρ(1− c)− (γu+ τ+µ)It (4.9)
dIu
dt
= ΘwS(1−ρ)− (γu+µ)Iu (4.10)
dIr
dt
= ΘrS+ΘwSρc− (γr +µ)Ir (4.11)
dR
dt
= (γu+ τ)It + γuIu+ γrIr−µR (4.12)
where now the forces of infection are
Θw = βuIu+mβuIt and Θr = φβuIr.
We note that, though the model above is framed in the context of influenza, we speculate
that the scope of the insights gained from its analysis can go beyond this specific disease,
and inform treatment policy in the context of other etiologies, such as HIV, tuberculosis
and malaria, where drug-resistance is a pressing issue zur Wiesch et al. (2011).
In what follows, let σx be the total per-capita rate out of class Ix, i.e., σt = γu + τ + µ ,
σu=γu+µ , and σr=γr +µ .
tIt + uIu
S
It
Iu
Ir
RW
rIr
(1 c)
1
c
r
u
u +
N
Figure 4.2: Compartmental Model for Eqs. (4.8) - (4.12). In the schematic, W is not a class, but
instead is meant to represent Wild-type infections, which are then distributed into the three infection
compartments.
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Results
Reproduction Numbers
The basic reproduction number, R0, is the average number of secondary cases produced
by a typical infected individual in a completely susceptible population. We find R0 for the
system (4.8) - (4.12) for each strain using the Next Generation Operator (NGO) method
Van den Driessche and Watmough (2002). The non-zero eigenvalues of the NGO matrix
Rw0 = βu
{
mρ(1− c)
σt
+
(1−ρ)
σu
}
, (4.13)
Rr0 = βu
φ
σr
, (4.14)
are the reproduction number of the wild-type and resistant strains, respectively.
Fixed Points and Bifurcation Analysis
The system (4.8) - (4.12) has three fixed points: 1) a disease free equilibrium (DFE); 2) a
fixed point where only the resistant strain persists (resistance fixed point); and 3) a coex-
istence fixed point in which both strains coexist (coexistence fixed point). Conceptually,
these fixed points represent: 1) eradication of both resistant and wild-type strain, 2) eradica-
tion of the wild-type strain when treatment and/or relative transmissibility are high enough
to allow persistence of the resistant strain; and 3) coexistence of both strains due to low
treatment and/or low fitness of the resistant strain, where typically the resistant strain per-
sists at low levels. The fixed points are:
DFE:
{S1, I1t , I1u , I1r }= {1,0,0,0} (4.15)
Resistance fixed point:
{S2, I2t , I2u , I2r }=
{
1
Rr0
,0,0,
µ
φβu
(Rr0−1)
}
(4.16)
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Coexistence fixed point:
{S3, I3t , I3u , I3r }=
{
1
Rw0
,
(1− c)ρµ
σt
ξΨ,
(1−ρ)µ
σu
ξΨ,cρ
µ
σr
Ψ
}
(4.17)
where
ξ := 1− R
r
0
Rw0
and Ψ :=
Rw0 −1
Rw0 − (1− cρ)Rr0
. (4.18)
The recovered class fraction in each case is given by R∗=1−S∗− I∗t − I∗u − I∗r . These fixed
points are given in terms of fractions of the total population. To recover the actual values of
each fixed point we would make use of the scaling relations in (4.7). That is, each fraction
would be multiplied by the constant value of the asymptotic population size, Λ/µ , without
changing the relative values of each subclass in each of the fixed points.
Comparing the susceptible steady states in (4.16) and (4.17) suggests that for the resis-
tance fixed point, prevalent infections are attributable to the resistant strain, whereas for the
coexistence fixed point, the reproduction number of the wild-type strain determines how
prevalent the disease is.
With the new scaled variables, the biologically significant set for the steady states be-
comes
∆′={(S, It , Iu, Ir,R)∈ [0,1]5 |S+It+Iu+Ir+R=1}.
The resistance fixed point is biologically significant if Rr0 ≥ 1. For the coexistence
fixed point, Rw0 ≥ 1 must hold so that S3 ≤ 1. This also implies that the numerator of Ψ in
(4.18) is positive. For I3r to be non-negative, the denominator of Ψ must be positive, i.e.,
Rw0 >(1−cρ)Rr0, which implies Rw0 /Rr0>1−cρ . For I3t and I3u to be non-negative Rw0 /Rr0 ≥
1>1−ρc must hold. Therefore, the coexistence fixed point is biologically significant if
Rw0 ≥ 1 and Rw0 ≥ Rr0. (4.19)
Thus, the two strains coexist if the wild-type strain is transmissible enough to be able to
spread and also more transmissible than the resistant strain.
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Stability of Fixed Points.
For the stability analysis of the fixed points we study the eigenvalues of the matrix in
the linearized system around the fixed points: equilibria that have eigenvalues with negative
real part are stable, whereas equilibria that have eigenvalues with positive real part are
unstable Strogatz (1994). We present here the results of the analysis; detailed analytic
derivations can be found in Appendix A.3.
As expected, the DFE is globally stable if Rw0 < 1 and R
r
0 < 1. The resistance fixed point
is locally stable if Rr0 > R
w
0 . While determining the stability of the coexistence fixed point
is not analytically tractable, (4.19) states that the coexistence fixed point is biologically
significant if Rw0 ≥ 1 and Rw0 ≥ Rr0. Thus, the conditions in (4.19) imply that neither the
DFE nor the resistance fixed point are stable. We then conjecture that the coexistence
fixed point is biologically significant and globally stable if (4.19) holds. Epidemiological
arguments and numerical integrations support this hypothesis.
Bifurcation Analysis.
Depending on Rr0 and R
w
0 , the system has one, two, or three biologically significant fixed
points. Figure 4.3 features all four stability regions described above in the (φ ,ρ) and the
(Rw0 ,R
r
0) parameter space. The boundary of these regions can be found by solving
Rr0(φ
1)=1, Rw0 (ρ
1)=1 and Rw0 (ρ
∗)=Rr0,
yielding
φ1=
σr
βu
, ρ1=
(βu−σu)σt
βuσt−mβu(1− c)σu , (4.20)
and ρ∗(φ)=
(σr−φσu)σt
σr[σt−m(1− c)σu] . (4.21)
The boundaries are shown in Figure 4.3, where ρ∗ is the red-dashed line, ρ1 is the dashed
and horizontal line, and φ1 is the dashed and vertical line. The intersection of these curves
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(black dot) represents the overall disease threshold: any increase in φ or decrease in ρ
away from this intersection would result in an epidemic. Moreover, Eq. (4.20) shows that,
for appropriate parameter values, increasing τ or decreasing m, decreases the ρ-coordinate
(ρ1) of the overall disease threshold point. Thus, increasing the recovery rate or decreasing
the transmission rate of those treated, represents an epidemiological trade-off: it jointly
expands the “DFE” and the “Resistance” stability regions, making it more likely for the
system to either stay disease-free or give rise to prevalent resistance (see Figures B.4–B.7
in Appendix for details).
Figure 4.3: Stability regions in the (ρ , φ ) and (Rw0 ,Rr0) parameter space. Coexistence 2FP (CFP
stable, DFE unstable); Coexistence 3FP (CFP stable, DFE unstable, RFP unstable); Resistance
(DFE unstable, RFP stable). When the system crosses any of the region boundaries it experiences a
transcritical bifurcation.
4.3 Optimal Treatment Regimes
The main goal of this work is to derive treatment regimes (i.e., treated fractions) that
minimize the wild-type infections while restraining the spread of resistance. From the
CFP, it is clear that for very low treatment levels, the wild-type strain is prevalent in the
population, and the resistant strain prevalence stays at minimal levels Levin et al. (1999),
i.e., Rw0 (ρ = 0)>R
r
0. Additionally, treatment will reduce the viral shedding (mβu < βu)
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and increase the recovery rate by τ , implying that ∂Rw0 /∂ρ < 0. Thus, treating a larger
proportion of the population will reduce the number of wild-type infected. However, it will
also increase the number of de novo resistant cases, as well as the pool of susceptibles for
the resistant strain to spread in.
These observations intuitively suggest that an effective treatment strategy should mini-
mize Rw0 by increasing ρ , while keeping R
w
0 ≥Rr0. Formally,
ρ∗=argmin
ρ
Rw0 (ρ), s.t. R
w
0 ≥ Rr0. (4.22)
Since Rr0 does not depend on ρ (Eq. (B.12)), and assuming R
w
0 (ρ=0) > R
r
0, (4.22) can be
solved by reducing Rw0 until R
w
0 (ρ)=R
r
0. This equality yields ρ
∗ as in (4.21), a linearly
decreasing function of the relative transmissibility, φ (see Figure 4.3).
However, (4.22) is inadequate since it does not consider the fitness advantage that de-
velopment of de novo resistant cases give to the resistant strain. As R0 is the expected
number of new cases produced by a typical infected person in a susceptible population, this
quantity can be considered a measure of the fitness of a pathogen at the population level.
Additionally, in our model, c is directly related to the within-host fitness of the resistant
pathogen. The overall fitness of the resistant strain is the added contributions of the fitness
at the population and the within-host level. To estimate this overall fitness, assume, for the
sake of clarity, σi = σ , ∀i ∈ {u, t,r}. Let also Inr and Inw= Inu+Int be the number of resistant
and wild-type cases in the nth “epidemic generation” (with duration approximately 1/σ )
in a predominantly susceptible population. Defining Fr= In+1r /I
n
r and Fw= I
n+1
w /I
n
w as the
overall fitness of the resistant and wild-type strains, respectively, we obtain (see Appendix
A.3 for details):
Fw = Rw0 H(ρ
∗−ρ) and Fr = Rr0+
ρc
1−ρcR
w
0 H(ρ
∗−ρ), (4.23)
where H(x) is the Heaviside step function (H(x)= 1 if x≥ 0, and H(x)= 0 otherwise),
i.e., if ρ >ρ∗, the wild-type strain goes extinct. It is then clear that Fr has an additional
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contribution from the de novo cases. More importantly, from the sole comparison of the
reproduction numbers we cannot infer properly which strain will dominate, nor can we
devise effective treatment regimes 2.
A more appropriate way to optimize the treatment regime is attained by focussing on
the fixed points (FPs). The system has two FPs where the disease is endemic (RFP and
CFP). On the one hand, if the CFP is stable, the optimal treatment regime, ρe, is defined
as the fraction treated that yields the minimum number of wild-type infected, while the
resistant is kept at lower endemic levels than the wild-type. Formally,
ρe = argminρ (I
3
w), s.t. I
3
w ≥ I3r (4.24)
where I3w≡ I3u + I3t . The regime ρe can then be found by solving for ρ in I3w = I3r (see
Eq. (4.26)).
On the other hand, if the RFP is stable, then treatment will have no effect on the preva-
lence of the resistant strain since I2r is not a function of ρ . Two scenarios are then possible:
(A) I3r (ρe)< I2r , or (B) I3r (ρe)≥ I2r . An assessment of these two scenarios yields our defini-
tion of overall optimal treatment regime ρopt : if (A) is true, ρopt will minimize the endemic
levels of the wild-type strain, while keeping the resistant strain at comparatively low levels;
2Interestingly, the issue of R0 not accurately representing the value of the pathogen’s fitness, is also present
in the context of backward bifurcations Feng et al. (2000); Brauer (2004); Sa´nchez et al. (2007). The main
feature of these models is the existence of multiple endemic equilibria for R0<1, suggesting that reducing
R0 bellow one may not be sufficient to eradicate the disease. Clearly, this behavior may have important
consequences in planning how to control a disease. Our claim here is that, in such models, the expression
for R0 neglects some of the processes influencing disease transmission; thus R0 becomes a less reliable (i.e.,
incomplete) quantity to describe the overall potential burden of the disease (although it still quantifies the
secondary number of cases an average infected produces in a susceptible population). For example, in Feng
et al. (2000), the expression for R0 does not contain any information about the reinfection process, and it is
precisely the incorporation of this process what allows the emergence of the backward bifurcation. In our
case, Rr0 does not account for the added fitness that de novo resistance confers to the resistant strain.
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if (B) holds, ρopt will transition the system to the RFP stability region. Hence, in case (A)
it is best to maintain the system within the CFP limits, whereas in (B) the RFP will be
preferred. The latter can be achieved by increasing ρ beyond ρ∗. Formally,
ρopt =
 ρe, if I
3
r (ρe)< I2r , (A) (4.25a)
(ρ∗,1], if I3r (ρe)≥ I2r . (B) (4.25b)
We now show that conditions (A) and (B) can be expressed in terms of our two key param-
eters: relative transmissibility, φ , and the frequency of de novo resistance, c. To find ρe we
solve for ρ in I3w= I3r , or equivalently,
Rw0 = R
r
0+R
w
0
[
σuσtcρ
(1− c)ρσuσr +(1−ρ)σtσr
]
. (4.26)
Within the CFP limits, (4.26) indicates when the overall fitness of both strains are equal
(notice the similarity of the left hand side and the right hand side of (4.26) with, respec-
tively, Fw and Fr in (4.23), when σi = σ ,∀i ∈ {u, t,r}). The explicit expression for ρe is
given in Appendix A.3. Noteworthy, ρe is the only value of ρ in (0,ρ∗) for which I3w= I3r .
This claim is justified as follows: I3w(ρ) is a monotonically decreasing function of ρ in
(0,ρ∗), with I3w(0)> I3r (0) and Iwr (ρ∗)< I3r (ρ∗). Additionally, I3r (ρ) is either increasing
or concave in (0,ρ∗) (see Figure 4.4). In both cases, I3w and I3r intersect at only one point
(green dots in Figure 4.4). See Appendix A.3 and Figure B.10 for analytic details.
It is easy to show that I3r (ρ∗)= I2r (gray dots in Figure 4.4). However, we also find that
I3r (ρr)= I2r , where
ρr =
Rr0−1
Rr0c
. (4.27)
Then, if 0< ρr < ρ∗, the term ρr represents the treatment regime within the region of
coexistence (CFP) for which the resistant strain is as prevalent as in the resistant-only
stability region (RFP) (red dot in Figure 4.4). Additionally, it can be deduced from (4.27)
that
ρr < ρ∗ =⇒ Rr0 < (1−ρ∗c)−1. (4.28)
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Figure 4.4: The two possible monotonicity behaviors of I3r (ρ). In black, I3r (ρ) is concave
for Rr0(φ)< (1− ρ∗c)−1 (solid lines) (φ = 0.42), and monotonically increasing for Rr0(φ)≥ (1−
ρ∗c)−1 (dashed lines) (φ=0.55). Red lines are the corresponding I3w(ρ) curves. The x-values of the
green and gray dots represent ρe and ρ∗, respectively, while the x-value of the red dot represents
ρr. As φ (or Rr0) increases, the red dot moves rightward, surpassing the green dot (ρr =ρe), and
eventually surpassing the gray dot as well (ρr=ρ∗). When ρ = ρ∗, the system displays a transcritical
bifurcation between the CFP and the RFP. Other parameters: γr = γu = 0.2,τ = 0,βu = 0.5,m=
0.34,c=0.2. A large value of c was used to magnify the difference between the two cases.
In the Appendix A.3 we show that when (4.28) holds, I3r (ρ) is concave for ρ ∈ (0,ρ∗).
The concavity of I3r (ρ) means, biologically, that the resistant strain prevalence is sustained
largely by de novo resistant cases. Put differently, Rr0 is not large enough for the resistant
strain to self-sustain high levels of prevalence in the absence of treated wild-type infected.
Recalling that I3r (ρr)= I2r and I3r (ρ∗)= I2r , if I3r (ρ) is concave for ρ ∈ (0,ρ∗) and ρr<
ρe<ρ∗, then I3r (ρe)> I2r (condition (B)), indicating that the RFP is preferred over the CFP
(solid curves in Figure 4.4). Furthermore, condition ρr<ρe<ρ∗ reduces to ρr<ρe given
that I3w(ρ)=I3r (ρ) for ρ∈(0,ρ∗). If instead ρr>ρe, then condition (A) applies and keeping
the system in the CFP while applying a treatment regime ρe will be the best option (dashed
curves in Figure 4.4).
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These observations along with expression (4.27) allow to restate conditions (A) and
(B), and therefore the optimal treatment, in terms of φ (through Rr0) and c as
ρopt =

ρe, if
Rr0−1
Rr0c
> ρe, (A)
(ρ∗,1], if
Rr0−1
Rr0c
< ρe. (B)
In case (A), which corresponds to a high φ and low c scenario, the CFP is stable with
the wild-type and the resistant strains kept at low levels. In case (B) (i.e., low φ and
high c), shifting the stability to the RFP is preferable since only the resistant strain will
persist at low levels (see Figure 4.4). In other words, if the resistant strain features high
relative transmissibility and de novo resistance is rare, the best treatment regime would be
at intermediate levels (ρe); whereas if the opposite holds true, treating a fraction larger than
ρ∗ of the infected population is preferred.
Recalling that ρe and ρ∗ are found from solving (4.26) and solving Rw0 =R
r
0, respec-
tively, and noticing that as c→0+ expression (4.26) reduces to Rw0 =Rr0, we conclude that
ρe→ρ∗ as c→0+. For this reason, when c is small (. 10−2) ρ∗≈ρe+ε , with 0<ερe,
becomes a good treatment strategy if (A) holds. Moreover, as c→0+, it is expected that
(A) holds, at least in the epidemiologically interesting cases where Rr0 will likely be greater
than (1− cρe)−1&1 (i.e., the resistant strain can emerge and spread in the population). In
conclusion, when c is small, then ρ=ρ∗− ε is a good treatment regime to minimize both
the wild-type and the resistant strains (green bands in Figure 4.5).
Despite the large uncertainties in the frequency of patients that will develop de novo
resistance Regoes and Bonhoeffer (2006), c can be assumed to be relatively small. Fig-
ure 4.5 ilustrates how, for c=0.002 (as in Lipsitch et al. (2007)), ρ=ρ∗−ε is the optimal
treatment fraction: it diminishes the prevalence of the sensitive strain as much as possible,
while hindering the emergence of the resistant strain. For low levels of treatment the CFP
is stable: the wild-type strain prevails and the resistant strain (I3r ) remains at low levels.
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As soon as ρ>ρ∗≈ρe, the resistant strain out-competes the wild-type strain. Expectedly,
if treatment further reduces the infectious period (i.e., larger τ , dashed lines), increasing
treatment reduces the wild-type strain prevalence more effectively. In this case, the optimal
levels of treatment are lower. A similar behavior is obtained when, instead of increasing τ ,
we reduce m (reduction of viral shedding due to treatment).
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Figure 4.5: Effectiveness of ρ∗ for c= 0.002 and Rr0 > (1−ρ∗c)−1. Prevalences I2r and I3r are
depicted in black and I3w in red, for two different treatment recovery benefits (τ = 0.1, solid; τ =
0.8, dashed). The RFP is unstable for ρ <ρ∗ (blue dashed line). Strain dominance transition at
ρe≈ ρ∗ (vertical dashed lines). Optimal treatment regimes (ρ∗−ε) in green bands. Parameters:
µ=4.6×10−5, γu=γr=0.2, βu=0.5, m=0.34, φ=0.6 (see also Figure B.9).
Is there a local minimum for the overall endemic equilibrium?
In Lipsitch et al. (2007) it is shown that, in the single epidemic case, the total final epidemic
size (i.e., the sum of both the final size of the sensitive and the resistant strains), has a local
minimum for a certain intermediate value of the treatment regime (see also Figure 4.8
below). Put differently, there exists an “optimum” value of the treatment regime such that
the overall burden of an epidemic is minimized. Here we show that, in the endemic case,
such a local minimum exists under certain conditions.
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Formally, we define the total endemic equilibrium as IT = I3r +I
3
w for 0 ≤ρ <ρ∗ and
IT =0+I2r for ρ∗<ρ≤1. Figure 4.6 shows a similar situation as in Figure 4.5, with the
addition of a new curve for the total endemic equilibrium (in blue). When treatment does
not decrease the average recovery time (i.e., τ = 0), the left panel of Figure 4.6 shows that
as the treatment regime increases, the total endemic equilibria decreases for ρ < ρ∗, and,
as expected, flattens out for ρ > ρ∗. That is, for τ = 0, a local minimum does not exist.
Conversely, when treatment speeds up recovery (i.e., τ > 0), the right panel of Figure 4.6
shows a local minimum in the total endemic equilibrium for a value of ρ less than ρ∗.
In the supplementary material we derived a sufficient condition for the existence of this
minimum. Using this condition we demonstrate why there is a minimum for the scenario
depicted in the right panel of Figure 4.6, and not one for the left panel. Moreover, we show
that τ > 0 is a necessary– but not sufficient– condition for the existence of this minimum.
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Figure 4.6: Local minimum in the total endemic equilibrium. Prevalences I2r and I3r are de-
picted in black and I3w in red. The sum I
3
r + I
3
w for ρ ∈ [0,ρ∗) and 0+ I2r for ρ ∈ (ρ∗,1] is depicted in
blue, with (left) τ=0 and (right) τ=0.2. Other parameters: c=0.02,µ=4.6×10−5, γu=γr=0.2,
βu=0.5, m=0.34, φ=0.6.
Arguably, the most intuitive way to define the optimal treatment regime, namely ρmin, is
through the proposition that min(IT (ρ)) = IT (ρmin). That is, the optimal treatment regime
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is the one that minimizes the total endemic equilibrium. If so, then the optimal regime
would be ρmin < ρ∗ for the case depicted on the right panel of Figure 4.6, with min(IT )< I2r .
This conclusion qualitatively agrees with that reached before: the best treatment regime is
slightly less than ρ∗ (see Figure 4.5). However, for the case depicted on the left panel of
Figure 4.6, we see that ρmin ∈ [ρ∗,1], with min(IT ) = I2r . In this case, we argue that, even
though the minimum of IT is reached for values of ρ larger than ρ∗, this is not the opti-
mal treatment regime given the high endemic levels of resistance present in this scenario.
Instead, we argue that a better treatment regime is ρ = ρe, with ρe < ρ∗ as shown before.
That is, we trade higher overall levels of the disease (i.e., IT (ρe) > min(IT )), for lower
endemic levels of resistance. We recognize, however, that for the rigorous assessment of
whether ρe is a better or worse treatment strategy than ρmin, more information is needed
(e.g., how virulent are each of the strains, what are the prospects for the development in
the near future of a new drug that is effective at killing the strains that were resistant to the
current drug).
Frequency of de novo resistance and endemic levels of resistance
We have shown how the frequency of de novo resistance, c, plays a crucial role in devising
effective treatment strategies. In addition, we find that smaller values of c lead to more
abrupt transitions from wild-type to resistant strains. In other words, the smaller the prob-
ability of developing de novo resistance, the faster the RFP gains stability when the system
is close to the threshold Rw0 =R
r
0 (Figure 4.7). Thus, for small c, the system becomes more
sensitive to variations in ρ , τ , m, and φ near this threshold. This represents a potentially
dangerous scenario: if the likelihood of de novo resistance is small, a policy-maker might
underestimate the prospects of resistance emergence and, consequently, increase treatment
levels to eradicate the wild-type strain. However, if treatment is increased above ρ∗, an
abrupt transition may occur to a state where only resistant strains persist.
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Figure 4.7: Resistant strain prevalence vs. treatment fraction. Smaller c leads to more abrupt
transitions from wild-type to resistant strains. Larger c renders ρ∗ ineffective as a treatment regime.
Mathematically, this “abrupt transition” can be justified as follows: if c 1, then Rw0 −
(1− cρ)Rr0 ≈ Rw0 −Rr0; hence, when Rr0 ≈ Rw0 , there is a “singularity” for Iw3 and Ir3 in the
CFP (4.17). Biologically, it is clear from (4.23) that limc→0+ Fr=Rr0 and limc→0+ Fw=R
w
0 .
That is, as c→0+, the reproduction numbers become the overall fitness of each strain, and
Rw0 =R
r
0 represents the condition for which both strains are equally fit. Thus, the resistant
strain outcompetes the wild-type strain as Rr0 surpasses R
w
0 .
4.4 The Single Epidemic Case
Frequently, public health programs and interventions are designed to prevent the emer-
gence of drug resistance within a single epidemic. To address this issue, we model a closed
population (i.e., µ=0 in model (4.8)-(4.12)), and examine again the role of i) the relative
transmissibility (φ ) and ii) the frequency of de novo resistance (c) on the effectiveness of
treatment regimes. In this assessment we focus on the final epidemic size (FS), defined
as the proportion of the population infected during the epidemic. As in Lipsitch et al.
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(2007), we introduce the following correction to our numerical integrations: if Ir(t)< 1
then Ir(t)=0. This prevents spurious results induced by the transmission of “non-cases”
(since Ir(0)=0, initially Ir(t) can only increase due to de novo resistant cases; given that
Ir(t) is continuous in the ODE framework, the condition above avoids that a fraction of a
de novo resistant case can cause a direct resistant infection). Throughout this section the
following parameters are fixed: N=5×105,m=0.34, γr=γu=0.2, τ=0.1, Ir(0)=It(0)=0
and Iu(0)=1.
Figure 4.8 shows a feature demonstrated previously Lipsitch et al. (2007); Althouse
et al. (2013b); Moghadas (2008): the existence of an “optimal” level of treatment for
which the total FS is minimized. We can readily see this minimum is a function of c:
as c increases, the dip in the combined FS curve vanishes. Furthermore, the treatment
regimes that minimize the total FS, are not optimal in terms of avoiding the emergence of
resistance. Let ρmin= argminρ FS(ρ). We find that ρ∗<ρmin, where as before ρ∗ satis-
fies Rw0 (ρ
∗)=Rr0. That is, the minimum in the FS is reached when resistance has already
significantly spread in the population. Additionally, Figure 4.8 shows that for larger c (dia-
mond curves), ρ∗ represents a value of the treatment fraction for which the resistant strain
has already spread considerably throughout the population. This suggests that, as in the
endemic case, the effectiveness of ρ∗ depends on the frequency of de novo resistance: as
c increases, the validity of ρ∗ becomes compromised (notice similarity in black curves of
Figures 4.7 and 4.8).
Notice also in Figure 4.8 that the epidemic is eradicated if ρ exceeds ρ1 (Eq. (4.20)),
where Rw0 (ρ
1)=1. That is, when the treatment fraction is large enough to rapidly halt the
spread of the wild-type strain, the resistant strain will not emerge. This is possible, in part,
given our assumption that treatment is implemented early on in the epidemic (i.e., Iw(0)
is small). In conclusion, if c is relatively small and treatment is put in place later in the
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epidemic or it cannot surpass ρ1(>ρ∗), then ρ∗ will ensure minimal spread of the resistant
strain.
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Figure 4.8: Final epidemic size of both strains vs. ρ . (c=0.002 as asterisks and c= 0.02
as diamonds) Vertical dashed lines represent ρ∗(c); higher c, lower ρ∗. Note that ρ∗ is effective
in halting the spread of resistance but not in reducing the total FS. Also, for larger c, ρ∗ loses its
effectiveness in avoiding the spread of resistance. Other parameters: βu=0.6,φ=0.5.
We now wish to contrast the effectiveness of ρ∗ and ρmin as a function of the relative
transmissibility φ , assuming relatively low frequency of de novo resistance (c= 0.002).
Figure 4.9 shows the FSs (due to resistant strain (black) and total (blue)) vs. φ for ρ=ρ∗
and ρ=ρmin. A treatment regime ρ∗ would “prioritize” the avoidance of resistance, while
compromising the reduction of the overall epidemic; conversely, ρmin will, by definition,
“prioritize” the minimization of the total epidemic size, while disregarding the spread of
resistance. As a result, ρ∗ is more effective than ρmin at halting the spread of resistance in
the population, whereas ρmin is a better option to reduce the overall epidemic. Moreover,
since ∂ρ∗/∂φ <0 (see (B.11)), as φ increases, a treatment regime ρ∗ will systematically
diminish the spread of resistance by reducing the treated fraction. Consequently, for higher
φ , ρ∗ will have minimal effects on reducing the total epidemic size (compare the diamond
with the horizontal blue line, where no treatment is applied). Therefore, the decision to use
ρ∗ or ρmin as a treatment regime will mainly depend on how policy makers balance a larger
epidemic produced largely by the wild-type strain, with minimal resistant cases (using ρ∗,
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for which we have a better biological and mathematical understanding), versus a smaller
overall epidemic with higher resistance incidence (using ρmin).
To summarize, when the fraction of de novo resistant cases and the relative transmis-
sibility are rather small, ρ∗ constitutes a useful quantity for treatment policies in a single
epidemic outbreak provided it can contain the overall epidemic while restraining the spread
of resistance in the population.
4.4.1 Relative transmissibility and non-pharmaceutical interventions
It is likely that treatment alone cannot completely quell an emerging epidemic Longini
et al. (2005). In such cases, non-pharmaceutical interventions (e.g., social distancing, case
isolation, travel restrictions) could help to significantly mitigate the extent of the epidemic
Regoes and Bonhoeffer (2006); Ferguson et al. (2006, 2005). These can affect the transmis-
sibility of the wild-type and the resistant strain while maintaining the relative transmissibil-
ity of the latter (φ ). Here we investigate the competition dynamics between the wild-type
and the resistant strain as a function of φ , and the transmissibility of the wild-type strain βu
(which varies due to non-pharmaceutical interventions) under different treatment regimes.
The total FS is comprised by the resistant-strain cases (FSres) plus the wild-type cases
(FSw). To determine the dominant strain, we compare FSres and FSw. Figure 4.10 shows
numerical results of FSres− FSw in the (βu/γu,φ ) parameter space (γu fixed). For instance,
if FSres− FSw > 0 (gray-black region), the resistant strain is accountable for more cases
than the wild-type strain. The wild-type dominated region is in red.
The resistant strain can only spread in the βu region for which the wild-type strain
significantly spreads: notice in each graph, a vertical light-red region where only the wild-
type strain minimally spreads, and to its right we see regions of coexistence. The value of
βu defining the split of these two regions, β 1u , is such that Rw0 (β
1
u ,ρ)=1; if βu<β 1u (ρ), the
wild-type strain will only generate few infections and consequently the resistant strain will
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Figure 4.9: Final Sizes vs. relative transmissibility for ρ=ρ∗ and ρ=ρmin. The figure shows
the effectiveness of ρ∗ and ρmin vs. the relative transmissibility. For any value of φ , ρ∗ is more
effective than ρmin at avoiding the spread of resistance in the population (black diamond vs. black
dashed curves). However, ρmin is more efficacious at reducing the overall epidemic (blue dashed vs.
blue diamond). Solid line corresponds to ρ=0. Other parameters: βu=0.6,c=0.002.
mainly be in rare de novo resistant cases. A similar consideration was presented in Figure
4.8.
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Figure 4.10: FSres−FSw in the (βu/γu,φ ) parameter space. γu is fixed, and ρ = 0.3,0.5,0.7
(left to right). Gray-black regions are dominated by the resistant strain. As treatment increases the
resistant strain 1) benefits from higher wild-strain transmissibility, 2) increases the range of relative
transmissibility for which it can spread, and 3) expands the region in which it can extensively spread
(black region).
In general, for lower φ the resistant strain cannot spread, while the wild-type strain
produces an increasingly larger number of infections as βu increases. As treatment (ρ)
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increases, the resistant-dominated region shifts to higher values of βu, while expanding the
range of φ for which it can significantly spread (darker areas).
These observations suggest that if the wild-type strain features relatively low transmis-
sion, the best strategy to contain both strains is to treat “hard and early.” However, if the
transmissibility is higher and the fitness cost of resistance is low, then this strategy can have
devastating consequences as the resistant strain can infect a large fraction of the population.
This demonstrates the importance of effective non-pharmaceutical interventions that could
reduce βu.
For larger values of φ an interesting process occurs. Starting from low βu the wild-
type dominates. As βu increases – crossing the “vertical” null isocline where both FSs
are equal – the resistant strain begins to prevail, until crossing the “slant” null isocline
where the wild-type strain starts to regain its dominance. A possible explanation for this
dominance shift is that as the wild-type strain becomes more transmissible, it depletes the
pool of susceptibles too quickly, leaving the resistant strain with few individuals to infect
once it emerges. However, for even larger φ and high ρ , increasing βu also increases the
FS of the resistant strain. In this scenario, the relative transmissibility is so high that even
if the wild-type strain can spread rapidly, the resistant strain will eventually “catch up” and
outcompete it.
Thus, when trying to predict the outcome of the competition dynamics between wild-
type and resistant strains, knowing the relative transmissibility of the latter is not sufficient.
One must also know the actual value of its transmissibility. In the endemic case, however,
when treatment is fixed, the relative transmissibility completely determined which strain
ultimately dominated (Figure 4.3). These considerations complement observations made
in Lipsitch et al. (2007).
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4.5 Discussion
The rapid development of an effective vaccine against an emerging novel influenza
virus presents considerable challenges. Thus, antiviral agents could play a central role as
a first-line defense against emerging epidemics of influenza. The large-scale use of these
drugs could, in turn, select for the evolution of drug-resistant strains Regoes and Bonho-
effer (2006), making the strategic distribution of antivirals essential in quelling the spread
of drug-resistance while limiting the overall epidemic size. In this work we have discussed
the influence of two key parameters on the effectiveness of treatment: the relative trans-
missibility of the drug-resistant strain (φ ), and the frequency of de novo resistance (c). We
extended a previous model Lipsitch et al. (2007) to include demography and performed
analytical calculations of the reproductive numbers, stability of the fixed points, and con-
ditions for the exclusion or coexistence of resistant and wild-type pathogen strains.
In the endemic case we found that, depending on the values of Rr0 (or equivalently φ )
and c, the optimal treatment regime will be at intermediate (case (A) for high φ and low c
) or more extreme values (case (B) for low φ and high c). Intuitively it is clear that if the
resistant strain is highly transmissible (high φ ), then treatment should be moderate in order
to limit the selective advantage of drug-resistant phenotypes. Conversely, if the resistant
strain is weakly transmitted (low φ ), then more intense treatment regimes are preferred
since resistance-only endemic levels will be relatively low. These recommendations are
valid as long as infections with a wild-type or a resistant strain represent the same harm to
the host (e.g., strains with similar infectious periods and virulence). In addition, we also re-
marked that when c is low, the optimal treatment regime can be approximated by ρ∗. In the
single epidemic case, numerical simulations also suggest that if c and φ are low, ρ∗ is still
a useful quantity when designing treatment strategies. However, in contrast to the endemic
case, knowing the relative transmissibility of the resistant strain is not enough to predict
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the final outcome of the competition between the two strains. In this case, the strain that
successfully spreads first has a significant impact on which strain infects more individuals
during the epidemic. Our results also indicate that early and high treatment regimes are
most effective at reducing the number of infections while hindering the rise of resistance,
when the transmissibility of the wild-type strain is relatively low. This emphasizes the im-
portance of non-pharmaceutical interventions aimed at reducing the transmission rate of
the disease.
An interesting similarity across time scales is the impact of the frequency of de novo
resistance on ρ∗: as c increases, the effectiveness of ρ∗ becomes compromised. While
we give mathematical and biological arguments for this property, the inherent uncertainty
in the empirical values of c make this observation potentially relevant to the designing of
treatment strategies Regoes and Bonhoeffer (2006).
Our model, like any other, is not exempt of simplifying assumptions, or uncertainties
about the model parameter values and transmission dynamics of wild-type and resistant
strains. Thus, rather than providing specific quantitative recommendations for treatment
policies, we emphasize the qualitative character of our observations. Moreover, we recog-
nize that even if these uncertainties were resolved, we still face ethical issues when deciding
to implement treatment policies based on our recommendations; e.g., treat only a certain
fraction of those infected if relative transmissibility is high and de novo resistance is un-
likely. This is a difficult case for the public health planner, and the choice is left to them. If
relative transmissibility is low and de novo resistance is more likely, then our recommenda-
tions are less controversial: treat people as they come in based on their clinical profile. In
terms of the assumptions made in our analysis, we considered that treatment and de novo
resistance happen immediately after infection. In Appendix A.3 we present a model that
features stage progressions (treatment and de novo resistance occur at certain rates rather
than instantaneously) and show that its dynamics are analogous to those presented here (see
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Figures B.1–B.3). We also assumed that the fraction of treated individuals can, with no re-
gard to economic and social costs, attain any value between 0 and 1, and remain constant
throughout time. This is generally not true as treatment availability and costs vary with time
and socioeconomic context (models in Hansen and Day (2011); Moghadas et al. (2008);
Jaberi-Douraki et al. (2012); Moghadas (2008) explore different time-dependent treatment
regimes). We have considered a model with equal birth and death rates, thus, it may also be
important to study the impact of demographics on the effectiveness of treatment regimes,
though less so in the single epidemic case. We have also excluded coinfection with both
strains, which is known to affect the evolution of the influenza virus (e.g., viral reassortment
Nelson and Holmes (2007)), and could in turn influence the development of drug-resistant
phenotypes. We suspect that accounting for coinfection might lead to new and interesting
dynamics.
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Chapter 5
MANAGING DRUG RESISTANCE IN STRUCTURED POPULATIONS
5.1 Introduction
Two strong simplifications made in the previous model were to ignore the complex
contact structure of human populations and the stochastic nature of the transmission and de
novo resistance dynamics. While these assumptions allowed us to obtain closed-form solu-
tions for effective treatment regimes, the social network underlying the epidemic process is
known to have non-trivial effects on transmission dynamics Pastor-Satorras and Vespignani
(2001); Read and Keeling (2003b); Keeling and Rohani (2008a); Althouse et al. (2013b).
In fact, the bulk of studies investigating the spread of resistance in host populations
have ignored stochasticity and heterogeneous contact structures. To address this need, we
will construct a model equivalent to (4.8)-(4.12) that features contact structure Barabasi
and Albert (1999) and stochasticity Newman (2002).
5.2 The model
In this section we construct a model equivalent to (4.8)-(4.12) that features contact
structure and stochasticity. Details of this model can be found in He´bert-Dufresne et al.
(2013) and Althouse et al. (2013a), both papers that I have coauthored. Basically, we
constructed a model consisting of individuals embedded in a contact network, where each
of them can be in one of five states, as before: susceptible (S), infectious and untreated
(Iu), infectious and treated (It), infectious with a resistant strain (Ir), or recovered (R). The
dynamics then obey the following rules: (i) A link from Ix to S leads to an infection at a rate
βx, x ∈ {u, t,r}; (ii) a wild strain infection is untreated (S→ Iu) with a probability 1−ρ , or
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treated with a probability ρ; (iii) treatment is effective (S→ It) with a probability 1− c, or
leads to resistance mutation (S→ Ir) with a probability c; (v) Infectious individuals of type
Ix recover at a rate γx. One of the benefits of network modeling resides in the possibility to
account for heterogeneity in the contact structure of a population. Hence, we consider a fat
tailed distributions of links per node (or degree distribution) to simulate a heterogeneous
network (see Figure 5.1).
5.3 Effective Treatment Regimes in Structured Populations
Like in the previous chapter, we aim to find treatment regimes (i.e., fraction of the
population treated) that are effective in containing both the overall epidemic size and the
spread of resistance. With a similar parametrization as for the deterministic case, we again
assume c=0.002, and utilize Monte-Carlo (MC) simulations to assess the effectiveness of
ρ∗ (Eq. (B.11)) in single epidemic situations.
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Figure 5.1: The fat-tailed degree distribution (contact per individual) with power-law tail
and exponential cut-off. Used to generate heterogeneous networks for the MC simulations.
To perform MC simulations of the model, we generated networks of size N=25×104
with fat-tailed degree distributions {pk} (distribution of number of contacts per individual,
shown in Figure 5.1), via the Configuration Model algorithm Newman (2010). For every
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generated network, a randomly chosen individual is infected with the wild-type strain and
the dynamics are then simulated in discrete time:
i. each time step, every susceptible neighbor S of every infectious individual Ix is in-
fected with probability βx∆t;
ii. wild-type infections are treated with probability ρ , leading to resistance-conferring
mutation with probability c;
iii. each time step every infectious individual Ix recovers with probability σx∆t (with
µ=0).
Figure 5.2 shows the variation in the final epidemic size (FS) of the system due to the
contact heterogeneity and the inherent stochasticity of the disease and pathogen mutation
processes. The worst-case scenarios (the highest FS obtained for a given value of ρ) follow
qualitatively the same behavior as the ODE model above (blue curves in Figure 4.8). More
importantly, the predicted optimal treatment fraction ρ∗ provides a good approximation to
what could be considered the best treatment plan, yielding the lowest total FS while halt-
ing the spread of resistance (Figure 5.2, greener dots). As in the deterministic case, for
ρ>ρ∗, resistance spreads widely. Hence, when the frequency of de novo cases is small,
the efficacy of the treatment fraction ρ∗ to minimize both the epidemic size and the risks
of resistance emergence, is robust to both the heterogeneity of population structure as well
as the stochasticity of transmission and mutation dynamics.
5.4 ‘Superbugs’ and Targeted Treatment in Structured Populations
This network framework is also suitable to address issues such as the effects of treat-
ment regimes (targeted versus non-targeted) on the development and persistence of re-
sistance. That is, does targeted treatment give rise to more resistance than non-targeted
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Figure 5.2: Monte Carlo simulations on a network with heterogeneous contact structure.
(c = 0.002). Every point represents one of over 10,000 simulations on networks of size 250 000,
with color indicating the proportion of resistance in the FS (from black, 100% wild-type, to green,
100% resistant). ρ∗ (Eq. (B.11)) is shown in dashed black line. The effectiveness of ρ∗ is robust to
stochasticity and heterogeneous contact structures. Other parameters: βt =0.3,m=0.3,φ=0.5,τ=
0,βu/γu = 0.6, and Ru0 = 〈k′〉βu/γu = 9.6, where 〈k′〉 is the average excess degree in the network
Newman (2002).
treatment. Also interesting in the light of recent studies on the evolution of transmissibility
of highly pathogenic avian influenza (H5N1) Lipsitch et al. (2012); Herfst et al. (2012);
Russell et al. (2012); Imai et al. (2012), is to investigate what are the implications of a
highly pathogenic resistant strain evolving in a pandemic context where treatment is being
deployed?
One of the most interesting epidemiological insights in He´bert-Dufresne et al. (2013) is
that, initializing the epidemic with a single wild-type infected, if the resistant strain is com-
pensated (i.e., more transmissible than the treated wild-type strain), it can largely spread in
the population, even when the wild-type strain is below its epidemic threshold (i.e., when
only a few wild-type infections occur without causing an wild-type strain epidemic). In
fact, if wild-type strains are bellow its epidemic threshold, the few wild-type cases can
potentially lead to the emergence of highly transmissible resistant mutants in highly con-
nected nodes, which can in turn unleash an epidemic of drug-resistant strains that benefit
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from the lack of competition from its wild-type counterpart. This result points to the great
danger that represents the evolution of “superbugs”, that is, drug-resistant pathogens that
are also highly transmissible.
In Althouse et al. (2013a) we explore additional questions. For instance, what is the
role of initial conditions on the effectiveness of treatment? and which treatment regime,
targeted by degree or not, leads to the least amount of resistance?
For the first question we found that when resistance has no fitness cost (βr > βu), bista-
bility emerges (where, for the same wild-type transmissibility βu, two final epidemic sizes
can be reached in different stochastic simulations), and the timing of treatment, measured
by the number of infected individuals at the start of treatment, is crucial. More specifically,
treating when the number of initially infected is high (i.e., late in the epidemic) could be
very detrimental, with larger final epidemic sizes than without treatment. Also in the sce-
nario of βr > βu, we find that models that include stochasticity and contact structure predict
less worse scenarios than mean field models. If, on the contrary, βr < βu, then treatment is
always beneficial.
Now, assuming treatment is expected to be beneficial (βr < βu), we can explore two
different forms of treatment: non-targeted, where ρ is a percentage of the population se-
lected at random for treatment, and targeted, where ρ is a function of node degree. That
is, an individuals probability of being treated, namely PT , depends on its degree, and it is
given by PT (k) = 1− (1−ρ)k
PT (k) = 1− (1−ρ)k
1.
1This formula is obtained from considering, for example, an scenario in which each of the k neighbors of
a given individual (a node of degree k), will select this individual to get vaccinated with probability ρ . The
probability that none of your neighbors selected you to get vaccinated is (1−ρ)k, thus the probability that at
least one neighbor selected you is PT .
149
Simulations show the expected transition from wild type to resistant infections as treat-
ment levels increase, and reach a minimum in disease prevalence at intermediate levels
of treatment (see Figure 5.3). Interestingly, we see higher levels of resistance at lower
treatment percentages in the targeted treatment regime. Under the non-targeted treatment
regime, the resistant strain dominates when ρ > 85%, whereas under the targeted treatment
regime, resistance is dominant when ρ > 52%. This happens because targeted treatment
increases the chances of resistance occurring in high-degree nodes. Once resistant mutants
arise in highly connected nodes, they will have a high probability of being widely transmit-
ted. In addition to the take over of the resistant strain in the targeted treatment regime, we
see high levels of total infection with increasing percentage treated due to treatment failure
in the resistant cases. We note, however, that in cases where drugs are scarce, the amount
of resistance expected to appear is low and treatment targeted by node degree is preferable
to no treatment or non-targeted treatment.
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Figure 5.3: Comparison of random and targeted treatment. The left panel shows the final size for
wild-type, resistant and both infections as a function of percentage treated, ρ , for targeted (dashed
lines) and non-targeted (solid lines) treatment regimes. We see a transition from wild-type to re-
sistant infections at a lower treatment percentage in the targeted treatment regime. The right panel
shows the percent of total infection that is the resistant strain for the targeted (dashed line) and
non-targeted (solid line) treatment. Figure taken from Althouse et al. (2013a)
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5.5 Discussion
In this chapter we showed that for small c (frequency of de novo resistance is rare),
the effectiveness of the parameter ρ∗ is robust to the presence of contact heterogeneity and
stochasticity, as it still minimizes both the epidemic size and the risks of resistance emer-
gence. This reinforces the public health implications of the effective treatment expressions
derived herein.
In light of recent findings suggesting the possible evolution of highly pathogenic in-
fluenza strains, our results addresses the epidemiological impact of a highly transmissible
strain evolving resistant traits and reaching a human population. We showed that if this type
of drug resistant strain emerges, it can infect a considerable fraction of the host population,
even when its wild-type counterpart is unable to spread (i.e., is below its epidemic thresh-
old). This evidence, although the result of simulations using a relatively simple model,
indicates the possibility of a devastating scenario should these “superbugs” are allowed to
evolve and come in contact with the general population.
In addition, we demonstrated that when the emergence of drug resistance is a potential
thread, targeting treatment policies should be carefully assessed given that prioritizing indi-
viduals with higher number of contacts can indeed facilitate the emergence and population
wide spread of resistant pathogens. These results are counter to previous ones demonstrat-
ing that targeted treatment is optimal to keep absolute numbers of infecteds low. Thus,
in structured populations, non-targeted treatment is preferable if resistance is to be mini-
mized. This implies that in populations where the development of resistance is of concern,
resources do not need to be spent on targeting treatment.
The results from this chapter and the previous one shed light on the epidemiological
impact of the interplay between treatment regimes and relative transmissibility of a strain
of influenza resistant to antiviral treatment and the frequency of de novo resistance, both
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aspects which are difficult to assess empirically. These situations are explored both in
unstructured as well as in structured populations, and therefore our conclusions could have
important implications for the strategic distribution of antivirals in a population in response
to the emergence of a novel influenza strain.
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Chapter 6
FITNESS COST HETEROGENEITY AND THE CONTROL OF ANTIBIOTIC
RESISTANCE
The emergence and spread of drug-resistance is an almost inevitable consequence of
the rampant use of antivirals during influenza epidemics. However, drug-resistant strains
are not all created equal, and as a result the nature of fitness in drug-resistant strain is of-
ten unpredictable (example in influenza A viruses Hai et al. (2013)). Moreover, not only
could different strains present a different genetic makeup, which would lead on its own to
different phenotypic expression (e.g., virulence and transmissibility), but the specificity of
human-pathogen interactions (e.g., hosts with different immune systems and/or drug ad-
herence practices), could also lead to a myriad of drug-resistance phenotypes. Therefore,
within an epidemic, instead of a single resistant phenotype, a distribution of resistant phe-
notypes with different fitness costs could evolve. To be sure, two phenotypes are different
if their ability to infect a susceptible host (i.e., transmissibility) differ.
Cohen and Murray (2004) addressed the issue of fitness cost heterogeneity in the con-
text of multi-drug resistant (MDR) tuberculosis. Using a deterministic framework, and
with two co-circulating drug-resistant phenotypes, this study showed that even if the de
novo appearance of highly transmissible MDR strains is rare, they may eventually become
a major public health threat.
We will build upon this model, first, by considering not only two drug-resistant phe-
notypes, but non pre-defined number of these, each with different fitness costs (i.e., fitness
heterogeneity); and second, by accounting for the stochastic nature of the transmission pro-
cess and developing of de novo resistance (i.e., stochasticity). Thus we propose to study
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the effect of transmission heterogeneities among resistant strains on epidemic outcomes
and the effectiveness of treatment strategies.
6.1 The model
Our modeling framework assumes a host population of size N where individuals mix
randomly as to allow a potential transmission event to occur between any infected and sus-
ceptible hosts. Since we are interested in short term outcomes (i.e., single epidemics), no
births or deaths are considered. Individuals can be in one of five states, as before: sus-
ceptible (S), infectious and untreated (Iu), infectious and treated (It), infectious with the
ith evolved resistant strains (Iri), or recovered (R). The dynamics then obey the following
rules: (i) A contact between Ix and S leads to an infection at a rate βx, x ∈ {u, t,ri}; (ii) a
wild strain infection is untreated (S→ Iu) with a probability 1−ρ , or treated with a proba-
bility ρ; (iii) treatment is effective (S→ It) with a probability 1−c, or leads to a resistance
mutation (S→ Iri) with a probability c; (v) Infectious individuals of type Ix recover at a rate
γx.
Modeling Phenotypic Heterogeneity
To explicitly model the heterogeneity of resistant strains, let κM and κm be the maxi-
mum and minimum fitness cost of resistance that we arbitrarily assume. We then postulate
that the fitness cost of resistant strain i is given by
κi = κM− (κM−κm)ωi (6.1)
where ωi ∈ [0,1] is sampled from a Beta distribution (see Figure 6.1). Cases ωi = 0 and
ωi = 1 represent, respectively, maximum fitness cost and minimum fitness cost– the latter
being equivalent to sensitive strains if κm = 0. This idea is incorporated into the modeling
framework by assuming that the transmission rate of resistant strain i is βri = βu(1−κi).
That is, the relative transmissibility of strain i is given by φi = βri/βu = (1−κi).
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Within this framework we can address interesting questions such as: 1) What is the
impact of the distribution’s variance (extent of phenotypic heterogeneity) on the risk of an
epidemic of resistant strains? 2) How does this variance affects the effectiveness of treat-
ment strategies?
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Figure 6.1: Top Beta distributions with mean 0.5 and a = 0.1 (black), a = 1 (green), and a =
100 (red). Bottom Three hypothetical examples of fitness cost distributions in the population of
drug-resistant strains. Plot generated using 1000 samples of a Beta distribution with mean 0.5 and
increasing values of parameter a, and κm = −0.1,κM = 0.4. In black (a = 0.1), a profile in which
most emerging resistant strains are either highly fit or poorly fit. In green (a = 1), all resistant
phenotypes are equally likely to emerge in the population. In red (a = 100), a profile in which most
resistant strains present the same fitness cost.
Modeling Transmission Events
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The transmission events are modeled probabilistically. More specifically, let θi(t) be
the rate at which a susceptible individual, indexed i, becomes infected between time t and
t+dt with either phenotype. Then,
θi(t) = [βu(Iu(t)+mIt(t))︸ ︷︷ ︸
drug−sensitive
+ βu ∑
j∈Ω(t)
φ j︸ ︷︷ ︸
drug−resistant
](dt/N) (6.2)
where Iu(t) and It(t) are, respectively, the number of untreated and treated infected individ-
uals at time t. To account for the rate of resistance infections we add the term ∑ j∈Ω(t)φ j,
with Ω(t) being the set of all extant resistant strains at time t. This term adds the fit-
ness of each resistant strain present at the moment of the infection. That is, whereas all
sensitive-strain infecteds are counted as 1 in the force of infection rate (i.e., their relative
transmissibility is 1 by definition), the drug-resistant infecteds are counted by the relative
transmissibility of the resistant strain they are infected with, which could be less or greater
than 1 (depending on the values of km and kM)1.
If we assume that the transition processes from one class to another is a homogeneous
Poisson process 2 Ross (2006), the probability that a susceptible individual, indexed i, is
infected with either strain between time t and t+dt is given by
PiI (t) = 1− exp−θi(t) . (6.3)
1For the simulations we do not explicitly model each strain, or count how many people it infected and so
on. Instead, we only model individual hosts. To determine which strains a given infected host carries, we
assign to each infected host a value corresponding to the relative fitness of the strain with which is infected.
This allows us to determine how infectious this person is, and thus how likely it is to infect another susceptible
host. This is also convenient since we do not need to explicitly model and keep track of all the strains that
could evolve (which number we do not know a priori).
2This assumption is valid if i) the number of individuals in the simulation is large enough, ii) at most
one event happened to an individual within a small interval dt, and iii) what happens to a given individual is
independent of what happened to any other individual in the population.
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Once an individual is infected, we must decide to what infected class it will transition
to. To determine that, we need to compute the probabilities of the individual going to each
of the infected classes Iu, It and Ir, given that it is infected. These are
Pr[S→ Iu] = βu(Iu+mIt)θi × (1−ρ) (6.4)
Pr[S→ It ] = βu(Iu+mIt)θi ×ρ(1− c) (6.5)
Pr[S→ Ir] = βu(Iu+mIt)θi ×ρc︸ ︷︷ ︸
de novo resistance
+1− βu(Iu+mIt)
θi︸ ︷︷ ︸
resistant infection
(6.6)
(6.7)
These transition probabilities (which sum to 1, as expected) are enough to determine
the type of infection that occurred. However, if the infection is by a resistant strain, we still
need to determine the fitness cost of the infecting resistant strain. If, on the one hand, the
infection is due to a de novo resistance event within a treated individual i, the fitness cost of
such resistant strain is ki, which is obtained using (6.1). If, on the other hand, the infection
is due to a transmission event from an individual infected with a resistant strain, we then
need to decide which resistant phenotype is the one being transmitted. In fact, we assume
that the probability pz(t) that the resistant strain z is the one being transmitted at time t is
proportional to its relative transmissibility φz, and is given by
pz(t) =
φz
∑ j∈Ω(t)φ j
. (6.8)
6.2 Simulations
In this section we show simulations results from the model described above. We specif-
ically address the following question: how does the phenotypic diversity of resistant strains
affects the emergence and spread of resistance in different treatment scenarios?
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We model a population of N = 10× 103 for a total of T = 700 days (unit time). The
time step is dt = 0.1 of each day. To model three different heterogeneity profiles of the
resistant strains, we use a Beta distribution with mean 0.5, and with a parameter equal to 0.1
(high heterogeneity), 1 (medium heterogeneity) and 100 (low heterogeneity) as in Figure
6.1. In addition, to explore the impact of pathogen transmissibility, we use βu = 0.5 (low
transmission), and βu = 0.8 (high transmissibility), which taking ρ = 0.5 in the expression
for R0 in (4.13) (in Chapter 4) yields R0=1.53 and 2.45, respectively. Also, the probability
of treatment varies from 0 to 1, increasing in 1/20 step increments. The other parameters
are: m = 0.34, γu = γr = 0.2, τ = 0.1,c = 0.005. For each parameter combination, 50
realizations were executed, from which the mean and standard error (thus, 95% confidence
intervals) of final epidemic sizes are obtained (including epidemic die-outs). Finally, the
probability of an epidemic was computed (we defined an epidemic of either strain as the
event where at least 0.1% of the population was infected by either strain).
6.3 Discussion
Figure 6.2 shows that, as expected, when the treatment probability, ρ , increases, the
number of sensitive-strain infections decreases systematically. The effect of ρ on the final
epidemic size of the resistant strains is a bit less obvious, as the the resistant strain can only
emerge in treated sensitive-strain infected individuals (as we have assumed). As a result,
resistant strains are most benefited when the probability of treatment is such that sensitive-
strain’s final size is largely reduced, decreasing the competition for susceptible individuals,
but still large enough as to guarantee the emergence of several resistant strains.
In the case of βu = 0.5, when ρ becomes large enough (i.e., greater tan 0.8), we can see
that the sensitive strain final size is very close to zero. Accordingly, the final epidemic size
of the resistant strains is also reduced to almost zero. This is the scenario where treatment
did not allow for a considerable number of sensitive strains to spread, also reducing the
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Figure 6.2: Mean final epidemic sizes versus treatment fraction for different phenotypic profiles
a = 0.1,1.0 and 100. The semitransparent ribbons represent the 95% confidence intervals
chances for several resistant strains to emerge and spread, even though these faced almost
no competition for susceptible individuals. As a result, the resistant strain’s final size peaks
at intermediate values of ρ . Note that when βu is larger (i.e., 0.8), the sensitive strain
can still infect a non-negligible fraction of the population even when the probability of
treatment is close to 1. As a consequence, the resistant strain’s final size peaks at larger
values of ρ .
Thus, from these observations we can conclude that the larger the “baseline” transmis-
sion rate of the sensitive strain, βu, the larger the treatment probability at which the final
epidemic size of resistant strains peaks.
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Similar insights can be obtained when focusing on the probability of large epidemic
sizes (at least 1% of the population became infected with that type of strain). As Figure
6.3 demonstrates, the larger the “baseline” transmission rate, βu, the larger the treatment
probability at which the probability of large epidemic of resistant strains peaks, whereas
the probability of large epidemic of the sensitive strain decreases systematically with larger
treatment probability.
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Figure 6.3: Probability of sensitive (top) and resistant (bottom) strains epidemic.
The results in Figures 6.2 and 6.3 suggest, surprisingly, that phenotypic heterogeneity
in the drug resistant strains– as modeled here– does not have a major impact on epidemic
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outcomes such as final epidemic size and probability of large epidemics, nor does it affect
the uncertainty (as measured by the 95% confidence bands) around the average final sizes.
Arguably, the final epidemic size of the resistant strain is, on average, slightly larger when
phenotypic heterogeneity is larger in the case the transmission rate βu = 0.5 (see bottom
left panel in Figure 6.2).
This last observation hints that, if the parameter space is more exhaustively explored,
particularly for transmission rates near the epidemic threshold, the effect of large pheno-
typic heterogeneities could be more noticeable and more impactful on epidemic outcomes.
However, the results presented thus far, do not indicate any major epidemic differences due
to different resistance phenotypic profiles.
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Chapter 7
FINAL REMARKS
A healthy society can be achieved through the improvement of the medical industry,
or by focusing instead on preventive strategies (e.g., social, economical, environmental,
logistical) to reduce the incidence of disease in the first place Lo¨nnroth et al. (2009). The
investigations of the first half of this dissertation (Chapter 2 and 3) were motivated by
the latter approach. As cities become the bedrock of human activity, urbanization may
ultimately remain the most sustainable solution to our planet’s environmental challenges,
as it appears to foster innovations and economic growth, as well as greener environments
as the economies-of-scale observed in their physical infrastructure indicate Bettencourt and
West (2011).
How can we tell if a population is thriving? One standard answer is based on eco-
nomic wellbeing, measured by metrics such as gross national product, average income, or
consumption patterns. A better approach, however, could be to measure health status of
individuals. It is challenging, nevertheless, to convince policy makers that the health of the
population is important precisely because it is a way to determine whether or not a popula-
tion is benefiting from a set of social arrangements. Marmot (2005) states: “action on the
social determinants of health is necessary not only to improve health but also because such
improvement will indicate that society has moved in a direction of meeting human needs.”
The insights put forward in this work, which are at the intersection of technology, ecol-
ogy and biology, could inform public health policies and interventions, as well as urban
planning and sustainability Batty (2008); Bettencourt and West (2010). In fact, urban plan-
ning historically grew out of a public health crisis in the 19th century, when the industrial
revolution led to overcrowded and unhygienic cities that offered suitable conditions for
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pathogens to readily spread and cause major morbidity and mortality. A key example is
that of British physician John Snow, who in 1854 used geographic mapping of an outbreak
of cholera in London to identify a public water pump as the source of the outbreak. Today
there is a growing appreciation for the value of planning and designing cities to support
healthy lifestyles and environments without giving up the significant benefits and opportu-
nities that large and socially connected cities offer. To this end, this research could help
identify the socio-economic and demographic conditions that may help cities grow without
increasing the burden of infectious diseases.
Inferring the underlying dynamics and processes that could have generated epidemic
patterns can help us obtain insights about the possible impact of different socio-economic
environments and interventions on the spread of diseases. For this inference, we need
to construct falsifiable and testable theories and models. Admittedly, the models used
throughout this dissertation are a crude simplification of complex realities. Our model
building has being guided by the parsimony reflected in Occam’s razor principle, which
states that one should proceed with simpler theories and models until simplicity can be
traded for greater explanatory power. One of the reasons for adopting this view is that
model simplicity facilitates the falsifiability and testability of the theory or hypothesis put
forward, both fundamental aspects of the scientific method. For example, it is easier to test
whether effect A1 causes (or is associated with) event B, than testing whether any of the
effects A1,A2...An cause event B. In addition, simple models, as it often happens, can lead
to insights of a general nature about the factors dictating disease patterns Watts (2004),
not to mention the extensive and sometimes arbitrary parametrization needed to extract
information from more complex models.
As a result, this dissertation presents relatively simple models that aim to improve our
understanding of incredibly complex phenomena, such as the dynamics of STDs in urban
areas, or how the control of antimicrobial resistance in host populations. In fact, any model
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that tries to explain complex socio-economic and biological phenomena is necessarily an
oversimplification. The purpose of these theoretical investigations is to help determine
what factors seem to be relevant and which ways, and how can we try to change them to
solve existing problems.
Shall the factors and relationships deemed important by our models find limited sup-
port by later research, the models in this work can be rejected, or reassessed and still be
beneficial in the process finding other important factors unnoticed the first time around.
Not intending to provide quantitative predictions of future trends in disease incidence,
our aim was to, through the use of ‘prove-of principles’, improve our understanding of,
on the one hand, the impact of socio-economic factors that influence the incidence and
prevalence of STDs, and on the other hand, the effect of biological aspects of drug-resistant
viruses in the effectiveness of treatment strategies. In closing, “Mathematics is no more or
no less than a language for thinking about things in a precise way” Garnett and Anderson
(1996).
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APPENDIX A
SCALING OF STDS AND HEALTH CARE INEQUALITIES IN URBAN AREAS
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A.1 The issue of “abstinence-only” sex education policy
Here we investigate if the states with abstinence only sex ed differ, in terms of incidence
rates, from the states that do not enforce that policy. For this, we categorize states in terms
of their policy. In fact, there are three categorizations: states that require that, during class,
information on “abstinence only” is (1) stressed, (2) covered or (3) not at all. As Figure
A.1 shows, the average incidence rates are consistently higher in states in the (1) category,
for all three diseases. sexEd
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Figure A.1: Distribution of incidence rates in counties within states that have different sex-ed
policies.
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A.2 The burden of gonorrhea, syphilis, chlamydia and influenza in the U.S.
A.2.1 Gonorrhea
Gonorrhea is a sexually transmitted disease caused by the bacterium Neisseria gonor-
rhoeae, although it can also spread from an untreated mother to her baby during childbirth.
Gonorrhea is the second most commonly reported notifiable disease in the U.S. cdc (2011).
Symptoms can vary, with many cases experincing none at all. In men, common symp-
toms are burning sensation when urinating, painful or swollen testicles, or a white, yellow,
or green discharge from the penis that usually appears 1 to 14 days after infection. Most
women with gonorrhea do not have any symptoms, and when they do, these are often mild
and can be mistaken for a bladder or vaginal infection.
Infections due to N. gonorrhoeae are a major cause of pelvic inflammatory disease
(PID), which can lead to serious health issues in women, such as tubal infertility, ectopic
pregnancy, and chronic pelvic pain. Also, gonococcal infections facilitate the transmission
of HIV infection. In addition, the treatment and control of gonorrhea has been complicated
by the ability of N. gonorrhoeae to develop resistance to antimicrobial agents. Most re-
cently, fluoroquinolone resistance emerged and resulted in the availability of only a single
class of antibiotics that meet CDCs efficacy standards- the cephalosporins. The threat of
cephalosporin resistance highlights the need to better understand the epidemiology of gon-
orrhea. In fact, in a recent report CDC (2013) the CDC classified the issue of drug-resistant
N. gonorrhoeae as an urgent threat.
After a two-decade decline, gonorrhea cases hit their lowest rates in 2009 (see Figure
A.6). During 2009-2010, gonorrhea rates increased in the Northeast and West regions of
the US, however, as in previous years, the South and Midwest had the highest rates (see
Figure 2.19).
In 2010, gonorrhea rates were highest among adolescents and young adults, with the
highest rates being observed in women aged 15-24 years. Also, disease rates have remained
highest among blacks, especially men. In 2010, the gonorrhea rate in blacks was almost
20 times the rate in whites cdc (2011). In the last two decades there has been a significant
increase (5-fold) in the proportion of cases that are MSM cdc (2011). It is worth mentioning
that all these changes in gonorrhea rates may be masked by changes in screening practices,
as well as in reporting practices.
A.2.2 Syphilis
Syphilis is a sexually transmitted disease caused by the Treponema pallidum bacterium.
It is a genital ulcerative disease, that causes significant complications if untreated, including
death. Syphilis can be transmitted during vaginal, anal, or oral sexual contact. Pregnant
women with the disease can pass it to their unborn children. Untreated syphilis in pregnant
women results in perinatal death in up to 40% of cases and, if acquired during the 4 years
before pregnancy, can lead to infection of the fetus in 80% of cases cdc (2011). It also
facilitates the transmission of HIV infection.
This disease can have several stages if untreated. The Primary Stage is characterized by
the appearance of painless sores. Because the sore is painless, it can easily go unnoticed.
The sore lasts 3 to 6 weeks and heals regardless of whether or not a person is treated. If
untreated, the infection progresses to the Secondary Stage, marked by symptoms such as
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Figure A.2: Gonorrhea rates per 100,000 in U.S. Counties
skin rashes and/or sores in the mouth, vagina, or anus. These symptoms will disappear
with or without treatment. If untreated, infection will progress to the latent and possibly
late stages of disease, in which the infected person can continue to have syphilis in their
body even though there are no signs or symptoms. Symptoms of the late stage of syphilis
include difficulty with motor coordination, paralysis, gradual blindness, dementia, damage
to internal organs, which can result in death.
Although the rates of primary and secondary (P&S) syphilis in the US declined during
1990s to historically low values, rates increased during 2001-2009 (see Figure A.6). Over-
all, increases in rates were observed primarily among young men having sex with men
(MSM), characterized also by high rates of HIV co-infection. In fact, the estimated propor-
tion of P&S syphilis cases attributable to MSM increased from 7% in 2000 to 64% in 2004
cdc (2011).
In 2010, the rate of P&S syphilis was highest among persons aged 20-29 years. The
male-to-female ratio for P&S syphilis rates has risen steadily since 1996, reflecting higher
rates in men than women. In 2010, rates of P&S syphilis among men were highest among
black men, while rates among women were highest among black as well. In 2010, the P&S
syphilis rate among blacks was eight times the rate among whites.
Relevantly, syphilis remains a major health problem in urban areas (see Figure 2.6), as
well as in the South (see Figure 2.19).
A.2.3 Chlamydia
Chlamydia is a sexually transmitted disease caused by the bacterium Chlamydia tra-
chomatis. These infections are the most commonly reported notifiable disease in the world,
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Figure A.3: Syphilis rates per 100,000 in U.S. Counties
as well as the US (see Figure A.6), especially in the South region (see Figure 2.19).
Chlamydia is known as a “silent” infection because most infected people have no symp-
toms. Chlamydial infections in women can result in PID, as in the case of gonorrhea.
Chlamydial infection can facilitate the transmission of the HIV virus. In addition, preg-
nant women infected with chlamydia can pass the infection to their infants during delivery,
potentially resulting in neonatal ophthalmia and pneumonia cdc (2011).
In 2010, the overall rate of reported chlamydial infection among women in the U.S.
was over two and a half times the rate among men. Women aged 15-24 years present the
highest rates. In 2010, chlamydia rates were highest among black men and women, with
rates among blacks being more than eight times the rate among whites.
The continued increase in chlamydia case reports most likely reflects a continued in-
crease in screening for this infection, expanded use of more sensitive tests, and more com-
plete national reporting, but it also may reflect a true increase in morbidity. In fact, the
annual chlamydia screening rate increased from 25.3% in 2000 to 41.6% in 2007 among
sexually active females aged 16-25 years cdc (2011).
A.2.4 Influenza
Every year influenza viruses pose remarkable impacts on morbidity and mortality, as
well as socio-economic costs of medical care and loss of productivity. Worldwide, annual
influenza epidemics result in about three to five million cases of severe illness, and about
250,000 to 500,000 deaths, according to the WHO. In the U.S., influenza is the leading
cause of death among IDs, and continues to be an important cause of morbidity, with 5%–
20% of the U.S. population becoming ill each year Nichol et al. (2009). According to the
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CDC, influenza and pneumonia are the leading cause of death among infections diseases in
the U.S. WHO estimates that the burden of influenza in the US is currently 25–50 million
cases per year, leading to 150 000 hospitalizations and 30,000–40,000 deaths. In terms of
medical cost in the US, influenza accounts for $1 ∼ $3 billion per year, whereas the short-
term costs and long-term burden of seasonal influenza can amount to $26.8∼ $87.1 billion
a year Mao et al. (2012).
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Figure A.4: Chlamydia rates per 100,000 in U.S. Counties
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Figure A.5: Gini Coefficient levels and Education Index levels in U.S. counties
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Figure A.6: Infection rates (per 100,000) for gonorrhea, syphilis and chlamydia from 1985 to
2011 in all US population. These STDs are either on the rise (chlamydia) or have reached a plateau
in recent years. Source: CDC
A.3 From Poisson regression to weighted OLS regression
Assume that the underlying stochasticity of count data yi is Poisson distributed. As a
result, the uncertainty (standard deviation) is given by σi =
√
yi. If yi & 5 the stochasticity
approaches that of a Normal distribution with mean µ = yi and standard deviation σi =
√
yi.
When the stochasticity is normally distributed, we are then allowed to use the OLS regres-
sion machinery. However, in order to obtain unbiased estimators with minimum variance,
we must acknowledge that observations with smaller variance provide more reliable infor-
mation about the regression than those with larger variances Kutner et al. (2005). Thus, we
perform a weighted OLS regression.
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In order to determine the weights for each data point, we need to use propagation of
error theory. In statistics, propagation of uncertainty (or propagation of error) is the effect
of variable x’s uncertainty (or errors) on the uncertainty of a function f (x). Most commonly
the error on a quantity is given as the standard deviation, σx. When f (x) is a non-linear
function of x, the function f is usually linearized by approximation to a first-order Taylor
series expansion. Then, the propagation of error follows
σ f =
∂ f
∂x
σx. (A.1)
Let us now assume that we want to linearly regress log10(Y ) versus log10(N). Then,
using expression (A.1) and the fact that σi =
√
yi, the error of log10(yi) is σlogi =
1
yi ln(10)
√
yi =
1√
yi ln(10)
. The proportionality constant 1/ ln(10) does not affect the estimation, and
therefore is disregarded. We define the reciprocal of the variance of an observation as
its weight wi Kutner et al. (2005). That is wi =
1
σ2logi
, obtaining for our case wi = yi. As a
result, this more OLS method gives a less weight to the low-count data, as compared to an
unweighted least squares.
A.3.1 Scaling Patterns using weighted OLS and quasi Poisson regression
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Figure A.7: (left) Scaling of Chlamydia incidence with MSA population. Incidence is the sum of
reported cases between 2007 and 2011. For counties, a similar regression yields adjusted ad jR2 =
0.91, and αOLS = 1.07, αrobust = 1.09, p-value 0.01. (center) Scaling of Gonorrhea incidence
with MSA population. Incidence is the average of annual reported cases between 2007 and 2011.
For counties, a similar regression yields adjusted ad jR2 = 0.79, and αOLS = 1.03, αrobust = 1.05, p-
value 0.01. (right) Scaling of Syphilis incidence with MSA population. Incidence is the average
annual of reported cases between 2007 and 2011. For counties, a similar regression yields adjusted
ad jR2 = 0.70, and αOLS = 1.06, αrobust = 1.11, p-value 0.01.
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Table A.1: Weighted OLS Regression Results
Chlamydia Gonorrhea Syphilis
αˆ 0.996∗∗∗ 0.929∗∗∗ 1.065∗∗∗
(SE) (0.010) (0.019) (0.028)
log(Yˆ0) −1.633∗∗∗ −1.733∗∗∗ −3.916∗∗∗
(SE) (0.064) (0.122) (0.186)
Obs. 364 364 281
Adj. R2 0.964 0.863 0.833
Note: ∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table A.2: quasi-Poisson Regression Results
Chlamydia Gonorrhea Syphilis
αˆ 1.017∗∗∗ 1.003∗∗∗ 1.246∗∗∗
(SE) (0.0104) (0.0204) (0.0299)
log(Yˆ0) −1.780∗∗∗ −2.265∗∗∗ −5.157∗∗∗
(SE) (0.066) (0.130) (0.196)
Observations 364 364 364
A.4 Scaling exponents on a year basis.
The scaling patterns obtained in Chapter 2 of the main document, used the total number
of cases, for each STD, from 2007 to 2011. To investigate the yearly fluctuation of these
patterns we regressed (employing the Negative Binomial scheme) the STD data for each
year separately. The population estimates used in the regression were that of 2010 (source,
Census Bureau), as in Chapter 2.
The results are given in Figure A.8, where the scaling exponents for each disease and
for each year are reported, along with the 95% confidence intervals. These show that the
superscaling hypothesis (i.e., scaling exponents greater than one), cannot be rejected in any
of the cases.
A.5 Tables for factor regression with alternative models
Table A.3: Weighted OLS Factor Regression Results
Chlamydia Gonorrhea Syphilis
Covariates σα {p value} σY0 {p value} σα {p value} σY0 {p value} σα {p value} σY0 {p value}
%Poor 0.001 {0.837} 0.011 {0.764} -0.017 {0.366} 0.139 {0.199} -0.089 {0.008} 0.569 {0.003}
%Black -0.005 {0.011} 0.037 {0.003} -0.006 {0.02} 0.053 {0.003} -0.007 {0.418} 0.054 {0.27}
Gini -1.691 {0.043} 11.593 {0.026} -5.18 {0.007} 32.934 {0.005} -9.323 {0.005} 63.961 {0.003}
Education 0.013 {0.708} -0.1 {0.613} 0.078 {0.307} -0.5 {0.26} 0.27 {0.007} -1.677 {0.006}
P. Income 0 {0.163} 0 {0.104} 0 {0.114} 0 {0.072} 0 {0.09} 0 {0.057}
%Insured 0.004 {0.091} -0.025 {0.103} 0 {0.973} -0.002 {0.963} 0.007 {0.632} -0.062 {0.497}
A.6 Diagnostics for OLS model regressing rates versus socio-economic covariates
Diagnostic procedures are intended to check how well the assumptions of multiple lin-
ear regression are satisfied. A number of checks and tests help us to ensure that analysis
has proceeded within the bounds of the basic assumptions.
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Figure A.8: Scaling exponents for each disease and for each year, along with the 95% confidence
bands (dashed lines).
Table A.4: Poisson Factor Regression Results
Chlamydia Gonorrhea Syphilis
Covariates σα {p value} σY0 {p value} σα {p value} σY0 {p value} σα {p value} σY0 {p value}
%Poor 0.001 {0.86} 0.009 {0.801} -0.015 {0.456} 0.117 {0.292} -0.03 {0.356} 0.237 {0.201}
%Black -0.006 {0.001} 0.04 {0} -0.006 {0.028} 0.051 {0.006} -0.011 {0.054} 0.084 {0.029}
Gini -1.831 {0.036} 12.315 {0.026} -5.056 {0.014} 32.327 {0.012} -7.88 {0.007} 53.591 {0.005}
Education 0.011 {0.717} -0.092 {0.606} 0.048 {0.465} -0.358 {0.348} 0.157 {0.052} -1.06 {0.036}
P. Income 0 {0.327} 0 {0.199} 0 {0.339} 0 {0.182} 0 {0.787} 0 {0.985}
%Insured 0.005 {0.121} -0.031 {0.121} 0.001 {0.901} -0.008 {0.881} 0.011 {0.396} -0.093 {0.29}
Residual plots are a simple yet elucidating tool to check for violation of assumptions
such as, constancy of variance across levels of the explanatory variables, linearity of fitted
relationships and normality of errors. Plotting residuals (res= Yˆ −Yobs), or better yet, stan-
dardized residuals (calculated by dividing the residual by its standard error) on the Y axis
against fitted values on the X axis we can assess these issues. If the model is appropriate
for the data, the plot should show an even (no pattern) scatter. Outliers are another issue
that can be identified in such a plot. Observations with standardized residuals exceeding 3
could be potential outliers. Such data points are of interest because they have an influence
on the parameter estimates. A normal Probability Plot (QQ plot) of the residuals, along
with its distribution also help to check the assumption about normality.
Figures A.9 show these diagnostic plots for the regression models for each disease.
The normality assumption seems to hold in all three cases. The residuals plots show no
particular tendency or pattern, suggesting that the linearity assumption holds. However,
it appears as if the constancy of variance assumption might be violated, with variance
decreasing as population size increases.
For this reason, we employed a more formal test to assess the constancy of error vari-
ance assumption, that is, the Breusch-Pagan method that tests the null hypothesis that the
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Table A.5: quasi-Poisson Factor Regression Results
Chlamydia Gonorrhea Syphilis
Covariates σα {p value} σY0 {p value} σα {p value} σY0 {p value} σα {p value} σY0 {p value}
%Poor 0.002 {0.772} 0.007 {0.852} -0.012 {0.523} 0.113 {0.301} -0.061 {0.058} 0.404 {0.028}
% Black -0.005 {0.008} 0.039 {0.002} -0.007 {0.021} 0.056 {0.004} -0.011 {0.06} 0.084 {0.024}
Gini -1.592 {0.056} 10.923 {0.037} -5.304 {0.008} 33.895 {0.006} -9.665 {0.003} 64.748 {0.002}
Education 0.015 {0.654} -0.116 {0.553} 0.079 {0.308} -0.538 {0.236} 0.147 {0.06} -0.961 {0.048}
P. Income 0 {0.203} 0 {0.134} 0 {0.218} 0 {0.134} 0 {0.87} 0 {0.927}
%Insured 0.004 {0.081} -0.027 {0.081} 0 {0.981} -0.003 {0.939} 0.008 {0.505 ) -0.068 {0.365}
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Figure A.9: Diagnostics for regres-
sion of rates with the model selected by
the stepAIC algorithm: chlamydia (top
left), gonorrhea (top right) and syphilis
(bottom left)
error variances are equal across all levels of the explanatory variable, versus the alternative
that the error variances are a multiplicative function of one or more variables. If the p-value
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is close to zero, then the null can be rejected, implying non-constancy of variance. In all
three cases a low p-value suggest that the constancy of variance assumption is violated.
We also tested, using the Durbin-Watson method, for autocorrelation among the errors.
A p-value close to 1 in all three cases indicates the errors are serially uncorrelated. To
formally assess the issue of outliers in the data, we employed the Bonferonni test. Since
the p-values were all less than 0.05, the data showed no outliers.
A.7 Tables for alternative regression models: comparison across US regions
Table A.6: Weighted OLS Regression Results by Region
Chlamydia Gonorrhea Syphilis
Regions αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE)
Northeast 1.094 ( 0.022 ) -2.32 ( 0.146 ) 1.06 ( 0.045 ) -2.737 ( 0.302 ) 1.398 ( 0.027 ) -6.362 ( 0.191 )
Midwest 1.054 ( 0.015 ) -1.971 ( 0.095 ) 1.075 ( 0.028 ) -2.569 ( 0.173 ) 1.378 ( 0.047 ) -6.082 ( 0.308 )
West 1.03 ( 0.018 ) -1.888 ( 0.117 ) 1.153 ( 0.036 ) -3.431 ( 0.233 ) 1.314 ( 0.058 ) -5.598 ( 0.386 )
South 0.926 ( 0.02 ) -1.171 ( 0.121 ) 0.891 ( 0.027 ) -1.429 ( 0.163 ) 1.012 ( 0.044 ) -3.449 ( 0.273 )
Table A.7: Poisson Regression Results by Region
Chlamydia Gonorrhea Syphilis
Regions αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE)
Northeast 1.105 ( 0.001 ) -2.405 ( 0.005 ) 1.11 ( 0.001 ) -3.117 ( 0.01 ) 1.433 ( 0.008 ) -6.614 ( 0.057 )
Midwest 1.067 ( 0.001 ) -2.059 ( 0.004 ) 1.117 ( 0.001 ) -2.868 ( 0.007 ) 1.479 ( 0.009 ) -6.784 ( 0.059 )
West 1.048 ( 0.001 ) -2.015 ( 0.004 ) 1.219 ( 0.002 ) -3.894 ( 0.011 ) 1.401 ( 0.007 ) -6.221 ( 0.047 )
South 0.952 ( 0.001 ) -1.347 ( 0.003 ) 0.95 ( 0.001 ) -1.826 ( 0.006 ) 1.194 ( 0.005 ) -4.665 ( 0.03 )
Table A.8: quasi-Poisson Regression Results by Region
Chlamydia Gonorrhea Syphilis
Regions αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE) αˆ (SE) Yˆ0 (SE)
Northeast 1.105 ( 0.022 ) -2.405 ( 0.146 ) 1.11 ( 0.046 ) -3.117 ( 0.307 ) 1.433 ( 0.026 ) -6.614 ( 0.181 )
Midwest 1.067 ( 0.015 ) -2.059 ( 0.095 ) 1.117 ( 0.028 ) -2.868 ( 0.174 ) 1.479 ( 0.039 ) -6.784 ( 0.254 )
West 1.048 ( 0.019 ) -2.015 ( 0.119 ) 1.219 ( 0.036 ) -3.894 ( 0.234 ) 1.401 ( 0.047 ) -6.221 ( 0.309 )
South 0.952 ( 0.02 ) -1.347 ( 0.121 ) 0.95 ( 0.028 ) -1.826 ( 0.169 ) 1.194 ( 0.05 ) -4.665 ( 0.315 )
A.8 Other functionalities of c(N)
Motivated by the idea that increasing population size should enable more human inter-
actions Bettencourt and West (2011), we postulate that the contact rate grows with pop-
ulation size. In fact, we propose three functionalities for c(N) satisfying such condition,
power law (the one used before), linear and saturating, respectively,
cP(N) = bNa (Power law) (A.2)
cL(N) = aN+b (Linear) (A.3)
cS(N) =
aN
N+b
(Saturating) (A.4)
where a and b and positive constants. Hence, in this simple model we are only accounting
for the effect of increasing population size on transmissibility. That is, we are not consider-
ing the effect of other socio-economic aspects on the transmission potential of the disease.
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Substituting expressions (A.2)–(A.4) in (2.19) yields
I∗P(N) = N
[
1− 1
bNa
]
I∗L(N) = N
[
1− 1
aN+b
]
I∗S (N) = N
[
1− N+b
aN
]
. (A.5)
It is clear that limN→∞ I∗P(N) = N and limN→∞ I∗L(N) = N. In contrast, limN→∞ I∗S (N) =
N(1− 1/a), a quantity that is less than N if a > 1, which is the case when R0(∞) > 1.
To show these three tendencies, expressions in (A.5) are plotted in Figure A.10, where
superlinear scaling is obtained again.
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Figure A.10: Scaling of the endemic equilibrium with population size for the power law and the
linear contact rates.
For all three cases, Nmax = 106 and Nmin = 104. Parameters p,γ,a and b were chosen
so that Rmin0 = R0(Nmin) = 1.1 and R
max
0 = R0(Nmax) = 1.5. For the power law case, a =
log(Rmax0 /R
min
0 )/ log(Nmax/Nmin), and b = R
min
0 /(Nmin)
a. For the linear case a = (Rmax0 −
Rmin0 )/(Nmax−Nmin) and b = Rmin0 −aNmin. For the saturating case
b =
Nmin(Rmin0 /R
max
0 −1)
1− (NminRmin0 )/(NmaxRmax0 )
and a = (Nmax+b)/(Rmax0 Nmax). For simplicity, we have
assumed ω = p/γ = 1 is independent of population size.
In all cases, we obtain a behavior akin to superlinear scaling, at least for larger values
of N, as in the real data. This simple approach suggests that indeed, as cities grow they
promote an increase in the contact rates of its dwellers.
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A.9 Estimating the Reproduction Numbers from Scaling Behaviors
The data suggest that the incidence incidence follows a superlinear scaling pattern. In
this section we investigate the implications that superlinear scaling has on the reproduction
number and its dependence with population size. That is, given the (scaling) patterns we
observe in the data at a systemic level, we want to infer a more mechanistic and individual-
based metric such as the reproduction number. This could effectively be regarded as a novel
framework to estimate the basic reproductive number R0– one of the most important epi-
demiological quantities for characterizing the dynamic behavior and transmission potential
of a disease– in different populations. In this context, the data ingredient for estimating R0
is the prevalence levels– or final epidemic sizes– in different urban areas.
Let I∗ be the equilibrium prevalence level in a population of size N. Let also R0(N) =
β (N)/γ , where we assume that the transmission rate varies with population size and γ is
assumed constant. The simpler SIS type model in (2.17)-(2.18) renders
I∗ = N(1−1/R0), (A.6)
with the superscaling relation being
I∗ = I0Nα . (A.7)
Together expressions (A.6) and (A.7) yield
R0(N) =
1
1− I0Nα−1 . (A.8)
The Single Epidemic Case (SIR)
Let F be the final epidemic size in a population of size N Brauer (2006). Like before,
let also R0(N) = β (N)/γ . The final epidemic size relation states
F
N
= 1− exp−R0(N)F/N , (A.9)
whereas the superscaling suggest that
F = F0Nα . (A.10)
Equations (A.9) and (A.10) yield
R0(N) =− log(1−F0N
α−1)
F0Nα−1
. (A.11)
A.10 Epidemic Outcomes and Inequalities when the Recovery Times are Gamma
distributed
Let the random variable X follow a Gamma distribution, with 0 ≤ x ≤ ∞, and a shape
parameter k and a scale parameter θ . Its probability density function (pdf) is given as
P[X ∈ (x,x+dx)] = fG(x,k,θ)dx = 1Γ(k)θ k x
k−1e−
x
θ dx, (A.12)
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with mean and variance given, respectively, by
µG = kθ , σG = kθ 2. (A.13)
Fixing the mean
Suppose µG is fixed at a value, say m. Then the two-parameter pdf looses one degree of
freedom, and its variance can be calibrated with only one of the parameters, say k. Deriving
θ(µG)= µG/k from the expression of the mean in (A.13), and substituting in the expression
for the variance, we get
σG(k|µG = m) = m
2
k
. (A.14)
To determine the effect of increasing k on the value of the variance, we find the partial
derivative of the expression above, yielding
∂σG(k|µG = m)
∂k
=−m
2
k2
. (A.15)
Since m > 0, then we can conclude that ∂σG/∂k < 0 for all k. In words, increasing the
parameter k when the mean is fixed, decreases the variance of the distribution.
Figure A.11 shows the conduciveness of this distribution for testing different inequal-
ities scenarios. Figure A.12 shows that decreasing the variance of the recovery times (by
increasing k), yields larger prevalence levels. The right-skewness of the distributions in
Figure A.11 can help us understand why is this the case: smaller variance are associated
with distributions in which most observations are around the mean, whereas larger variance
yields most observations to the left of the mean (that is, most individuals recover faster than
the average).
Thus, using the Gamma distribution, as well as the Beta kernel, to model the distribution
of recovery periods yields that larger variance (i.e., larger inequalities) is associated with
lower prevalence levels.
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Figure A.11: Sampling 10000 r.v. from fG with and µG = 33.5 days. The parameter k controls
the variance of the Gamma distribution.
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APPENDIX B
TREATMENT STRATEGIES TO HINDER DRUG RESISTANCE
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B.1 R0 and the Next Generation Operator
The basic reproductive number, R0, is the average number of secondary cases produced
by a typical infected individual in a completely susceptible population. We proceed to
compute R0 using the Next Generation Operator based on the approach in van den Driess-
che and Watmough (2002). Considering only the infective states {It , Iu, Ir}, we obtain the
reduced system
dIi
dt
= Fi−Vi, i ∈ {t,u,r} (B.1)
where
F =
( S(Itmβu+ Iuβu)ρ(1− c)
S(Itmβu+ Iuβu)(1−ρ)
SIrφβu+S(Itmβu+ Iuβu)cρ
)
and V =
(It(τ+ γu+µ)
Iu(γu+µ)
Ir(γr +µ)
)
(B.2)
The Jacobian matrices of both F and V , evaluated at the disease free equilibrium (DFE)
X0 = (S∗ = 1, I∗t = 0, I
∗
u = 0, I
∗
r = 0), (B.3)
are
DF(X0) =
(mβuρ(1− c) βuρ(1− c) 0
mβu(1−ρ) βu(1−ρ) 0
mβucρ βucρ φβu
)
(B.4)
and
DV (X0) =
(τ+ γu+µ 0 0
0 γu+µ 0
0 0 γr +µ
)
(B.5)
The Next Generator Operator (NGO) matrix is defined as M = DF×DV−1. Using the
inverse
DV−1 =

1
τ+γu+µ 0 0
0 1γu+µ 0
0 0 1γr+µ
 (B.6)
we obtain
M =

mβuρ(1−c)
(τ+γu+µ)
βuρ(1−c)
(γu+µ) 0
mβu(1−ρ)
(τ+γu+µ)
βu(1−ρ)
(γu+µ) , 0
mβucρ
(τ+γu+µ)
βucρ)
(γu+µ)
φβu
γr+µ
 (B.7)
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The eigenvalues of M are
λ1 = Rw0 = βu
{
mρ(1− c)
γu+ τ+µ
+
(1−ρ)
γu+µ
}
, (B.8)
λ2 = Rr0 = βu
φ
γr +µ
, (B.9)
λ3 = 0. (B.10)
where Rw0 and R
r
0 are the reproductive number of the wild-type and resistant strains,
respectively. The condition Rw0 = R
r
0 yields
ρ∗=
[(γr +µ)−φ(γu+µ)](γu+µ+τ)
(γr +µ)[(γu+µ+τ)−m(1− c)(γu+µ)] (B.11)
B.2 Analogous Model
In the original model it is assumed that treatment and de novo resistance happen imme-
diately after infection. Here we present a model that features stage progressions (treatment
and de novo resistance occur at certain rates rather than instantaneously). Susceptible hosts,
S, enter the population at a per-capita rate µ . The per-capita death rate of all classes is also
µ . Since the population is kept constant, we assume N = 1. Susceptible individuals can be
infected by either a wild-type or drug-resistant strains, progressing into the Iu and Ir classes,
respectively. Those infected with the wild-type strain recover at rate γu, or get treated at
rate α , entering the treated It class. From this class, individuals recover at rate γu + τ , or
develop de novo resistance at rate ν . Those infected with the resistant strain recover at rate
γr. The pathogen induces sterilizing immunity.
The ordinary differential equation (ODE) model describing the above dynamics is (see
Figure B.1)
dS
dt
= µ− (θw+θr +µ)S
dIu
dt
= θwS− (γu+µ+α)Iu
dIt
dt
= αIu− (γu+ τ+µ+ν)It
dIr
dt
= θrS+νIt− (γr +µ)Ir
dR
dt
= (γu+ τ)It + γuIu+ γrIr−µR
with forces of infection θw=βuIu+mβuIt and θr=φβuIr, where φ = βr/βu and m= βt/βu.
Therefore, in this model 1/α represents the average amount of time a wild-type in-
fected, that will be treated, spends untreated, while 1/ν represents the average amount of
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Figure B.1: Compartmental diagram for the analogous model.
time it takes for those treated that will develop de novo resistance to actually become resis-
tant to treatment. Moreover, the fraction of wild-type infections treated, ρ , and the fraction
of those treated that develop de novo resistance, c, are given by
ρ =
α
α+ γu+µ
and c =
ν
ν+ γu+ τ+µ
.
Notice that we have intentionally used the same terminology as in the manuscript.
In this model, the basic reproduction numbers are given by
Rw0 = βu
{
1
α+ γu+µ
+m
(
α
α+ γu+µ
)(
1
ν+ γu+ τ+µ
)}
,
Rr0 = βu
φ
γr +µ
(B.12)
where Rw0 and R
r
0 are the reproductive number of the wild-type and resistant strains, respec-
tively. Note that 1−ρ = (γu+µ)/(α+γu+µ), and 1−c= (γu+τ+µ)/(ν+γu+τ+µ).
Thus, we can rewrite the reproduction numbers in (B.12) as
Rw0 = βu
{
1−ρ
γu+µ
+mρ
1− c
γu+ τ+µ
}
,
Rr0 = βu
φ
γr +µ
which coincide with the reproduction numbers presented in the manuscript, i.e., expres-
sions (B.8) and (B.9). To compare the temporal dynamics and final states of the original
model (the one in the main text) and the model with stage progression, Figure B.2 and
Figure B.3 show numerical integrations with the similar parameters (we have used a higher
birth/death rate to increase the endemic equilibria and better convey our message) as in the
original model for the endemic and single epidemic case, respectively. The qualitative be-
havior is quite similar. Note that the endemic equilibria and the total final sizes are the same
in both models, which is expected since the two models have equal reproduction numbers.
Thus, the two models are qualitatively analogous.
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Figure B.2: Comparison of the two models in the endemic case. Although their temporal
dynamics are not equivalent, their endemic equilibria coincide.
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Figure B.3: Comparison of the two models in the single epidemic case. The original
model over estimates the resistance prevalence in comparison with the model with stage
progression. The total final sizes coincide.
B.3 Stability of Fixed Points
Linearizing the system around the steady states, we found the respective eigenvalues λi,
i= 1,2,3,4. The sign of their real part determines the stability of the steady states Strogatz
(1994).
B.3.1 Stability of DFE
For the DFE
λ 11 =−µ (B.13)
λ 12 = (γr +µ)(R
r
0−1) (B.14)
λ 13 =−(γu+µ)−
1
2
[τ− (1−ρ)βu− (1− c)ρβt ]−
√
1
4
[τ− (1− c)ρβt − (1−ρ)βu]2+(1−ρ)τβu (B.15)
λ 14 =−(γu+µ)−
1
2
[τ− (1−ρ)βu− (1− c)ρβt ]+
√
1
4
[τ− (1− c)ρβt − (1−ρ)βu]2+(1−ρ)τβu (B.16)
The first eigenvalue is always negative; λ 12 < 0 if R
r
0 < 1. In addition, λ
1
3 and λ
1
4 have
zero imaginary part if the term inside the square root is positive. The stability of the DFE
depends on the respective signs. We prove below that λ 13 < 0 and λ
1
4 < 0, if R
w
0 < 1. Thus,
as expected, the DFE is stable if Rw0 < 1 and R
r
0 < 1.
197
The stability of the DFE depends on their respective signs. Lets momentarily define
A :=
1
2
[τ− (1−ρ)βu− (1− c)ρβt ]. (B.17)
Then,
λ 13 =−(γu+µ)−A−
√
A2+(1−ρ)τβu (B.18)
λ 14 =−(γu+µ)−A+
√
A2+(1−ρ)τβu. (B.19)
Therefore, λ 13 < 0 and λ
1
4 < 0 simultaneously if
(γu+µ)+A >
√
A2+(1−ρ)τβu
=⇒ [(γu+µ)+A]2 > A2+(1−ρ)τβu
=⇒ (γu+µ)2+2A(γu+µ) > (1−ρ)τβu
=⇒ (γu+µ)+2A > τ (1−ρ)βuγu+µ .
Substituting A and defining Ru0 =
(1−ρ)βu
γu+µ
and Rt0 =
ρ(1− c)βt
γu+ τ+µ
, with Rw0 = R
t
0+R
u
0,
one gets
(γu+µ)+ τ− (γu+µ)Ru0− (γu+ τ+µ)Rt0 > τ(Rw0 −Rt0)
=⇒ (γu+µ)+ τ− (γu+µ)Ru0− (γu+µ)Rt0 > τRw0
=⇒ (γu+µ)+ τ− (γu+µ)Rw0 > τRw0
=⇒ γu+µ+ τ > (τ+ γu+µ)Rw0
=⇒ 1 > Rw0
Thus, the DFE is stable if Rw0 < 1 and R
r
0 < 1.
B.3.2 Stability of RFP
For the RFP
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λ 21 =−
µ
2
Rr0−
√
µ(γr +µ)
(
1−Rr0+
µ
4(γr +µ)
(Rr0)2
)
(B.20)
λ 22 =−
µ
2
Rr0+
√
µ(γr +µ)
(
1−Rr0+
µ
4(γr +µ)
(Rr0)2
)
(B.21)
λ 32 =−
1
2Rr0
{
(2γu+ τ+2µ)Rr0− (γu+ τ+µ)Rt0− (γu+µ)Ru0 (B.22)
+ {
√
[τRr0− (γu+ τ+µ)Rt0]2+2(γu+µ)Ru0(τRr0+(γu+ τ+µ)Rt0)+(γu+µ)2(Ru0)2
}
(B.23)
λ 42 =−
1
2Rr0
{
(2γu+ τ+2µ)Rr0− (γu+ τ+µ)Rt0− (γu+µ)Ru0 (B.24)
−
√
[τRr0− (γu+ τ+µ)Rt0]2+2(γu+µ)Ru0(τRr0+(γu+ τ+µ)Rt0)+(γu+µ)2(Ru0)2
}
.
(B.25)
For λ 21 and λ 22 to be a pair of conjugate complex numbers with negative real part, it is necessary that
1−Rr0+
µ
4(µ+ γ)
(Rr0)
2 < 0. (B.26)
Solving for Rr0 gives the condition
2(γ+µ)
µ
(
1−
√
1− µ
γ+µ
)
< Rr0 <
2(γ+µ)
µ
(
1+
√
1− µ
γ+µ
)
. (B.27)
If (B.27) holds, then the RFP is represented by a stable spiral when projected in the
(It , Iu) plane. Typically µ 1, thus the conditions above can be approximated to 0< Rr0 <
4(γ+µ)
µ  1. This range usually encompasses the range of plausible values of Rr0. Thus, λ 21
and λ 22 will most likely be a pair of conjugate complex numbers with negative real part.
The term inside the square root in the conjugate pair λ 32 ,λ
4
2 is always positive, thus
λ 32 ,λ
4
2 ∈R. Hence, the stability of the RFP depends on their signs. We now prove that λ 32 <
0 and λ 42 < 0 simultaneously if R
r
0 > R
w
0 . First note that λ
3
2 < 0 and λ
4
2 < 0 simultaneously
if
[
(2γu+ τ+2µ)Rr0− (γu+ τ+µ)Rt0− (γu+µ)Ru0
]
>
√
[τRr0− (γu+ τ+µ)Rt0]2+2(γu+µ)Ru0(τRr0+(γu+ τ+µ)Rt0)+(γu+µ)2(Ru0)2.
Squaring both sides yields[
(2γu+ τ+2µ)Rr0− (γu+ τ+µ)Rt0− (γu+µ)Ru0
]2
> [τRr0− (γu+ τ+µ)Rt0]2+2(γu+µ)Ru0(τRr0+(γu+ τ+µ)Rt0)+(γu+µ)2(Ru0)2.
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Expanding the left-hand-side yields
[(2γu+ τ+2µ)Rr0]
2+[(γu+ τ+µ)Rt0]
2+[(γu+µ)Ru0]
2−
−2{[(2γu+ τ+2µ)Rr0(γu+ τ+µ)Rt0]+ [(2γu+ τ+2µ)Rr0(γu+µ)Ru0]− [(γu+ τ+µ)Rt0(γu+µ)Ru0]}>
> [τRr0− (γu+ τ+µ)Rt0]2+2(γu+µ)Ru0[τRr0+(γu+ τ+µ)Rt0]+ [(γu+µ)Ru0]2.
Canceling [(γu+µ)Ru0]
2 and expanding [τRr0− (γu+ τ+µ)Rt0]2 yields
[(2γu+ τ+2µ)Rr0]
2+[(γu+ τ+µ)Rt0]
2−
−2{[(2γu+ τ+2µ)Rr0(γu+ τ+µ)Rt0]+ [(2γu+ τ+2µ)Rr0(γu+µ)Ru0]− [(γu+ τ+µ)Rt0(γu+µ)Ru0]}>
> [τRr0]
2+[(γu+ τ+µ)Rt0]
2−2[(γu+ τ+µ)Rt0][τRr0]+2(γu+µ)Ru0τRr0+2(γu+µ)Ru0(γu+ τ+µ)Rt0].
Canceling [(γu+ τ+µ)Rt0]
2 one obtains
[(2γu+ τ+2µ)Rr0]
2−
−2{[(2γu+ τ+2µ)Rr0(γu+ τ+µ)Rt0]+ [(2γu+ τ+2µ)Rr0(γu+µ)Ru0]− [(γu+ τ+µ)Rt0(γu+µ)Ru0]}>
> [τRr0]
2−2[(γu+ τ+µ)Rt0][τRr0]+2(γu+µ)Ru0τRr0+2(γu+µ)Ru0(γu+ τ+µ)Rt0].
Canceling 2[(γu+ τ+µ)Rt0(γu+µ)R
u
0] yields
[(2γu+ τ+2µ)Rr0]
2−2{[(2γu+ τ+2µ)Rr0(γu+ τ+µ)Rt0]+ [(2γu+ τ+2µ)Rr0(γu+µ)Ru0]}>
> [τRr0]
2−2[(γu+ τ+µ)Rt0][τRr0]+2(γu+µ)Ru0τRr0.
Dividing both sides by Rr0 renders
Rr0[(2γu+ τ+2µ)]
2−2[(2γu+ τ+2µ)(γu+ τ+µ)Rt0]−2[(2γu+ τ+2µ)(γu+µ)Ru0]>
> τ2Rr0−2[(γu+ τ+µ)Rt0]τ+2(γu+µ)Ru0τ.
Factoring R0 terms we get
−2[(2γu+ τ+2µ)(γu+ τ+µ)− (γu+ τ+µ)τ]Rt0−2[(2γu+ τ+2µ)(γu+µ)+ τ(γu+µ)]Ru0 >
> [τ2− [(2γu+ τ+2µ)]2]Rr0.
Expanding and canceling τ terms yields
−2[(2γu+2µ)(γu+ τ+µ)]Rt0−2[(2γu+2τ+2µ)(γu+µ)]Ru0 > [−(2γu+2µ)2−2(2γu+2µ)τ]Rr0.
Dividing both sides by 4 yields
−[(γu+µ)(γu+ τ+µ)]Rt0− [(γu+ τ+µ)(γu+µ)]Ru0 > [−(γu+µ)2− (γu+µ)τ]Rr0.
Dividing both sides by (γu+µ) renders
(γu+ τ+µ)Rt0+(γu+µ+ τ)R
u
0 < (γu+µ+ τ)R
r
0.
Dividing both sides by (γu+ τ+µ) we finally get
Rw0 < R
r
0.
Thus, the RFP is stable if Rw0 < R
r
0.
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Figure B.4: Transcritical Bifurcation be-
tween DFE and CFP.
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Figure B.5: Transcritical Bifurcation be-
tween RFP and CFP.
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Figure B.6: Transcritical Bifurcation be-
tween the DFE and the RFP.
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Figure B.7: Transcritical Bifurcation be-
tween RFP and CFP.
B.3.3 Effect of varying ρ and φ : phase planes
In the figures below the following parameters have been fixed: c= 1500 , µ = 4.57 ·10−5,
γ = 15 , βu =
1
2 , m = 0.34. The death rate expresses a mean life expectancy of 60 years. βu
and γ yield R0 = 2.5.
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B.3.4 Summary of the Stability Behavior of the System
Figure B.8 summarizes the stability behavior of the system as a function of Rw0 and
Rr0, and shows which key parameters need to change to shift from one stability region to
another.
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Figure B.8: Stability behavior of the system. Depending on the values of Rw0 and R
r
0, the
system transits through different stability regions by varying specific parameters.
Going clockwise, starting in the top-left corner with high ρ and low φ , the DFE is stable.
As ρ decreases, Rw0 surpasses the threshold of 1 and the system enters the Coexistence
2FP region (CFP stable, DFE unstable). It is easy to show that if Rw0 = 1, then DFE =
CFP. Since the FPs also exchange their stability at this point, this represents a transcritical
bifurcation Strogatz (1994). Incrementing φ above φ1, Rr0 crosses the threshold of 1, and
shifts the system to the 3FP region (CFP stable, DFE unstable, RFP unstable). Further
increasing φ (increasing Rr0 beyond R
w
0 ) or increasing ρ(>ρ
∗) (reducing Rw0 bellow R
r
0), the
system enters the Resistance region (DFE unstable, RFP stable). If Rw0 =R
r
0, then CFP=RFP,
which implies that the CFP exits the BS area crossing through the RFP. Also here, the FPs
exchange stability, featuring a transcritical bifurcation. If ρ > ρ1 and φ < φ1, the system
goes from the Resistant to the DFE region. If Rr0=1, then DFE=RFP, and they exchange
stability, displaying once more a transcritical bifurcation.
B.3.5 Prevalence as a Function of ρ and φ
To have a broader idea of what effect the resistant strain fitness has on the overall
disease prevalence, Figure B.9 shows a plot of the prevalence as a function of ρ and φ .
For comparative purposes, the red-dashed line coincides with the red-dashed line in Figure
B.8 (right), and the red and black solid line represent the steady state trajectories in the
Figure 4.5 in the main text. For fixed φ , increasing ρ has an effect on the prevalence only
up to the red-dashed line (ρ = ρ∗). Conversely, for fixed ρ , increasing φ has no effect
on prevalence if Rw0 (ρ) > R
r
0(φ). After that threshold (red-dashed line), increasing φ also
increases prevalence of the resistant strain.
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Figure B.9: Prevalence as a function of ρ and φ with c = 1/500.
B.4 Finding the Optimal Treatment Regimes
The FP that dictate endemic levels of disease are :
RFP:
S2 =
1
Rr0
, I2t = 0, I
2
u = 0, I
2
r =
µ
φβu
(Rr0−1) (B.28)
CFP:
S3 =
1
Rw0
, I3t =
(1− c)ρµ
(γu+ τ+µ)
(
1− R
r
0
Rw0
)
Ψ, I3u =
(1−ρ)µ
(γu+µ)
(
1− R
r
0
Rw0
)
Ψ, I3r = cρ
µ
(γr +µ)
Ψ
(B.29)
where
Ψ :=
Rw0 −1
Rw0 − (1− cρ)Rr0
.
Clearly, the RFP does not depend on the treatment level ρ , while CFP does.
B.4.1 Overall fitness and the role of c
In this analysis, lets assume for simplicity that τ = 0 and γu = γr, yielding σi = σ , i ∈
{u, t,r}. From Eq. (4) in the model, we get for the resistant strain
dIr
dt
= θrS+θwSρc−σ Ir =
(
θr
Irσ
S+
θwρc
Irσ
S−1
)
σ Ir =
(
Rr0S+
θwρc
Irσ
S−1
)
σ Ir
Using the approximation
dIr
dt
≈ I
n+1
r − Inr
1/σ
,
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where 1/σ is the expected duration of an “epidemic generation” and n indexes the genera-
tions, renders
In+1r ≈
(
Rr0S+
θwρc
Irσ
S
)
Inr .
Assuming a susceptible-rich population, we can approximate S≈ 1, finally yielding
In+1r ≈
(
Rr0+
θwρc
Inr σ
)
Inr = R
r
0I
n
r +
θwρc
σ
(B.30)
Proceeding similarly for the wild-type strain we get
dIt
dt
= θwSρ(1− c)−σ It =⇒ In+1t ≈
(
ρ(1− c) θw
Int σ
)
Int
dIu
dt
= θwS(1−ρ)−σ Iu =⇒ In+1u ≈
(
(1−ρ) θw
Inuσ
)
Inu
Let In+1w = I
n
u + I
n
t , then
In+1w ≈
(
ρ(1− c)θw
σ
)
+
(
(1−ρ)θw
σ
)
=
(
(1−ρc) θw
Inwσ
)
Inw
=
(
(1−ρc)βuI
n
u +mβuInt
(Inu + I
n
t )σ
)
Inw
= (1−ρc)
(
βuinu+mβuint
σ
)
Inw
where inx is the fraction of the wild type infected that did not develop resistance and ended
up in class x ∈ {u, t} in generation n. It follows then that inu =
(1−ρ)
1−ρc and i
n
t =
ρ(1− c)
1−ρc .
Thus
In+1w ≈ (1−ρc)
βu (1−ρ)1−ρc +mβu ρ(1−c)1−ρc
σ
 Inw = Rw0 Inw (B.31)
Since (1−ρc) θw
Inwσ
= Rw0 , from Eq. (B.30) we then get
In+1r ≈ Rr0Inr +
ρc
1−ρcR
w
0 I
n
w (B.32)
The absolute fitness of strain k ∈ {w,r} can be defined as Fk =
In+1k
Ink
, that is, how many
new infections (“offspring”) did each infected contribute to the next generation on average.
For the wild-type strain this definition holds. However, for the resistant strain the de novo
resistant cases are not “produced” by resistant strain infections, so the definition does not
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hold for the de novo contribution term. Instead, the de novo term should be divided by Inw.
Then, from Eq. (B.31) and Eq. (B.32) we obtain
Fw = Rw0 H(ρ
∗−ρ) and Fr = Rr0+
ρc
1−ρcR
w
0 H(ρ
∗−ρ).
where H(x) is the Heaviside step function: H(x) = 1 if x> 0, and H(x) = 0 otherwise. It is
used to signify that if ρ > ρ∗, there are no more wild-type cases, and therefore, no de novo
cases either. The de novo term can be interpreted as the number of new de novo infections
that each wild-type infected legated to the next generation, in average. Note that as c→ 0,
then Fw→ Rw0 and Fr→ Rr0.
B.4.2 Exploring the monotonicity of I3r (ρ) in (0,ρ∗)
From the expression of I3r it is clear that
∂ I3r
∂ρ
=
cµ
γr +µ
Ψ+
cµρ
γr +µ
∂Ψ
∂ρ
=
cµ
γr +µ
(
Ψ+ρ
∂Ψ
∂ρ
)
(B.33)
Thus, for
∂ I3r
∂ρ
> 0 we must show that Ψ+ρ
∂Ψ
∂ρ
> 0, where
Ψ+ρ
∂Ψ
∂ρ
=
Rw0 −1
Rw0 − (1− cρ)Rr0
+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0)− (Rw0 −1)cRr0(
Rw0 − (1− cρ)Rr0
)2
=
(Rw0 −1)(Rw0 − (1− cρ)Rr0)+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0)− (Rw0 −1)cρRr0
(Rw0 − (1− cρ)Rr0)2
(B.34)
Since the denominator of this last expression is always positive, we focus only on the sign
of the numerator
(Rw0 −1)(Rw0 − (1− cρ)Rr0)+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0)− (Rw0 −1)cρRr0
=(Rw0 −1)Rw0 − (Rw0 −1)(1− cρ)Rr0+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0)− (Rw0 −1)cρRr0
=(Rw0 −1)Rw0 − (Rw0 −1)Rr0+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0)
=(Rw0 −1)(Rw0 −Rr0)+ρ
∂Rw0
∂ρ
(1− (1− cρ)Rr0) (B.35)
From (B.34) notice that
1− (1− cρ)Rr0 ≤ 0 =⇒ Rr0 ≥
1
1−ρc . (B.36)
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If the inequality in (B.36) holds, and recalling that Rw0 > 1, R
w
0 > R
r
0 and
∂Rw0
∂ρ
< 0, for
ρ < ρ∗, we have found sufficient conditions to show that
∂ I3r
∂ρ
> 0.
Since we are working on the range 0≤ ρ < ρ∗, we get that 1
1−ρc <
1
1−ρ∗c . Thus, if
the inequality in (B.36) does not hold (i.e., 1≤ Rr0 <
1
1−ρ∗c )
1, we cannot assure that I3r is
a monotonically increasing function of ρ .
To approach the question of whether
∂ I3r
∂ρ
> 0 or not if 1 ≤ Rr0 <
1
1−ρ∗c given ρ ∈
[0,ρ∗], we proceed as follows. Showing that
∂ I3r
∂ρ
∣∣∣
ρ=ρ∗
< 0 is a sufficient condition to
prove that I3r is not a monotonically increasing function of ρ in the interval ρ ∈ [0,ρ∗].
Recalling that Rw0 (ρ
∗) = Rr0, expression (B.35) becomes
ρ∗
∂Rw0
∂ρ
(1− (1− cρ∗)Rr0).
Then, it is easy to see that if Rr0 <
1
1−ρ∗c , then the above expression is negative. Thus,
we have shown that in this case, I3r is not a monotonically increasing function of ρ in the
interval ρ ∈ [0,ρ∗]. Moreover, numerically we find that in such case I3r (ρ) is a concave
function in the interval [0,ρ∗] (see Figure B.10). This behavior is more accentuated for
larger c.
B.4.3 Showing that
∂ I3w
∂ρ
< 0 for 0 < ρ < ρ∗
Let I3w = I
3
u + I
3
t and ξ := 1−
Rr0
Rw0
, then
I3w = ξΨ
[
ρ
(
(1− c)µ
σt
− µ
σu
)
+
µ
σu
]
. (B.37)
Therefore
∂ I3w
∂ρ
=
(
∂ξ
∂ρ
Ψ+ξ
∂Ψ
∂ρ
)[
ρ
(
(1− c)µ
σt
− µ
σu
)
+
µ
σu
]
+ξΨ
(
(1− c)µ
σt
− µ
σu
)
(B.38)
Notice that since Ψ > 0 and ξ > 0 in this epidemiological context, the second term in
(B.38) is always negative (recall σu < σt). Expanding the term in brackets in (B.38) we
get
ρ
(
(1− c)µ
σt
− µ
σu
)
+
µ
σu
= µ
(
ρ(1− c)σu−ρσt +σt
σtσu
)
= µ
(
ρ(1− c)σu+(1−ρ)σt
σtσu
)
> 0
1Since ρ ∈ [0,ρ∗], then (1− ρc)−1 < (1− ρ∗c)−1. Also, the interesting cases are those in which the
resistant strain can potentially emerge and persist, i.e., I2r > 0. Thus, R
r
0 ≥ 1.
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Figure B.10: I3r (ρ) for 1 < Rr0 <
1
1−ρ∗c (black, solid) (φ = 0.42) and for R
r
0 >
1
1−ρ∗c (red,
solid) (φ = 0.5). Dotted lines are the corresponding I3w(ρ) curves. The vertical dashed lines are the
values of ρ∗ corresponding to φ = 0.42,0.5. If we are in the first case, then increasing treatment is
the best. Other parameters: γr = γu = 0.2,τ = 0,βu = 0.5,m = 0.34,c = 0.2. A low value of c was
used to magnify the difference between the two cases.
Thus, from (B.38) it is clear that to prove
∂ I3w
∂ρ
< 0 we need to prove
(
∂ξ
∂ρ
Ψ+ξ
∂Ψ
∂ρ
)
< 0.
We have
∂Ψ
∂ρ
=
Rr0
(Rw0 )
2
∂Rw0
∂ρ
and
∂ξ
∂ρ
=
∂Rw0
∂ρ
[1− (1−ρc)Rr0]− cRr0(Rw0 −1)
[Rw0 − (1−ρc)Rr0]2
Thus,
(
∂ξ
∂ρ
Ψ+ξ
∂Ψ
∂ρ
)
becomes
[
∂Rw0
∂ρ
[1− (1−ρc)Rr0]− cRr0(Rw0 −1)
][
(Rw0 )
2−Rw0 Rr0
]
+Rr0
∂Rw0
∂ρ
(Rw0 −1)[Rw0 − (1−ρc)Rr0]
(Rw0 )2[R
w
0 − (1−ρc)Rr0]2
(B.39)
Recognizing that the denominator of (B.39) is always positive, we focus on the sign
of the numerator. The second term in the sum of the numerator is always negative given
that
∂Rw0
∂ρ
< 0. In the first term, the term in the second square brackets is always positive.
Conversely, the term in the first square brackets is negative if 1−(1−ρc)Rr0 > 0. If this last
inequality holds, then we have found sufficient conditions to prove that
(
∂ξ
∂ρ
Ψ+ξ
∂Ψ
∂ρ
)
<
0 and consequently that
∂ I3r
∂ρ
> 0 in (0,ρ∗).
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We now use heuristic arguments to show
∂ I3w
∂ρ
< 0 for the case 1 < (1− ρc)Rr0. For
this case we already showed analytically that
∂ I3r
∂ρ
> 0 for ρ ∈ [0,ρ∗]. We interpret these
partial derivatives as flows from and to the infected and the susceptible classes. For instance,
FS =
S(ρ)−S(ρ+δρ)
δρ
is the flow of individuals to the S class due to a change in treatment
δρ . Based on a conservation of mass (individuals) argument, we can write
FS3 +FI3w +FI3r ≡ 0. (B.40)
Notice that, unlike the unidirectional flow of individuals in time (measured by the time
derivatives), the flow with respect to ρ allows individuals to move back and forth within
these classes. If 1< (1−ρc)Rr0, then FI3r is positive. It is also easy to check that if
∂Rw0
∂ρ
< 0,
then FS3 ≈
∂S3
∂ρ
=− 1
(Rw0 )
2
∂Rw0
∂ρ
> 0. Hence, increasing ρ increases the flow of individuals
towards S3 and I3r ; thus to satisfy expression (B.40) we must have FI3w ≈
∂ I3w
∂ρ
< 0 for ρ ∈
[0,ρ∗]. This proves that
∂ I3w
∂ρ
< 0 also for the case 1< (1−ρc)Rr0, and since we had already
proved it when 1 > (1−ρc)Rr0, we have shown that indeed
∂ I3w
∂ρ
< 0 for ρ ∈ [0,ρ∗].
B.4.4 Conditions for the existence of a minimum in the total endemic equilibrium
Formally, we define the total endemic equilibrium as IT = I3r +I
3
w for 0 ≤ρ <ρ∗ and
IT = 0+I2r for ρ∗< ρ ≤ 1. The question we address is whether there is a minimum in
IT (ρ) for 0 ≤ρ <ρ∗. The existence of this minimum could be proven by showing that
∂ IT/∂ρ = 0 for ρ < ρ∗;. Or, we can show the presence of the minimum by first assum-
ing that there is at most one local minimum in the interval 0 ≤ρ<ρ∗, and showing that
limε→0+
[
∂ IT
∂ρ
∣∣∣ρ = (ρ∗− ε)]> 0. Here we take the second approach.
First we need to compute ∂ IT/∂ρ . For this we use the expressions in Eq.(B.33) and
Eq.(B.38). Evaluating this expressions at ρ = ρ∗, and noting that ξ (ρ∗) = 0, ∂ξ∂ρ
∣∣∣ρ∗ =
1
Rr0
∂Rw0
∂ρ
∣∣∣ρ∗ and Ψ(ρ∗) = 1ρ∗c (1− 1Rr0), we get
∂ I3r
∂ρ
∣∣∣ρ∗ = cµγr +µ
ρ∗
(
∂Rw0
∂ρ
∣∣∣ρ∗)(1− (1−ρ∗c)Rr0)
(Rr0ρ∗c)2
 (B.41)
and
∂ I3w
∂ρ
∣∣∣ρ∗ = µΨ(ρ∗)∂ξ∂ρ ∣∣∣ρ∗
[
ρ∗(1− c)
σt
+
1−ρ∗
σu
]
= µ
1
ρ∗c
(
1− 1
Rr0
)(
1
Rr0
∂Rw0
∂ρ
∣∣∣ρ∗)[ρ∗(1− c)σt + 1−ρ
∗
σu
]
.
(B.42)
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Then
∂ IT
∂ρ
∣∣∣ρ∗ = µ(∂Rw0∂ρ ∣∣∣ρ∗
){
1
ρ∗c
(
1− 1
Rr0
)(
1
Rr0
)[
ρ∗(1− c)
σt
+
1−ρ∗
σu
]
+
c
γr +µ
[
(1− (1−ρ∗c)Rr0)
ρ∗(Rr0c)2
]}
= µ
(
∂Rw0
∂ρ
∣∣∣ρ∗){ 1ρ∗c
(
Rr0−1
(Rr0)
2
)[
ρ∗(1− c)
σt
+
1−ρ∗
σu
]
+
[
1− (1−ρ∗c)Rr0
σrρ∗c(Rr0)2
]}
. (B.43)
Note that ∂R
w
0
∂ρ
∣∣∣ρ∗ < 0. Therefore, to show that ∂ IT∂ρ ∣∣∣ρ∗ > 0, we must show that the term
inside curly brackets in (B.43), namely χ , is negative as well. For example, in the simplified
case where σi = σ , i ∈ {u, t,r}, we obtain that χ = 1σ(Rr0)2 > 0. Thus,
∂ IT
∂ρ
∣∣∣ρ∗ < 0, and there
is no minimum. This is verified in Figure 6 (left) in the main text (where τ = 0). When
τ 6= 0, yielding σt > σu, and assuming σr = σu, we obtain
χ =
σt +(1− c)[(Rr0−1)σu−Rr0σt ]
c(Rr0)
2σuσt
(B.44)
Since the denominator in Eq.(B.44) is always positive, we focus in the sign of the numera-
tor, and more specifically, find conditions for it to be negative. The numerator of χ can be
simplified to τ+ cσu− (1− c)τRr0. Thus, when this expression is negative, χ will also be
negative, and the derivative of IT at ρ∗ will be positive, indicating the existence of a local
minimum. To test whether this result matches the numerical integration shown in Figure 6
(right) in the main text, we substitute the parameter values to generate that figure into this
expression, namely, τ=0.2, c=0.02, µ=4.6× 10−5, γu=0.2, βu=0.5, φ =0.6. In fact,
the result is -0.899. That is, χ is negative, and therefore IT has a local minimum, as seen
in the figure. The interesting insights from all these analysis is that, if treatment speeds up
recovery, then there could exist a minimum for the total endemic equilibrium.
B.4.5 Finding ρe and ρr
We obtain ρe from equating I3w(ρe) = I3r (ρe), yielding
ρe =
1
2α1α2
{
σ2t (2σr +σu(c−φ))− (1− c)σtσu(σr−σuφ +σrm)−
√
σ2t {−4α1(σr−σuφ)α2+[cσtσu−σu(σt − (1− c)σu)φ +σr[2σt − (1− c)σu(1+m)]]2}
}
where we have defined σt = γu+ τ+µ,σu = γu+µ and σr = γr +µ . Also α1 = cσtσu+
σr(σt− (1− c)σu) and α2 = σt− (1− c)σum.
We derive ρr from I3r = I2r , yielding
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I3r (ρ) = I
2
r
cρ
µ
σr
Rw0 −1
Rw0 − (1− cρ)Rr0
=
µ(Rr0−1)
φβu
cρ
Rw0 − (1− cρ)Rr0
=
(Rr0−1)
Rr0(R
w
0 −1)
cρ =
(Rr0−1)
Rr0(R
w
0 −1)
(Rw0 − (1− cρ)Rr0)
cρ =
(Rr0−1)(Rw0 −Rr0)
Rr0(R
w
0 −1)
+
(Rr0−1)
Rr0(R
w
0 −1)
cρRr0
cρ
[
1− (R
r
0−1)
Rr0(R
w
0 −1)
Rr0
]
=
(Rr0−1)(Rw0 −Rr0)
Rr0(R
w
0 −1)
cρ
[
Rr0(R
w
0 −1)− (Rr0−1)Rr0
Rr0(R
w
0 −1)
]
=
(Rr0−1)(Rw0 −Rr0)
Rr0(R
w
0 −1)
cρ [Rr0(R
w
0 −1)− (Rr0−1)Rr0] = (Rr0−1)(Rw0 −Rr0)
cρ
[
Rr0R
w
0 − (Rr0)2
]
= (Rr0−1)(Rw0 −Rr0)
=⇒ ρr = R
r
0−1
Rr0c
.
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